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Neisseria  meningitidis  (Nm)  causes  potentially  fatal  bacterial  sepsis  and 
meningitis  in  susceptible  individuals,  but  induces  protective  immunity  in 
asymptomatic  carriers.  Nm  naturally  sheds  outer  membrane  vesicles 
(NOMVs) that contain a high proportion of lipopolysaccharide (LPS) and outer 
membrane  proteins.  NOMVs  are  known  to  induce  serum  bactericidal 
antibodies  in  mice  and  humans,  but  their  inherent  adjuvanticity  of  humoral 
responses toward protein and carbohydrate antigens has not been studied in 
detail.  This  thesis  investigation  has  determined  that  NOMVs  are  potent 
intraperitoneal and intranasal adjuvants for model T-dependent antigens such 
as  Ovalbumin  and  T-independent  antigens  such  as  dinitrophenol-ficoll. 
Surprisingly NOMVs had little or no effect on the primary antibody responses 
towards  several  clinically  relevant  capsular  polysaccharides  from 
Streptococcus pneumoniae regardless of the route of immunisation.  NOMVs 
induced  the  proliferation  of splenic  B  cells,  and  the  production  of cytokines 
from splenocytes and bone marrow-derived dendritic cells from not only wild- 
type  but  also  LPS-hyporesponsive  mice  which  indicates  that  both  LPS  and 
non-LPS  components  have  immunomodulatory  properties.  Despite  the 
potential  of NOMVs  inducing  proinflammatory responses,  preliminary results 
showed  that  intranasally  applied  NOMVs  suppressed  allergen  induced  or 
respiratory  syncytial  virus-induced  airway  eosinophilia  in  mouse  models. 
Together  our  results  provide  important  insights  into  the  role  of  NOMVs  in 
inducing  protective  immunity  against  meningococcal  diseases,  and  their 
immunomodulatory  properties  that  could  be  useful  separately  or 
synergistically in adjuvant development or immunotherapy.
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12CHAPTER 1
Introduction
1.1  General Introduction
Neisseria  meningitidis (Nm)  is  a  human  pathogen  that  is a  major cause  of 
septicaemia and meningitis worldwide.  It is an encapsulated, Gram negative 
diplococcus that colonises the nasopharynx.  Between one and  12 cases of 
meningococcal  disease  per  100,000  population  occur every year with  most 
cases  seen  in  children  aged  six  months  to  two  years  (Kolb-Maurer  et  a/., 
2001;  Pollard,  2001;  Unkmeir  et  al.,  2002).  The  rate  of  asymptomatic 
carriage of meningococci during endemic disease is thought to be 10-30% of 
the  general  population  (Caugant  et  al.,  1994;  Yazdankhah  et  al.,  2004). 
Rates  of  transmission  and  carriage  tend  to  be  higher  among  populations 
living in confined areas (military recruits and students) (Stephens,  1999).  In 
most  cases  Nm  colonises  the  human  nasopharynx  stimulating  natural 
immunity by inducing bactericidal antibodies in serum  (Goldschneider et al., 
1969a;  Goldschneider et al.,  1969b).  It  is thought that this  is essential  for 
protection  (Saunders  et  al.,  1999).  However  in  a  number  of  cases 
colonization of Nm can lead to dissemination from local tissues into the blood 
causing meningococcal disease (Quakyi et al., 1999; Katial etal., 2002).
Meningococci are traditionally classified based on the antigenicity of surface 
structures  with  the  serogroup  of  the  organism  being  determined  by  the 
polysaccharide  capsule  it  expresses.  Further  classification  depends  on
13antigenic differences in the major outer membrane proteins PorB and  PorA, 
and on lipopolysaccharide (LPS) structures that define the  12 immunotypes 
of  the  organism  (Morley  and  Pollard,  2002).  More  recently  multi-locus 
enzyme electrophoresis (MLEE), which measures the electrophoretic mobility 
of  cytoplasmic  enzymes  (Caugant  et  al.,  1986)  and  multi-locus  sequence 
typing  (MLST),  which  uses  molecular  sequence  data  from  housekeeping 
genes (Maiden et al.,  1998), are used to determine evolutionary changes in 
the meningococcus due to phase variation and high variability of antigens.
In developed countries the majority of meningococcal disease  is caused  by 
serogroup  B  and  C  meningococci,  with  serogroup  B  accounting  for 
approximately  50%  of  these  cases.  Meningococcal  disease  caused  by 
serogroup A is most frequently seen in Sub-Saharan Africa where epidemics 
have a  regular cyclic pattern occurring every five to eight years.  However, 
the  first  serogroup  W135  meningococcal  outbreak  was  reported  in  2002 
(Nicolas et al., 2005).
A high level of mortality (30-60%) is associated with meningococcal disease, 
however  both  early  recognition  of  the  disease  and  the  introduction  of 
antibiotic therapy have lowered these levels.  The use of some antibiotics has 
also been shown to decrease the carriage rate of meningococci (Hart et al., 
1993;  Yazdankhah  et al.,  2004).  Nevertheless,  antibiotic  resistant  strains 
exist and these could pose a problem for future treatment of meningococcal 
disease (Van  Esso et al.,  1987;  Hart et al.,  1993).  It is for this reason that 
although  for  the  time  being  we  are  able  to  treat  meningococcal  disease, 
prevention of the disease by vaccination would be better.
14Vaccines to serogroups A,  C, Y and W135 have been developed  based  on 
the capsular polysaccharides (CPSs).  The importance of anti-polysaccharide 
antibodies in humans against serogroup A and C meningococcal disease has 
been  demonstrated  (Goldschneider  et  al.,  1969a;  Goldschneider  et  al., 
1969b).  It  was  shown  that  highly  purified,  high  molecular  weight 
polysaccharides  (Gotschlich  et  al.,  1969c)  were  immunogenic  in  adults 
(Gotschlich et al.,  1969a; Gotschlich et al.,  1969b) however they were poorly 
immunogenic in infants and  young children (Gold et al.,  1975) and  provided 
no protection one-year post vaccination (Reingold et al., 1985).
The immunogenicity of these vaccines has improved through conjugation to 
protein  carriers,  although  there  is  a  need  to  further  understand 
polysaccharide  vaccines,  as  they  are  not  effective  in  young  children.  At 
present  there  is  no  universally  effective  vaccine  to  serogroup  B 
meningococci, which is the major cause of meningococcal disease in Europe 
and the United States of America.
1.1.1  Capsular polysaccharides
Capsular  polysaccharides  (CPSs)  are  essential  virulence  factors  that  are 
used  to  classify  meningococcal  serogroups.  There  are  13  reported 
serogroups: A, B, C,  D, 29E, H,  I, K, L W135, X, Y and Z.  Serogroups A,  B, 
C, W135 and Y cause more than 90% of meningococcal disease worldwide. 
The  CPSs vary in chemical  structure.  The capsules of serogroups B,  C,  Y 
and  W135  all  contain  A/-acetylneuraminic  acid  (sialic  acid),  whereas  the 
capsule of serogroup A is composed of A/-acetylmannosamine-1-phosphate.
15The  CPS  protect from  the  actions  of complement  in  the  absence  of  CPS- 
specific antibodies.  CPS-specific serum  IgG  antibodies  induce  complement 
mediated lysis of serogroups A, C, W135 and Y and opsonophagocytic killing 
of serogroup  B.  It  has  been  suggested  that enhanced  colonisation  of the 
human  nasopharynx  occurs  due  to  a  loss  of  capsule  expression 
(Hammerschmidt et al., 1996).
1.1.2  Polysaccharide and Conjugate vaccines
CPS-based  vaccines  have  been  formulated  and  are  effective  against 
serogroups A,  C,  W135  and  Y.  Two vaccines are  routinely  used  covering 
either serogroups A and C, or A, C, Y and W135.  However their usefulness 
has  been  hampered  due  to  being  poorly  immunogenic  in  infants  and  the 
duration  of immunity  is  limited.  In  order to  improve the  immunogenicity of 
these vaccines, polysaccharide capsules were conjugated to protein carriers. 
The  Haemophilus  influenza  type  B  vaccine  (Hib)  showed  the  potential  of 
conjugate  vaccines  by  eliciting  a  high  protective  efficacy  (Heath,  1998). 
Meningococcal  conjugate vaccines were first described  in  the  early  1980s, 
however  the  method  of  improving  immunogenicity  of  polysaccharide 
capsules  by  conjugation  to  protein  carriers  was  first  demonstrated  in  the 
1930s (Avery and Goebel,  1931).  Jennings and Lugowski (1981) described 
the  coupling  of  serogroup  A,  B  and  C  polysaccharides  to  tetanus  toxoid. 
They found  the  conjugate  vaccines for polysaccharides A and  C  produced 
high  levels  of  polysaccharide-specific  bactericidal  antibodies  in  mice  and 
rabbits,  whereas  the  conjugate  polysaccharide  B  vaccine  did  not.  A 
conjugate vaccine composed of meningococcal A and C polysaccharides and
16a  non-toxic  mutant  of  diphtheria  toxin  (MenAC)  was  first  to  be  tested  in 
human trials.  Phase  1   trials showed the vaccine to be immunogenic and to 
significantly increase antibodies to A and C meningococcal CPSs (Costantino 
et  al.,  1992).  Due  to  the  low  prevalence  of  serogroup  A  meningococcal 
disease  in  the  UK,  attention  was  focused  on  developing  a  vaccine  for 
serogroup C disease (MenC).  Trials were carried out with the MenC vaccine 
and  it was found to  be immunogenic after a three-dose schedule  in  infants 
(Richmond et al.,  1999) and after a single-dose in toddlers (Richmond et al., 
2001).  It was established that some disease isolates lacked O-acetyl groups 
(OAC-ve)  found  in  the  polysaccharide  capsule,  therefore  an  alternative 
vaccine  was  produced  that  contained  OAC-ve  polysaccharide  capsule 
coupled  with  tetanus  toxoid  (MenC-TT).  This  vaccine  also  proved  to  be 
immunogenic  in  adults  after a  single  dose  (Richmond  et al.,  1999)  and  to 
produce  bactericidal  antibodies  to  OAC+ve  and  OAC-ve  isolates  in  infants 
(Richmond et al., 2001).
In  1999,  the  UK became the first country to introduce  routine  immunisation 
with  MenC.  A three-dose  course  was  introduced  for  infants,  and  a  single 
dose for children aged  1-17 years.  Within  18  months an  81%  reduction  of 
confirmed  meningococcal  C disease was observed  (Miller et al.,  2001) and 
vaccine  efficacy was  calculated  at  93%  for teenagers  (Bose  et al.,  2003), 
92%  for toddlers  (Ramsay et al.,  2001;  Balmer et al.,  2002) and  91.5%  for 
infants (Balmer et al., 2002).  The impact of the MenC vaccine was vast due 
to a dramatic decrease in the incidence of serogroup C disease and fatalities.
17The  development  of  the  conjugate  vaccine  against  meningococcal 
serogroups  A,  C,  Y  and  W135  (MenACYW)  has  the  potential  to  tackle 
serogroup  A  meningococcal  infection  in  sub-Saharan  Africa  as  well  as 
disease associated with serogroup Y which is prevalent in the USA (Snape et 
al.,  2005).  Initial  results  with  a  single  immunisation  with  MenACYW 
conjugated to diphtheria toxoid (MCV-4) in adults (Campbell et al., 2002) and 
toddlers  (Rennets  et  al.,  2002)  were  immunogenic  and  well  tolerated. 
However the vaccine was only moderately immunogenic in infants (Rennels 
et  al.,  2004).  In  January  2005,  the  US  Food  and  Drug  Administration 
licensed MCV-4 for use in adults aged 11 to 55 years (Plotkin et al., 2006).
1.1.3  Serogroup B CPS
The  chemical  composition  of  the  CPS  of  serogroup  B  meningococci  is 
structurally  and  antigenically  similar  to  glycans  on  the  human  neural  cell 
adhesion  molecule (N-CAM) (Finne et al.,  1983), therefore purified group  B 
CPS  is  weakly  immunogenic  and  an  autoantigen  in  humans  (Wyle  et  al., 
1972).  Antibodies to the CPS have the potential to bind with host cells, and it 
is not known whether this would be harmful therefore it has not been used in 
a CPS-based vaccine.  It has also been shown that IgM antibodies to group 
B CPS are naturally present in humans, however these antibodies are of low 
avidity  and  have  low  bactericidal  activity  and  therefore  their  importance  in 
protective immunity against serogroup B meningococci is disputed (Leinonen 
et  al.,  1982).  It  is  due  to  these  reasons  that  the  focus  for  developing  a 
vaccine  for  serogroup  B  meningococci  has  turned  to  the  outer  membrane 
proteins (OMPs) and LPS.The success of the MenC vaccine could not be extrapolated to serogroup B 
disease.  It appears that conjugation of the polysaccharide from serogroup B 
to  a  protein  carrier  does  not  elicit  a  T  cell  dependent  response  to  the 
polysaccharide.  Although bactericidal activity and IgG responses have been 
seen  in  animai  studies  (Bartoloni  et  al.,  1995;  Devi  et  al.,  1997),  the 
bactericidal activity was not due to the serogroup B polysaccharide but was 
attributed  to  non-capsular antigens  such  as  OMPs and  LPS  which  show a 
great  deal  of  antigenic  variability  limiting  their  use  as  vaccine  candidates 
(Jones et al., 1979).
At  present there  is  no  universally effective vaccine to  serogroup  B  disease 
however several vaccines  have  been produced  by using  naturally occurring 
vesicles containing OMPs and LPS.
1.2  Non-capsular meningococcal surface antigens
1.2.1  Class I, II and III OMPs: PorA, PorB2 and PorB3
Neisserial  porins are  in  abundance on the outer membrane of Nm  and  are 
potential  vaccine and  adjuvant candidates.  They are co-expressed trimeric 
proteins  which  function  as  pores  and  are  essential  to  the  survival  of  the 
bacteria  because  they  mediate  the  exchange  of  ions  between  the 
surrounding  environment  and  the  bacteria  (van  der  Ley  et  al.,  1991; 
Mackinnon et al.,  1999).  Meningococcal porins can be separated into three 
classes:  class  I  (PorA,  approximately 45kDa), and class  II or III  (PorB2 and 
PorB3, approximately 40-42kDa and 37-39kDa respectively).  Meningococcal 
porins share 60-70% amino acid homology to gonococcal porins.  Each porin
19is made up of three single polypeptides of approximately 35kDa and contains 
a  high  proportion  of  p-pleated  sheets  (Massari  P,  2003).  PorA  and  PorB 
show  antigenic variability  and  are  used  to  determine  serosubtypes  of  Nm. 
Studies  of  these  proteins  have  determined  that  there  are  eight  surface- 
exposed  hydrophilic  loop  structures,  with  the  sites  of  most  variability 
corresponding  to  loops  I  and  IV  (Wright  et  al.,  2002;  Clarke  et  al.,  2003; 
Vermont et al., 2003).
Neisserial  and  other  Gram  negative  bacterial  porins  are  able  to  induce 
inflammation  in  mice,  as well  as  releasing  cytokines from  human  cells  and 
activating  both  human  and  murine  B  cells.  Investigations  using  human 
monocyte-derived  dendritic  cells  (mo-DC)  indicated  that T  cell  proliferation 
could  be  induced  after  stimulation  with  meningococcal  outer  membranes 
deficient in LPS, implying that non-LPS components could be involved in the 
activation of DCs (Al-Bader et al., 2003).  Further investigations by the same 
group demonstrated maturation of mo-DC as well as increased expression of 
chemokines such as IL-8 and RANTES by recombinant (r)PorA.  Low levels 
or  no  secretion  of  pro-inflammatory  cytokines  such  as  TNF-a,  and  anti­
inflammatory  cytokines,  such  as  IL-10  were  secreted  from  mo-DC  after 
stimulation  with  rPorA  indicating  that  PorA  is  more  likely  involved  with  the 
recruitment and activation of immune cells (Al-Bader et al., 2004).
Activation of B cells and DCs by porins has been shown to be dependent on 
TLR2  and  MyD88  by  using  both  TLR2  and  MyD88  knockout  mice 
(Mackinnon et al.,  1999;  Massari et al., 2002;  Massari  P, 2003;  Singleton et 
al., 2005).
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risk to immunological  attack,  due to a  reduced  size of the surface-exposed 
loop  structure.  Binding  of  monoclonal  antibodies  (mAbs) to  PorB3  on  live 
and  heat-  or  ethanol-killed  meningococci  revealed  that  PorB3  mAbs  were 
able to bind to killed but not live meningococci, indicating that PorB3 is buried 
in the outer membrane not accessible to antibody binding (Michaelsen et al.,
2001).  Estabrook and colleagues (2004) have demonstrated that PorB binds 
mannose-binding  lectin  (MBL)  and  purified  PorB  can  inhibit  the  binding  of 
MBL to meningococci.  MBL  is a  serum  collectin  resembling  IgM  and  C1q, 
which  can  bind  repeating  sugar  moieties  on  microorganisms  such  as 
encapsulated  serogroup  B  and  C  meningococci,  activating  the  lectin 
complement pathway leading to increased bacterial killing (Jack et al., 2001).
Neisserial porins have also been shown to upregulate CD86, a costimulatory 
molecule on the surface of B cells and DCs, increasing the involvement of T 
cells through CD28  (Wetzler et al.,  1996;  Mackinnon  et al.,  1999).  Studies 
using  PorB  conjugated  with  group  C  meningococcal  CPS  have  shown  that 
blocking CD86 greatly reduces the IgG response to the CPS, indicating that 
porins  are  able  to  provide  crucial  second  signals  for  T  cell-dependent 
induction  of  IgG.  Thus  neisserial  porins  are  potential  carrier and  adjuvant 
candidates (Mackinnon etal., 1999).
1.2.2  Class IV OMP: Reduction modifiable protein
The class IV OMP is called reduction modifiable protein (Rmp) because of its 
change in mobility in SDS-PAGE in the presence of a reducing agent.  Rmpis closely related to protein III (Pill) of N. gonorrhoeae with 96% homology in 
their DNA sequences (Lytton et al.,  1986;  Klugman et al.,  1989).  Both Rmp 
and  Pill  are constitutively expressed,  antigenically invariable  and  associate 
with  PorA and  PorB,  which  is  thought to  be  essential  for outer  membrane 
localisation and  stability (Jansen  et al.,  2000).  The function  of Rmp  in  the 
pathogenesis of Nm is relatively unknown, however mAbs against Rmp have 
been  reported  to  block  the  serum  bactericidal  activity  (SBA)  of  other 
antibodies  against  meningococci  (Munkley  et al.,  1991).  It  has  also  been 
demonstrated  that  Rmp  can  form  complexes  with  the  lactoferrin  receptor 
(LbpA), the transferrin receptor (TbpA) and the siderophore receptor (FrpB), 
resulting in the stabilisation of oligomeric forms of the iron-regulated proteins 
(Prinz et al., 2000).
1.2.3  Class V OMP: Opa and Opc proteins
Nm expresses colony opacity-associated (Opa) proteins involved in adhesion 
and invasion of host epithelial cells.  Meningococci are able to encode three 
or four Opa  proteins and at any one time,  may express zero, one or many, 
whereas gonococci  can  encode  up to  11  Opa  proteins  (Dehio et al.,  1998; 
Billker et al., 2000).  Unlike pili, Opa proteins are not required for colonization 
of the host, but have been known to interact with human cells leading to host 
cell  invasion.  In  circumstances  where  there  is  sialylated  LPS  or  an 
encapsulated  meningococcal  strain,  Opa  has  been  shown  to  be  a  poor 
mediator of bacterial adhesion (Pollard, 2001; Hauck et al., 2003).  According 
to  their  binding  specificity  for  human  surface  receptors  and  structural 
analysis, Opa proteins have been grouped into two major classes: the OpaH s
22(heparan  sulphate  recognising)  and  the  OpacEA-type  (carcinoembryonic 
antigen  recognising)  proteins  (Virji  et  al.,  1996;  van  Putten  et  al.,  1998). 
CD66 proteins are a subset of the CEACAM receptor family.  The function of 
CEACAM  receptors,  expressed  on  epithelial,  endothelial  and  phagocytic 
cells, is largely unknown however some members are known to mediate cell­
cell adhesion and have a possible role as regulatory and sensory molecules 
in the adhesion events (Billker et al., 2000; de Jonge et al., 2004).  Over 95% 
of meningococcal isolates are able to bind CD66a as are strains expressing 
capsule  and  sialylated  LPS  (Virji  et  al.,  1996).  Opa  binding  to  CD66a 
correlates with  bacterial  induction  of an  oxidative  burst  (Naids  et al.,  1991; 
Gray-Owen et al., 1997), which is preventable by Opa-specific antibodies and 
purified Opa proteins.  Recently it has been shown that MBL binds surface- 
exposed constant regions of Opa, however the effect of MBL binding remains 
to be investigated (Estabrook et al., 2004).
The Opc OMP is expressed at high levels in certain meningococcal strains. 
It  has  been  shown  to  be  structurally  and  antigenically  different  from  Opa 
proteins  (Achtman  et al.,  1988).  Merker and  colleagues  (1997)  devised  a 
structural  model  for  Opc  containing  10  transmembrane  strands  and  five 
surface-exposed  loops.  Adhesion and  invasion of endothelial  and  epithelial 
cells can be mediated by Opc (Virji et al., 1993) and it has been found to bind 
to heparin  and  heparan  sulphate proteoglycan receptors found  on epithelial 
cells (de Vries et al., 1998).
231.2.4  Iron-limited proteins
Iron acquisition is vital for all bacteria for its pathogenicity and iron-regulated 
proteins are essential for iron uptake.  Survival of bacteria inside the host can 
depend on the ability of the bacteria to scavenge for essential nutrients such 
as iron.  It has been well established that the growth of Nm depends on the 
availability  of  iron.  The  majority  of  iron  in  the  human  host  is  stored 
intracellularly  in  the  form  of  ferritin  and  haemoglobin.  Extracellular  iron 
sources  include transferrin found  in  body fluids  such  as  serum  and  lymph, 
and lactoferrin in milk and secretions.  Nm has to be able to survive in order 
to cause disease in various environments in the body containing a variety of 
forms  and  concentrations  of  iron  therefore  it  has  evolved  iron  acquisition 
systems to utilise the iron sources.
1.2.4a Transferrin binding proteins
During  iron-limited  growth,  the  acquisition  of iron  from  transferrin  is  by two 
transferrin binding proteins (Tbps), Tbp1  and Tbp2 with molecular masses of 
approximately  98  and  65-90  kDa  respectively,  depending  on  the  strain 
(Schryvers  et  al.,  1988).  These  Tbps  function  as  a  transferrin  receptor, 
localised  on  the  surface  of  Nm  (Ala'Aldeen  et  al.,  1993).  It  has  been 
demonstrated  that  antibodies  to  Tbp  are  sparsely  detected  in  sera  from 
healthy volunteers, whereas a clear antibody response is seen in sera from 
carriers  and  individuals  with  meningococcal  disease.  Antibodies  to  both 
Tbp1  and Tbp2 were detected,  and anti-Tbp antibodies were cross-reactive 
between strains (Gorringe et al., 1995).
24The  addition  of  Tbps  in  future  outer-membrane  based  meningococcal 
vaccines has been suggested due to their surface accessibility and potential 
of generating bactericidal antibodies.
1.2.4b Lactoferrin binding proteins
The  lactoferrin  binding  proteins,  LbpA  and  LbpB  make  up  the  lactoferrin 
receptor.  Using affinity isolation LbpA was identified as a 98kDa protein and 
under  more  stringent  conditions,  LbpB  an  84kDa  protein  (Schryvers  et a/., 
1998).  Lactoferrin binding and expression of the protein can be prevented by 
insertional  inactivation  of IbpA  in  Nm  (Quinn  et al.,  1994;  Schryvers  et al., 
1998).  The lactoferrin receptor has been found on all meningococcal strains 
tested  and  is thought to  be  a  major virulence factor as  lactoferrin  is found 
predominantly in the nasopharynx, which is the entry site for Nm.  It has been 
recently demonstrated  that  both  LbpA and  LbpB  are  accessible  at the  cell 
surface  and  are targets for bactericidal  antibodies.  These  antibodies were 
shown to have limited cross-reactivity, and a vaccine based on these proteins 
would  require a  number of variable  Lbps to  be  effective  against circulating 
strains (Pettersson et al., 2006).
1.2.5  Lipopolysaccharide
Lipopolysaccharide  is  a  major  glycolipid  and  is  the  most  abundant 
component on  the outer membrane  of  Nm.  Meningococcal  LPS  is distinct 
from  many  other  Gram  negative  bacteria  as  it  lacks  O-antigens  and  can 
therefore  be  more  properly described  as  lipooligosaccharide  (LOS).  There 
are  approximately  12  immunotypes  of  meningococcal  LPS,  controlled  by
25highly  regulated  genes  which  can  undergo  phase  variation  (Stern  et  al., 
1987).  Figure 1.1  shows possible LPS structures from N. meningitidis strain 
44/76.
Due  to  the  abundance  of  LPS  on  the  outer  membrane  it  is  accessible  to 
antibodies and with serum  levels of bactericidal antibodies to LPS shown to 
correlate  with  protection  against  meningococcal  disease,  LPS  has  been 
considered  as  a  possible  vaccine  candidate.  In  addition,  monoclonal 
antibodies (mAbs) to two LPS immunotypes have shown to be protective in 
an  infant  rat  model,  therefore  antibodies  to  LPS  may  be  important  in 
protection from meningococcal disease (Andersen et al., 2002).  However, as 
previously  mentioned  LPS  exhibits  endotoxic  properties  due  to  its  lipid  A 
moiety, and on removal of this portion a decrease in immunogenicity is seen 
(Preston,  1996;  Quakyi et al.,  1997;  Saunders et al.,  1999; Andersen  et al.,
2002).
Drabick  et  al.  (2000)  undertook  a  study  using  an  intranasal  (i.n.)  vaccine 
composed of NOMVs.  It was well tolerated, even though  LPS was present, 
as  no  harmful  side  effects were  observed.  Bactericidal  antibodies  to  LPS 
were also induced,  suggesting that the nasal  mucosal surface is insensitive 
to  LPS  and  i.n.  immunisation  could  therefore  provide  another  means  of 
investigating NOMV immunogenicity.
The functional activity of the murine mAb B5, which recognises a conserved 
LPS epitope was investigated by Plested et al. (2003).  They found that mAb 
B5 was able to protect infant rats from bacteremia caused by certain strains 
of Nm  serogroup B but not others.  They concluded that an  inner core  LPS 
epitope could provide a target for
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27protective  immunity,  however  a  mAb  with  greater  affinity  would  be  more 
useful.
1.2.6  Other OMPs
Neisserial surface protein A (NspA) is a highly conserved membrane protein 
that  is  reported to  be  accessible  at the  surface  of all  intact  meningococcal 
strains.  Data indicates that it could be a promising vaccine candidate as the 
recombinant  NspA  protein  induced  an  immune  response  in  mice  that 
protected  against  lethal  meningococcal  infection,  by  producing  serum 
bactericidal  and  protective antibodies against meningococcal  serogroups A, 
B and C (Martin et al., 1997; Cadieux et al., 1999).  However a study by Moe 
and  colleagues  (1999)  demonstrated  differences  in  surface  accessibility  of 
NspA  in  different  serogroup  B  strains,  therefore a  vaccine  based  on  NspA 
may have to be supplemented with additional antigens.
Another  iron-regulated  protein  is  the  37kDa  ferric  binding  protein,  FbpA 
(Mietzner et al.,  1984).  It is conserved in the genus Neisseria and has been 
found  to  be  immunogenic  and  surface  exposed  (Gomez  et  al.,  1996) 
although  no  significant  bactericidal  activity  directed  to  FbpA  has  been 
demonstrated (Gomez eta!., 1998).
Screening of the meningococcal serogroup B genome led to the discovery of 
NadA,  a  novel  surface  antigen.  It  was found  to  bind  host  cells  and  was 
postulated to belong to a novel class of adhesins (Comanducci et al., 2002). 
NadA induces strong bactericidal antibodies and was found to be protective
28in an infant rat model (Comanducci  et al., 2002).  It was also found to react 
with 60% of serogroup B and C isolates from Brazilian patients (Fukasawa et 
al., 2003).
1.3  Natural outer membrane vesicles
During  the  growth  of  Nm,  natural  outer  membrane  vesicles  (NOMVs)  are 
released  from  the  cell  surface.  They  are  often  referred  to  as  ‘blebs’  and 
contain  a  high  proportion  of LPS and  OMPs, which  is  representative of the 
meningococcal  outer membrane  (figure  1.2)  (Devoe  et al.,  1973;  Frasch  et 
al., 1982).  These blebs have been found to be highly immunogenic, although 
potentially toxic due to their high  LPS content however removal of the  LPS 
and phospholipids by using detergents reduces the toxicity (Saunders et al., 
1999;  Andersen  et  al.,  2002).  Haneberg  et  al.  (1998b)  showed  that 
application of detergent solubilised OMVs (DOMVs) on to mucosal surfaces 
in human volunteers induced both mucosal and systemic immune responses, 
therefore  proving that OMVs possess the necessary components to elicit a 
potentially  protective  response  against  meningococci.  Due  to  the 
immunogenicity  of  NOMVs  they  have  been  used  as  vaccines  in  several 
countries.
1.3.1  NOMV vaccines
Due  to the  high  incidence  of meningococcal  disease  in  Norway during  the 
1970-80s,  a  vaccine  against  serogroup  B  meningococcal  disease  was 
prepared from a B:15:P1.7,16 strain by detergent extraction and absorbed to 
aluminium hydroxide adjuvant.  It was found to be highly immunogenic in
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Surface structure of Neisseria meningitidis (modified) 
(Pollard, 2001)both  mice  and  humans  (Fredriksen  et  al.,  1991)  and  showed  significant 
protection against systemic serogroup B meningococcal disease in teenagers 
(Bjune et al., 1991).  IgG levels were shown to be dramatically increased and 
opsonic activity (Aase et al.,  1995; Aase et al., 2003) and a booster response 
were also observed (Aase et al.,  1995; Rosenqvist et al.,  1995;  Haneberg et 
al.,  1998a).  T cell  responses to OMVs and  PorA were also observed  after 
intramuscular (i.m.) and i.n.  immunisation (Naess et al.,  1998;  Oftung et al., 
1999).
The  Cuban  OMV  vaccine,  VA-MENGOC-BC,  contains  purified  CPS  of 
serogroup C  meningococci,  and  is  absorbed with aluminium  hydroxide  gel. 
Two trials were performed during which the efficacy and safety of the vaccine 
was  established.  Due  to  the  results  of  both  of  the  trials,  children  aged 
between three months and six years in the most affected provinces of Cuba 
received the vaccine (Sierra et al., 1991) and it has also been used during an 
epidemic in Sao Paulo, Brazil (de Moraes et al.,  1992; Milagres et al.,  1994). 
The  vaccine  has  been  shown  to  induce  a  characteristic  Th1  immune 
response  indicated  by the  presence  of  IFN-y  and  IL-2  mRNA after in  vitro 
OMV  challenge  of  peripheral  blood  mononuclear  cells  from  immunised 
subjects (Perez et al., 2001).
The  Dutch  OMV  vaccine  is  based  on  PorA.  Two  vaccine  strains  were 
produced  each  expressing  three  PorA  proteins  absorbed  to  aluminium 
hydroxide (Claassen et al.,  1996).  Bactericidal antibodies were found to be 
PorA  specific  in  immunised  humans,  and  half of the  volunteers  showed  a 
four-fold  or  higher  increase  in  bactericidal  antibody  titres  (Peeters  et  al.,
1996).  A follow up study by van der Voort and colleagues (1997) examined
31B and T cell responses in adult volunteers.  They observed strong IgG levels 
after the first immunisation,  however further immunisations did  not increase 
the  response.  T  cell  responses  determined  by  T  cell  proliferation  were 
observed  after the  first  and/or second  immunisation  but  not  after the  third 
immunisation.
The vaccine used in Iquique, Chile consisted of purified meningococcal group 
B OMP (B:15:P1.3:L3,7) noncovalently complexed to group C CPS absorbed 
to alum.  After further purification, the vaccine contained only approximately 
0.1% LPS and was well tolerated with minor side effects in volunteers.
Although  NOMV  and  DOMV  vaccines  have  been  widely  used,  they  have 
limited  immunogenicity  against  strains  that  the  vaccine  is  not  produced 
against,  and  are  not well  characterised  in  how they interact with the  innate 
immune system.
1.4  Innate immunity to meningococcal disease
The innate immune system provides the first line of defence against infection 
and depends on germline-encoded receptors to recognise features common 
to  many  pathogens.  The  components  of  innate  immunity  are  generally 
present before the onset of infection and do not require a prolonged period of 
induction.  Physical  barriers  such  as  epithelial  surfaces  and  mucous 
membranes  are  the  first  line  of  defense  against  pathogens  providing  a 
physical  barrier.  Physiological  barriers  such  as  pH,  temperature  and 
chemical  mediators  can  also  prevent  pathogens  from  crossing  epithelial 
surfaces.  On  penetration  of  these  barriers  phagocytic  cells  of  the  innate
32immune system such as macrophages and neutrophils play an important part 
of innate immunity by eliminating foreign material.
Pathogens  are  recognised  by  the  innate  system  by  receptors  known  as 
pattern-recognition  receptors  (PRRs),  which  recognise features common  to 
many  pathogens  also  known  as  pathogen-associated  molecular  patterns 
(PAMPs)  (Medzhitov  et  al.,  1997).  Many  different  PRRs  have  been 
identified.  Some  are  soluble  circulating  proteins  such  as  mannose-binding 
lectin (MBL), C-reactive protein (CRP), complement and LPS-binding protein 
(LBP)  whereas  others  such  as  Toll-like  receptors  (TLRs)  and  scavenger 
receptors (SRs) are found on the membrane of cells such as macrophages 
and DCs.
1.4.1  Macrophages and  dendritic cells  and their role in  meningococcal 
infection
Macrophages  and  DCs  are  professional  antigen  presenting  cells  (APCs). 
They  are  specialised  phagocytes  that  are  involved  in  the  clearance  of 
microbial  products  and  host cells.  They are found  throughout the  body  in 
areas where they are likely to encounter pathogens and  microbial  products. 
Not only are they efficient in the capture and processing of antigens, but they 
are also able to release large amounts of cytokines inducing responses upon 
binding to specific receptors.
DCs are  present  in  most tissues and  have a central  role  in the  initiation  of 
adaptive  immune  responses  (Janeway,  2001) as well  as the  modulation  of 
immune responses (Banchereau et al., 1998).  DCs are derived from myeloid 
progenitors within the bone marrow.  From the bone marrow they migrate to
33peripheral  sites  via  the  blood.  At  this  stage  they  are  considered  to  be 
immature  and  express  low  levels  of  MHC  proteins  and  costimulatory 
molecules,  therefore  unable to  stimulate  naTve T cells.  However,  they are 
able  to  take  up  antigens  by  phagocytosis  (Inaba  et  al.,  1993), 
macropinocytosis  (Sallusto  et  al.,  1995)  and  endocytosis  (Sallusto  et  al., 
1994).  These immature DCs are then stimulated by infection and migrate to 
lymphoid  tissue  such  as  the  spleen  and  lymph  nodes,  leading  to  an 
upregulation  of  costimulatory  molecules  and  also  activation  of  antigen- 
specific T cells (Banchereau et al., 2000).  The DCs at this stage are said to 
be ‘mature’ and have a reduced capacity to phagocytose antigens,  however 
they are able to present peptides from proteins acquired from infection due to 
high-level  expression  of  MHC  class  I  and  class  II  (Janeway,  2001).  Both 
inflammatory  products  and  infectious  agents  are  able  to  bring  about  these 
changes in DCs (Banchereau et al., 1998).
Many studies have shown that human and murine DCs can be stimulated by 
wild-type  Nm  to  induce  maturation  characterised  by an  increase  in  surface 
expression of costimulatory molecules such as CD40, CD86 and MHC II, and 
the  production  of  proinflammatory  cytokines  IL-6,  TNF-a  and  IL-1 a,  that 
correlate  with  severe  meningococcal  disease  (Dixon  et  al.,  2001;  Kolb- 
Maurer et al., 2001; Al-Bader et al., 2003).
The ability of meningococci to adhere to and  be phagocytosed  by DCs has 
been  investigated.  Several  studies  have  shown  that  the  meningococcal 
capsule prevents the adherence of the bacteria to DCs therefore preventing 
phagocytosis and killing of the bacteria (Kolb-Maurer et al., 2001; Unkmeir et 
al., 2002).  It has also been elucidated that although inactivated wild-type Nm
34is  readily  phagocytosed  by  DCs,  LPS-deficient  mutants  and  live 
encapsulated  wild-type  bacteria  are  not and  therefore  internalisation  of the 
bacteria is dependent on  bacterial expression of LPS in  intact Nm  (Uronen- 
Hansson et al., 2004a; Uronen-Hansson etal., 2004b).
The production of IL-12 by DCs has been shown with wild-type meningococci 
(Dixon  et  al.,  2001;  Al-Bader  et  al.,  2003)  and  is  again  dependent  on 
internalisation of the whole bacteria as the addition of purified LPS to a LPS- 
deficient  mutant,  IpxA  did  not  reconstitute  the  cytokine  response  by  DCs 
(Uronen-Hansson et al., 2004b).
The  interactions of DCs with  components of meningococci  have  also  been 
investigated.  Singleton and colleagues (2005) determined the effect of PorB 
on murine splenic and bone-marrow derived DCs (BMDCs).  They found that 
PorB  was  able  to  upregulate  the  surface  expression  of  costimulatory 
molecules  on  DCs  and  to  produce  IL-6  by  MyD88-  and  TLR2-dependent 
mechanisms.  In  contrast,  although  recombinant  PorA  (rPorA)  has  been 
shown to induce maturation of human  monocyte-derived  DCs,  low levels or 
no secretion of proinflammatory cytokines was observed and upregulation of 
TLR4 mRNA was induced whereas levels of TLR2 mRNA were  unchanged 
(Al-Bader et al., 2004).
Macrophages are the main phagocytic cells of the immune system. They are 
distributed  throughout  every  organ,  where  they  form  a  layer  beneath  the 
surface of epithelial cells in the gut,  lung,  kidney and skin.  It is here where 
they recognise a range of antigens through a variety of cell-surface receptors 
for  microbial  constituents,  such  as  the  mannose  receptor  and  CD14  -   a
35molecule  that  recognises  and  binds  LPS  (Aderem  et  al.,  1999).  Resting 
macrophages have few MHC class II molecules on their surface and do not 
express  B7  molecules.  However  the  expression  of  these  molecules  is 
induced  by ingestion of microorganisms.  Once bound,  microorganisms are 
engulfed  and  degraded  in  endosomes  and  lysosomes,  generating  peptides 
that can be presented by MHC class II on the cell surface.  At the same time 
MHC class II and B7 molecules are induced on the surface of macrophages 
(Janeway, 2001).
There  have  been  few  reports  studying  the  effects  of  meningococci  on 
macrophages.  Pridmore and colleagues (2001) showed that ten times more 
TNF-a  was  produced  by  stimulation  of  human  monocyte-derived 
macrophages  by  wild-type  Nm  than  by  the  IpxA  mutant.  Activation  of 
macrophages  by  meningococcal  LPS  has  been  shown  to  be  CD14/TLR4 
dependent.  This  was  shown  by  a  decrease  in  TNF-a  production  when 
antibodies to TLR4 and CD14 were used to block LPS activation.  A result of 
the  activation  of  macrophages  by  meningococcal  LPS  is  the  release  of 
cytokines, chemokines, nitric oxide and reactive oxygen species (Zughaier et 
al., 2004).
1.4.2  Soluble factors involved in the recognition of pathogens 
1.4.2a The complement system
The complement system helps to fight infection by opsonising pathogens and 
inducing  inflammatory responses.  It consists of more than  30  plasma  and 
cell surface proteins and can be activated via three pathways dependent on
36different molecules: (1) the classical pathway, (2) the mannose-binding (MB) 
lectin pathway and (3) the alternative pathway.
The classical pathway can be initiated by binding of C1q, which is part of the 
C1  complex,  to  the  surface  of  certain  pathogens  as  well  as  directly  to 
antigen:antibody complexes.  IgM,  lgG3 and to a lesser extent lgG1  are able 
to activate complement.  IgM is more efficient at activating complement than 
IgG  due  to  its  pentameric  structure  allowing  the  binding  of  two  or  more 
globular heads of the  C1q  molecule,  which  activates  it.  Binding  induces a 
conformational change in the C1s-C1r-C1r-C1s complex, which leads to the 
activation of enzymatic activity in C1r cleaving the associated C1s (Arlaud et 
al., 2001).  Components C4 and then C2 are cleaved by C1s to produce C4b 
and C2b which form the C3 convertase (Kerr,  1980).  This complex is linked 
to the  surface  of the  pathogen,  where  it  cleaves  C3  molecules to  produce 
C3b molecules that bind to the surface of the organism and act as opsonins 
(Rawal  et  al.,  2003).  The  other  cleavage  product,  C3a  promotes 
inflammatory responses.
The membrane attack complex (MAC) is initiated by binding of C3b to the C3 
convertase  to  form  a  C5  convertase,  which  is  cleaved  to  produce  the 
anaphylatoxin C5a (DiScipio,  1992) and C5b which initiates the ‘late’ events 
of the complement cascade by the terminal  complement components.  The 
MAC  is formed  by the terminal  proteins  C5,  C6,  C7,  C8  and  C9.  The  C8 
component  mediates  binding to C9,  which forms  pore-like  structures  in the 
membranes of some  pathogens that  may lead  to  lysis  (Gotze  et al.,  1970; 
Scibek et al., 2002).
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collectin  family  (Turner,  1996),  and  ficolins,  similar  to  C1q  to  trigger  the 
complement cascade.  They are able to recognise a  range of carbohydrate 
residues on the surface of bacteria, for example mannose and LPS on Gram 
negative  bacteria  and  eliminate  pathogens  by  acting  as  opsonins  (Turner,
1996).  MBL  forms  a  complex  with  serine  proteases  known  as  MBL- 
associated  serine  proteases  (MASPs)  (Matsushita  et al.,  1992;  Thiel  et al.,
1997).  Once  MBL is bound to the surface of bacteria,  the  MASPs become 
activated and cleave C4 and  C2 to form the C3 convertase and to activate 
the  complement  system  in  a  similar  way  to  the  classical  pathway.  The 
binding capacity of MBL to meningococcal isolates has been investigated.  It 
was initially observed  that encapsulated  meningococcal  strains significantly 
inhibited  binding  of  MBL  (van  Emmerik  et  al.,  1994).  However,  further 
studies have suggested that the level of MBL binding is determined more by 
LOS structure and sialylation.  Jack and colleagues (1998) demonstrated that 
isogenic  mutants  of  a  serogroup  B  strain  with  truncated  LOS  bound  MBL 
more  strongly  than  organisms  with  intact  LOS  and  sialylation  of  LOS 
prevented  binding.  This  was  further  supported  by  an  investigation  by 
Devyatyarova-Johnson  et  al.  (2000)  in  N.  gonorrhoeae  and  studies  using 
encapsulated strains of Nm serogroup C (Jack et al., 2001).
The alternative pathway can proceed in the absence of specific antibody and 
does not depend on a pathogen-binding protein for its initiation.  The pathway 
is  initiated  by binding of C3b to the  C3 convertase on to the surface of an 
activator.  These  activators  include  a  wide  range  of  pathogens.  Factor  B 
then  binds  to  the  activator  linked  to  C3b  to  form  C3bB  which  becomes
38susceptible to proteolysis by the serine  protease factor D.  Factor  B  is then 
cleaved  into  two fragments,  Ba  which  is  released,  and  Bb,  which  remains 
bound to C3b forming C3bBb, which is the C3 convertase of the alternative 
pathway (Xu et al., 2001).  The next stages are the same as for the classical 
pathway  in  that  C3b  binds  to  the  surface  of  pathogens  to  signal  the 
destruction of the pathogen by phagocytosis and C5 initiates the formation of 
the MAC complex.
The complement system  has been shown to be important in  meningococcal 
disease.  Deficiencies,  especially  of  the  late  complement  components, 
increase  the  risk  of  meningococcal  infection,  indicating  complement  to  be 
important in the defense against this pathogen (Ross et al., 1984; Fijen et al., 
1999).
1.4.2b C-reactive protein
C-reactive  protein  (CRP)  is  an  acute  phase  protein,  which  has  been  long 
recognised as an opsonin (Du Clos et al.,  1997).  It is a pattern recognition 
molecule made up of five identical subunits each with a high  binding affinity 
for phosphocholine (PC) when in the presence of Ca2 +  (Szalai, 2002).  PC is 
the  dominant  epitope  of the  cell  wall  polysaccharide,  C-polysaccharide,  on 
Streptococcus pneumoniae.  Gram  negative  bacteria such  as  Haemophilus 
influenzae and Nm have also been found to bear the PC epitope (Kolberg et 
al.,  1997).  Levels  of CRP  in  blood  have  been  shown  to  dramatically  rise 
during  inflammation and to complement activation and  cytokines.  CRP  has 
binding sites for effector molecules that bind with C1q to activate complement 
and the high affinity receptors for IgG,  FcyRI and  FcyRII on neutrophils and
39monocytic cells  (Marnell  et al.,  1995;  Bharadwaj  et al.,  1999).  It  has  also 
been  demonstrated  that  CRP  can  down-regulate  the  response  to  LPS  by 
binding  to  FcyR,  stimulating  the  production  of  IL-10  and  blocking  IL-12 
production (Mold et al., 2002), therefore possibly enhancing the clearance of 
meningococci.
1.4.3  Cell associated receptors involved in the recognition of pathogens 
1.4.3a Toll-like receptors
Toll-like receptors (TLRs) have been shown to have a crucial role in the first 
line of defence against pathogens (Akira et al., 2004).  To date 11  have been 
identified (TLR1-TLR11).  TLR family members are characterised by leucine- 
rich  repeats  and  a  Toll/IL-1  receptor  (TIR)  domain.  The  TIR  domain  has 
been shown to be similar to that of the IL-1  receptor family.  All members of 
the  TLR  family  appear  to  signal  through  the  same  molecules,  including 
MyD88,  IL-1  receptor-associated  kinase  (IRAK),  TNF  receptor  associated 
factor  (TRAF)  6,  TIR-domain-containing  adapter-inducing  IFN-beta  (TRIF), 
mitogen-activated protein (MAP) kinases and to activate nuclear factor (NF)- 
kB (Akira, 2003).  Figure 1.3 shows the signalling pathways for TLRs 1, 2, 6, 
5,  9  and  4.  Individual  TLRs recognise distinctive  structural  components  of 
pathogens, and TLR expression is varied depending on location in the body 
and  the  cell  type.  For  example,  urogenital  immunity  is  associated  with 
TLR11, whereas TLRs 2, 3, 4, and  5 have roles in defence of the bronchial 
and gastrointestinal epithelia (Hopkins et al., 2005).
The expression of different TLRs has been determined through a number of 
studies.  It has been shown that different subsets of DCs express different
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Figure 1.3: Schematic of TLR signalling pathways
41TLRs.  Plasmacytoid  DCs (pDCs) express TLR1, TLR7 and TLR9,  however 
other DC subsets such as monocyte-derived DCs do not express or express 
very little TLR9.  TLR3 is expressed by CD8a+  DC, however this subset does 
not express TLR5 or TLR7 (Edwards et al., 2003).  Hornung and colleagues 
(2002) demonstrated TLRs  1,  2,  6,  7,  9 and  10 to be present on  human  B 
cells.  Human eosinophils constitutively express mRNA for TLRs  1,  4,  7,  9 
and 10, whereas neutrophils express mRNA for TLRs 1, 2, 4, 5, 6, 7, 8, 9 and 
10 (Nagase et al., 2003).  The expression of TLRs 2, 4, 6 and 8 were found 
on  mast  cells  derived  from  mouse  bone  marrow  (McCurdy  et  al.,  2001; 
Supajatura et al., 2001).
TLRs and Bacterial Recognition 
TLR1, TLR2 and TLR6
TLR2  recognises  many  different  microbial  components  including 
peptidoglycan  from  Gram  positive  bacteria,  lipoproteins  and  lipopeptides, 
lipoarabinomannan  from  mycobacteria,  porins  from  Nm  and  zymosan,  a 
yeast cell-wall component (Takeda et al., 2003).  Ligand recognition by TLR2 
is generally in conjunction with TLR1  and TLR6.  TLR2 and TLR6 have been 
suggested to physically interact within the cell.  Studies using TLR2-deficient 
mice highlighted the importance of TLR2 in the recognition of peptidoglycan 
and  lipoproteins  however  a  recent  study  has  demonstrated  that  highly 
purified  peptidoglycan are not recognised through TLR2,  TLR2/1  or TLR2/6 
and this loss of recognition  is most likely due to the removal  of lipoproteins 
and lipoteichoic acids during purification (Travassos et al., 2004).
42TLR4
Studies  using  C3H/HeJ  (hyporesponsive to  LPS)  mice,  which  have a  point 
mutation  in  the  intracellular region  of the  Tlr4 gene,  and  the  generation  of 
TLR4-deficient mice demonstrated that TLR4 is an essential  receptor in the 
recognition  of  LPS  (Akira,  2003;  Takeda  et al.,  2003).  The  recognition  of 
LPS  by TLR4 also relies on several other molecules.  LPS initially binds to 
LPS-binding protein (LBP) found in serum.  This complex is then recognised 
by CD14, which is present on the surface of mononuclear phagocytes.  MD- 
2, which associates with the extracellular portion of TLR4, is also required.  It 
has  been  shown  that  macrophages,  DCs  and  B  cells  from  MD-2-deficient 
mice have severely limited responses to LPS.
The cell-surface protein,  radioprotective  105 (RP105) is a TLR-like molecule 
which  has  a  functional  association  with  TLR4  and  is  also  required  in  the 
recognition of LPS.  It contains a structurally related LRR domain found in the 
extracellular  portion  of TLRs,  but  lacks  a  Toll/IL-1  receptor  domain  and  B 
cells from mice deficient in RP105 have impaired responses to LPS (Miyake 
et al.,  1995).  Expression  of RP105  has  been  shown  to  be  dependent  on 
coexpression of MD-1  (Miyake et al.,  1998; Nagai et al., 2002).  RP105 was 
once thought to be primarily expressed on the surface of B cells,  however it 
has  been  recently  shown  that  RP105  is  also  expressed  on  human 
monocytes,  myeloid  DCs,  murine peritoneal macrophages, splenic DCs and 
BMDCs.  In  the  same  study  it was  also  shown  that  RP105  can  negatively 
regulate TLR4 signalling (Divanovic et al., 2005).
43TLR4  has  also  been  reported  to  recognise  several  other  ligands  such  as 
Taxol,  endogenous  ligands  such  as  heat  shock  proteins  and  extracellular 
matrix  components  including  fibronectin,  hyaluronic  acid  and  heparan 
sulphate.
TLR5
Flagellin, the main component of bacterial flagella, has been shown to signal 
through  TLR5  (Hayashi  et al.,  2001).  Flagellin  extends  out  from  the  outer
membrane  of  Gram  negative  bacteria  and  is  a known  virulence factor.
Flagella  act  as  propellers  to  move  bacteria  through  their  aqueous 
environment as well as facilitating  invasion by the attachment of bacteria to 
host cells.
TLR9
TLR9 is essential  in the recognition of and  responses to bacterial  DNA and 
synthetic oligodeoxynuceotides  containing  unmethylated  CpG  dinucleotides 
(CpG  DNA).  Proliferation  of  splenocytes,  cytokine  production  from 
macrophages and maturation of DCs were abolished in TLR9-deficient mice 
after stimulation with CpG DNA, a potent activator of immune cells, indicating 
the  importance  of  TLR9  in  these  responses (Hemmi  et  al.,  2000).
Unmethylated  CpG  motifs  found  within bacterial  DNA  have
immunostimulatory activity.  These motifs are rarely found in vertebrates, and 
if present they are generally methylated and lack immunostimulatory activity. 
CpG DNA is a possible adjuvant candidate as it has been shown to activate
44DCs  and  produce  cytokines  characteristic  of  a  Th1  immune  response 
(Wagner, 2001) and to trigger B cell proliferation (Krieg etal., 1995).
TLR11
TLR11  is expressed strongly in the liver and kidney, indicating a specific role 
in these organs and at low levels in the spleen.  It was established that cells 
expressing TLR11   respond to uropathogenic bacteria and this was supported 
by  studies  that  showed  TLR11  deficient  mice  to  be  highly  susceptible  to 
infections with uropathogenic bacteria (Zhang et al., 2004).
1.4.3b Scavenger receptors
Scavenger  receptors  (SRs)  are  glycoproteins  that  are  able  to  bind 
polyanionic  ligands  including  low-density  lipoproteins  (LDLs)  such  as 
oxidised LDL and acetylated LDL (Emi et al.,  1993; Kraal et al., 2000).  They 
were  originally  identified  on  macrophages,  however  endothelial  cells  and 
smooth  muscle  cells  also  express  SRs.  There  are  at  least  six  molecular 
forms that have  been classified  into subgroups according to their structure. 
These subgroups are SR-A (SR-AI,  SR-AII and  MARCO),  SR-B  (CD36 and 
SR-BI),  SR-C,  SR-D (CD68),  SR-E and SR-F.  The class A SR (SR-A) was 
initially  characterised  by two  isoforms  (SR-AI  and  SR-AII) which  are  splice 
variants  of the  same  gene  (Emi  et al.,  1993).  A third  variant,  SR-AI 1 1   has 
been described along with another member of the subclass, the macrophage 
receptor  with  collagenous  structure  (MARCO).  MARCO  has  a  similar 
structure  to  SR-AI  and  is  expressed  constitutively  on  defined  subsets  of 
macrophages (van der Laan et al.,  1999).  It is able to bind  Gram  positive
45and Gram negative bacteria as well as bacterial CpG DNA (Zhu et al., 2001), 
and  is  rapidly  induced  by  BCG  infection,  bacterial  sepsis  or  in  vitro  with 
bacteria or LPS  (Kraal  et al.,  2000;  Kvell  et al.,  2006).  Meningococci  have 
been shown to be able to bind bone-marrow derived macrophages (BMDMs) 
in  mice through  SR-A and  that the  ligand  for SR-A mediated  phagocytosis 
was not the lipid A component of LPS (Peiser et al., 2002).  Recent studies 
by  Mukhopadhyay  and  colleagues  (2004;  2006)  demonstrated  that  mouse 
and human MARCO can bind Nm independently of LPS.  They also indicated 
that the release of TNF-a and NO is not dependent on binding to MARCO or 
SR-A, therefore proposing that MARCO enhances the recognition and uptake 
of organisms such as Nm.
1.4.3c C-type lectins
C-type  lectins  and  lectin-like  receptors  are  expressed  on  the  surface  of 
APCs.  Many of the lectins are members of the calcium-dependent ‘C-type’ 
lectin  family  and  bind  sugars  via  conserved  carbohydrate  recognition 
domains  (CRDs).  Examples  of  C-type  lectins  are  the  mannose  receptor 
(MR) and DC-specific ICAM-3-grabbing non-integrin (DC-SIGN).
The  CRD  of the  MR  is  structurally  similar to that of  MBL.  The  MR  is  an 
180kDa  type  I  transmembrane  protein  expressed  on  macrophages,  DCs 
(Sallusto  et al.,  1995)  and  hepatic endothelial  cells  containing  eight  CRDs 
that  bind  mannose,  fucose,  N-acetylglucosamine  and  glucose  molecules 
found frequently on the surface of bacteria (Taylor et al.,  1990).  The  MR is 
able  to  bind  a  variety  of  pathogens  such  as  Mycobacterium  tuberculosis 
(Schlesinger,  1993),  Trypanosoma  cruzi  (Kahn  et  al.,  1995)  and
46Pneumocystis carinii (O'Riordan et al.,  1995).  Zamze and colleagues (2002) 
demonstrated  that  the  MR  was  able  to  bind  purified  CPSs  from  S. 
pneumoniae and LPS but not the CPS from Klebsiella pneumoniae.  The MR 
is  an  important  receptor  in  innate  immunity  as  it  mediates  phagocytosis 
(Stahl  et  al.,  1998)  and  endocytosis  of  soluble  antigens  to  enhance  the 
presentation of these antigens to T cells (Engering et al., 1997).  The MR has 
been  described  to  have  an  additional  role  in  the  clearance  of  pituitary 
hormones such as lutropin and thyrotropin in order to prevent desensitisation 
of the target cell receptors (Simpson et al., 1999).
DC-SIGN  is a  novel  C-type  lectin  highly expressed  on  DCs.  It  is a type  II 
transmembrane  protein  containing  one  CRD  and  ligand  binding  is  calcium 
dependent.  DC-SIGN binds ICAM-3 assisting in the adhesion of DCs with T 
cells  (Geijtenbeek  et  al.,  2000).  It  has  also  been  shown  to  recognise 
carbohydrate  structures  such  as  Lewis  X  and  D-Mannose  and  to  bind  a 
broad range of pathogens such as hepatitis C virus (Pohlmann et al., 2003), 
Dengue  virus  (Tassaneetrithep  et  al.,  2003),  Ebola  virus  (Alvarez  et  al., 
2002),  Mycobacteria  (Geijtenbeek  et  al.,  2003),  Helicobacter  pylori  and 
Leishmania  mexicana  (Appelmelk  et al.,  2003).  It  has  been  demonstrated 
that  pathogens  may  target  DC-SIGN  in  order to  alter the  Th1  versus  Th2 
balance.  The expression of DC-SIGN has been linked to Th2-type cytokines 
(Relloso  et  al.,  2002)  and  results  have  indicated  that  mycobacteria  can 
suppress DC function and alter immune responses by shifting the Th1  versus 
Th2 balance by targeting DC-SIGN (Geijtenbeek et al., 2003).
A murine homologue of human DC-SIGN has been isolated called SIGN-R1. 
It is one of five mouse genes to be identified and is found within a subset of
47macrophages  in  the  marginal  zone  of the  spleen  and  lymph  node  medulla 
(Geijtenbeek et al.,  2002;  Kang  et al., 2003).  SIGN-R1  has been  shown to 
be  involved  in  the  uptake  of  pneumococci  and  its  CPS  by  marginal  zone 
macrophages (MZM) (Kang etal., 2004) and mice lacking SIGN-R1  are more 
susceptible to pneumococcal  infection as the MZMs are unable to bind and 
phagocytose pneumococci efficiently (Lanoue et al., 2004).
1.4.3d Complement receptors
Phagocytic cells express complement receptors (CRs) to facilitate the uptake 
and  destruction  of  pathogens.  These  CRs  bind  pathogens  coated  in 
complement  components  such  as  C3b  and  C4b.  Complement  receptor  1  
(CR1/CD35) is expressed on macrophages, follicular DCs, eosinophils and B 
cells  and  binds  a  host of microbial  opsonins  including  C3b,  C4b  and  MBL 
(Ghiran et al.,  2000).  CR2 (CD21),  although not described as a phagocytic 
receptor,  is expressed on B cells and binds inactivated forms of C3b (iC3b). 
CR3  (CD11b/CD18,  Mac-1)  is  expressed  on  similar  cells  to  CR1  and 
recognise  iC3b  among  with  other  non-complement  ligands  (Ehlers,  2000). 
CR4  (CD11c/CD18)  has  not  been  well  characterised,  but  is  expressed  on 
DCs (Underhill et al., 2002).
1.5  Adaptive Response
Defense  against  meningococcal  disease  involves  both  innate  and  adaptive 
mechanisms.  Natural  humoral  immunity  in  the  majority  of  individuals  is 
successful  in  preventing  meningococcal  disease,  however some  individuals
48are more susceptible and the protective role of antibodies after immunisation 
has been demonstrated.
Adaptive immunity is essential when  innate  mechanisms have  been eluded 
or overwhelmed.  The adaptive immune response takes several days to be 
initiated.  As  previously described  DCs  are  important  in  the  initiation  of an 
adaptive response by the activation of antigen-specific naive T lymphocytes. 
T  cells are  needed for cell-mediated  immune  responses,  which  depend  on 
interactions  between  T  cells  and  cells  bearing  the  antigen  that the  T  cells 
recognise.  Cytotoxic  T  cells  express  CD8  on  their  cell  surface.  They 
function by targeting cells that have been infected by pathogens.  CD4 T cells 
can be divided into two subsets: Th1  cells which are important in the control 
of  intracellular  bacterial  infections  and  Th2  cells  whose  role  is  in  the 
destruction of extracellular pathogens by activating B cells.
1.5.1  T-dependent and T-independent antigens
Antigens have been classified on their ability to stimulate antibody production 
as  either  T  cell  dependent  (TD)  or  T  cell  independent  (Tl)  (Mond  et  al., 
1995a; Mond et al., 1995b).  TD antigens, such as proteins and peptides, are 
dependent on T cells for antibody production.  Antigen  bound  to the  B  cell 
receptor (BCR) is internalised and returned to the cell surface bound to MHC 
II  molecules which is recognised by T cell receptors (TCRs) recognising the 
MHC:peptide  complex.  The  interaction  between  CD40  on  the  B  cell  and 
CD40L on the T cell provide an essential second signal for B cell activation 
as well as for a sustained immune response including isotype switching.
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Tl antigens can be divided into two major categories: Tl type 1   (TI-1) and Tl 
type  2  (TI-2).  TI-2  antigens  are  unable  to  stimulate  B  cell  responses  in 
neonatal  mice or CBA/N  mice  (X-linked  B  cell  defect) whereas these  mice 
respond  normally  to  TI-1  antigens  and  produce  an  antibody  response 
(Amsbaugh etal., 1972).
TI-1  antigens are polyclonal  activators of B cells, as they are able to cause 
proliferation and differentiation of most B cells regardless of their specificities. 
They  can  stimulate  responses  in  both  mature  and  neonatal  B  cells.  An 
example of a TI-1  antigen  is  LPS,  which  after binding with  Lbp and  CD14 
associates with TLR4  on  B  cells  (Hoshino et ai,  1999).  TI-1  antigens are 
unable  to  induce  affinity  maturation  and  memory  B  cells,  both  requiring 
antigen-specific T cell help.
TI-2  antigens  are  predominantly  polysaccharides  that  are  large  molecular 
weight antigens  with  highly  repetitive  structures  and  a  long  half  live  when 
injected in vivo.  TI-2 antigens can only activate mature B cells, which would 
explain why infants are unable to make antibodies against polysaccharides, 
as most of their B cells are immature (Mond et ai., 1995b).  B cell activation is 
achieved by cross-linking a specific number of BCRs specific for the antigen.
1.5.2  B cell mediated immunity
Another arm of the adaptive response is via the humoral immune response, 
in which the spread of infection is prevented by the production of antibodies 
by  B  cells.  Activation  of  B  cells  into  antibody-secreting  plasma  cells  is 
triggered  by  antigen  and  generally  involves  T  cell  help.  Antibodies  can
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by binding to the pathogen in a process called neutralisation.  By binding to 
the  pathogen,  antibodies  are  able  to  encourage  opsonisation  as  well  as 
triggering complement activation.
1.5.2a Structure and assembly of antibody
Antibodies are the secreted form of the BCR constructed from paired  heavy 
and  light  polypeptide  chains.  The  variable  region  is  made  up  of  the  first 
domains  of the  heavy  and  light  chain  and  enables  the  binding  of  specific 
antigen.  There are two types of light chain, lambda (A) and kappa (k) with no 
functional  differences between them.  Immunoglobulins (Igs)  have either of 
these chains  but never one of each and the  ratio of the two types of chain 
varies between mammals.
The  class and  therefore the  effector functions of antibodies are defined  by 
the  structure  of the  heavy  chain.  They  are  denoted  by  p,  5,  y,  a,  and  e, 
representing the five main classes or isotypes: immunoglobulin M (IgM),  IgD, 
IgG,  IgA and IgE.  Some of the isotypes have several subtypes, for example 
in  the  mouse  IgG  has  subclasses  lgG1,  lgG2a,  lgG2b  and  lgG3  and  in 
humans lgG1, lgG2, lgG3 and lgG4.
1.5.2b Isotype switching
The  constant  region  of  the  heavy  chain  defines  the  class  of  Ig,  which  is 
important for determining its effector function.  Naive mature B cells express 
both  IgM  and  IgD  on  their  surface.  Upon  activation  by  antigen,  IgD 
expression is lost and the first antibody produced in an immune response is 
IgM.  Activated  B  cells  often  switch  to  express  a  different  heavy  chain
51constant region, resulting in a change of antibody class and effector function. 
Switching of antibody class is carried out by a deletional DNA recombination 
event called  switch recombination.  This occurs by looping-out and deletion 
of circular  DNA containing  the  sequences  between  short tandem  repeated 
sequences  called  switch  regions  (von  Schwedler  et  al.,  1990;  Stavnezer, 
1996).  Switch  regions  are  located  between  the  J  gene  segments  on  the 
heavy chain and the CM  gene, and at similar sites for the other heavy-chain 
isotypes, except IgD.
The class of antibody expressed  by mature B cells is influenced  by antigen 
exposure.  Signals  from  both  T  cells  and  cytokines  can  induce  isotype 
switching to TD antigens, whereas Tl antigens also respond to signals from 
cytokines and from cross-linking of surface Ig.  It has been shown that IL-4, 
TGF-(3 and IFN-y have roles in regulating isotype switching.  In both humans 
and mice IL-4 can induce IgE, additionally in humans it can induce lgG4 and 
in mice lgG1.  The addition of IFN-y to activated B cells can induce switching 
in  murine  B  cells  to  lgG2a.  In  contrast  it  inhibits  the  induction  of  IgE  by 
activated B cells plus IL-4.  Switching to IgA can be induced by the addition 
of TGF-p in activated mouse and human B cells (Stavnezer, 1996).
A study has shown a role for IL-27 in the induction of class switching.  IL-27 
is  a  member  of  the  IL-12  family  and  is  a  heterodimeric  cytokine.  It  is 
produced by activated APCs and is able to induce proliferation of naive CD4+  
T cells (Pflanz et al., 2002).  Splenic B cells were found to express functional 
IL-27R  and  activated  B  cells  stimulated with  IL-27 were  able to induce the 
expression  of  transcription  factor  T-bet  and  lgG2a,  but  not  lgG1.  Class 
switching  to  lgG2a  was  abolished  in  T-bet-deficient  B  cells  activated  with
52LPS suggesting a critical role for IL-27 in the expression of T-bet and lgG2a 
(Yoshimoto et al., 2004).
Isotype switching in  human  B cells can also be induced  by B cell-activating 
factor (BAFF)  and  A  proliferative-inducing  ligand  (APRIL),  two  members of 
the  tumour necrosis factor family  (Litinskiy et al.,  2002).  They  have  more 
recently been shown to influence isotype switching in murine B cells inducing 
lgG1, IgA and IgE (Castigli etal., 2005).
1.5.2c Functional differences
Antibodies  are  distributed  throughout  the  body  and  have  their  particular 
effector  function,  which  is  determined  by  their  isotype.  IgM  is  the  first 
antibody to be  produced  in a  humoral  immune response  because it can  be 
expressed  without  isotype  switching.  These  antibodies  tend  to  be  of  low 
affinity,  however  IgM  molecules  are  secreted  as  pentamers  and  bind 
simultaneously  to  multivalent  antigens.  Due  to  the  large  size  of  the 
pentamers,  IgM is mainly found in the blood.  It is also efficient in activating 
the  complement  system,  as  it  is  able  to  bind  multiple  epitopes  on  the 
pathogen surface.
The other isotypes -  IgG,  IgA and  IgE are smaller and therefore can  more 
easily diffuse out of blood into tissues.  IgG and IgE are always produced as 
monomers, whereas secreted  IgA can occur as either monomers or dimers. 
Dimerisation of IgA monomers is required for transport through the epithelia. 
The principle isotype found in the blood and extracellular fluid is IgG.  There 
are four human IgG subclasses: lgG1, lgG2, lgG3 and lgG4.  lgG1, lgG3 and 
lgG4 are able to cross the  placenta and therefore  have a  role in  protecting
53the  developing  foetus.  lgG3  is  the  most  efficient  at  activating  the 
complement  system,  whereas  lgG1  and  lgG3  are  able  to  mediate 
opsonisation by binding Fc receptors on phagocytic cells.
IgA  is  the  principle  isotype  found  in  secretions,  but  unlike  IgG  is  a  weak 
activator of complement and  a  less  potent opsonin  and  therefore functions 
mainly  as  a  neutralising  antibody  at  mucosal  surfaces.  Neutralising 
antibodies bind toxin molecules secreted  by bacteria.  This in turn prevents 
the  binding of the toxin to the cell and  protects the cell.  IgA is secreted  in 
breast  milk  and  is therefore  passed  from  a  mother to  her  baby  helping  to 
protect against newly encountered pathogens.
IgE is found at very low levels in the blood and extracellular fluid.  It mediates 
hypersensitivity reactions that are responsible for the symptoms of hay fever 
and  asthma  for example.  IgE  binds  to  Fc  receptors  on  the  membrane  of 
basophils and mast cells found beneath the skin and mucosa.  The basophils 
and  mast  cells  then  release  chemical  mediators  found  in  granules  when 
antigen binds the cell-associated IgE giving rise to allergic manifestations.
1.5.2d Antibody-mediated effector functions
As  described  in  section  1.4.2a,  the  classical  complement  pathway can  be 
initiated  by  antibodies  binding  to  the  complement  component  C1q.  In 
humans both IgM and IgG antibodies can bind C1q, when the antibodies are 
bound to the  surface of a  pathogen.  In  mice  IgM,  lgG2a,  lgG2b and  lgG3 
have been found to be able to fix complement (Klaus et al., 1979; Neuberger 
et al.,  1981).  This then  leads to the activation of enzymatic activity in  C1r, 
which triggers the complement cascade.
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neutrophils and trigger nonphagocytic cells such as NK cells and eosinophils 
to secrete stored mediators when Fc receptors are bound by antibody coated 
pathogens.  Fc  receptors  are  cell-surface  molecules  that  recognise  the  Fc 
portion of Igs.  Different cell types express Fc receptors for different isotype 
antibodies, therefore the antibody isotype determines which cell type will be 
engaged.  Once  the  antibody-coated  pathogen  binds  Fc  receptors  on  a 
phagocyte, the surface of the  phagocyte extends around the surface of the 
pathogen  enclosing  the  pathogen  in  a  phagosome.  This  then  fuses  with 
lysosomes to  become a  phagolysosome,  allowing  the  release of lysosomal 
enyzymes  and  toxic  nitrogen  and  oxygen-derived  products  to  destroy  the 
pathogen.
1.5.2e Natural IgM and B cells
Natural  antibodies  can  be  found  in  the  sera  of  mice  and  humans  prior  to 
infection.  They  are  generally of the  IgM  isotype,  and  can  bind  a  specific 
antigen  or pathogen  even  if the  host has  never experienced  the  pathogen. 
Natural antibodies are secreted by the B1  subset of B cells.  They are long- 
lived,  self-renewing  cells,  which  differ  from  B2  cells  by  the  way  they 
differentiate during foetal and neonatal development.  Natural antibodies are 
polyreactive  to  conserved  structures  such  as  nucleic  acids,  heat  shock 
proteins, carbohydrates and phospholipids (Kantor et al.,  1993; Hardy et al., 
1994).  Complement  activation  can  be  achieved  through  the  binding  of 
natural  IgM  to  bacteria,  demonstrating  its  importance  during  a  primary 
immune response (Boes et al.,  1998).  B1  cells can predominantly be found
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proportion  of  the  splenic  B  cell  population  in  foetal  and  neonatal  mice. 
Natural IgM has been reported to be of low antigen-binding affinity due to the 
lack of somatic mutation in the V region segment.
B1  cells and marginal zone B cells share functional characteristics, and are 
thought to  be  involved  in  immune  responses  to  Tl  antigens  (Martin  et al.,
2001).  It  has  been  recently shown  that  B1-a  cells are the  main  source  of 
natural  IgM  to  pneumococcal  CPS  and  that  B1-b  cells  are  the  major 
population producing antibodies after CPS immunisation (Haas et al., 2005).
1.5.2f Memory B cells
Immunological  memory  allows  a  more  rapid  and  effective  response  to 
pathogens that have been previously encountered.  It is thought that memory 
is sustained by long-lived antigen specific cells that were induced during the 
first contact with a pathogen and persist until the next exposure.
Memory  B  cells  are  differentiated  germinal  center  B  cells  that  were  once 
stimulated  by antigen  and  proliferated  in  the  germinal  center.  They divide 
very slowly and express surface Ig but secrete none or very little antibody.  At 
lower  doses  of  antigen,  memory  B  cells  are  able  to  produce  antibody  of 
higher affinity.
Although there is a lot of information on vaccine candidates and the role of 
antibodies  in  protection  against  meningococci,  the  mechanisms  of  natural 
immunity  is  not  clear.  It  is  thought  to  be  induced  through  prolonged  or 
intermittent colonisation at mucosal surfaces of the nasopharynx.  Davenport
56and  colleagues  (2003)  reported  that  T  cells  from  the  tonsils  are  able  to 
proliferate  in  response  to  NOMVs  and  proliferation  was  not  dependent  on 
LPS.  They also found that high proliferative responses were associated with 
NOMV-specific IgG responses, but not SBA.
Non-capsular  antigens  are  important  targets  for  vaccines  to  serogroup  B 
meningococci  due  to  poor  immunogenicity  of  the  CPS,  and  inducing 
immunity  against  a  mucosal  pathogen,  mucosal  immunisation  would  be 
sensible.
1.6  Mucosal immunity
The primary site of invasion and colonization of Nm is the nasopharynx.  Nm 
is able to adhere to the epithelial cells of the mucosa via pili and OMPs found 
on the surface of meningococci.  Several factors can lead to the invasion of 
the mucosal surface, including a change in the hydrophobicity and antigenic 
variability  of  the  cell-surface  components  involved  with  adhesion  and 
invasion.
The  upper  respiratory  tract  is  an  important  site  for  host  defence  against 
pathogens.  In mice, the nasal-associated lymphoid tissue (NALT) is thought 
to  resemble the Waldeyers’s  ring  in  humans,  having  a  cellular composition 
similar  to  that  of  Peyer’s  patches.  The  NALT  is  composed  of  two 
components, the O-NALT and the D-NALT.  The O-NALT is composed of a 
pair of organised  lymphoid  aggregates and  has been suggested to function 
as  a  mucosal  inductive  site,  and  the  D-NALT,  which  lines  the  nasal 
passages, is composed of less well organised lymphoid tissue and functions 
as  an  effector  site.  Previous  studies  have  shown  NALT  to  contain  major
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expressing the ap TCR (Liang et al., 2001; Zuercher et al., 2002).
The delivery of vaccines via a mucosal  route would  be advantageous,  as it 
would  provide  a  simple  way  of  administering  and  inducing  local  immune 
responses at the natural site of colonization and infection.  Protein vaccines 
administered i.n. do not induce strong immune responses and have therefore 
been enhanced by using mucosal adjuvants.
Recent studies of OMV vaccines administered i.n. have demonstrated that in 
both  mice  and  humans,  mucosal  and  systemic  antibody  responses  with 
substantial bactericidal activity and antigen-specific T cell responses can be 
induced  (Haneberg  et al.,  1998b;  Oftung et al.,  1999;  Guthrie  et al.,  2004). 
The  OMV  vaccines  proved  to  be  safe  and  well  tolerated  when  i.n. 
administered.
Studies  carried  out  by  Etchart  and  colleagues  (2006)  have  shown  that 
NOMVs  enhanced  mucosal  antibody responses toward  influenza  virus  and 
respiratory syncytial virus (RSV) following i.n. immunisation. In particular their 
results showed that NOMVs were able to raise long-lived serum RSV-specific 
IgG.  Although the mechanism for the NOMVs adjuvant effect has not been 
investigated,  it would  likely involve the interactions and  responses of APCs 
upon exposure to meningococcal NOMVs.
Immunisation  by the  mucosal  route  is  the  preferred  route  for a  number of 
reasons  including  the  potential  to  induce  both  systemic  and  mucosal 
immunity  and  the  elimination  of  needles.  Subunit vaccines  are  preferable 
over more complex cell- or extract-based vaccines as they may be safer and
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immunisation is dependent on the use of an appropriate adjuvant.
1.7  Adjuvants
Adjuvants are in general compounds or substances that are able to enhance 
antibody  responses  against  an  antigen,  as  well  as  being  able  to  bias  the 
immune  system  towards  either a  Th1  or Th2  immune  response  (Marciani, 
2003).  Adjuvants used in human vaccines must meet rigorous requirements 
such  as  being  non-toxic,  able  to  stimulate  strong  humoral  responses,  not 
induce autoimmunity and  be stable, therefore there are a limited  number of 
them.  Aluminium  based  adjuvants  and  MF59  are  examples  of  adjuvants 
licensed for use in humans (Alving, 2002).
Adjuvants exert their effects  by different mechanisms.  For example,  alum, 
which is an insoluble adjuvant, stays around the injection site and is released 
over  a  period  of  time  to  stimulate  APCs  (Marciani,  2003).  Jordan  et  al., 
(2004)  recently  described  how  immunisation  of  mice  with  alum  primed 
splenic  B  cells  and  caused  the  accumulation  of  a  previously  unknown 
population  of  IL-4  producing  Gr1+  cells  which  are  required  for  optimal 
antibody production.  Freund’s complete adjuvant (FCA) is a potent adjuvant 
too  toxic  for  use  in  humans  but  is  commonly  used  in  animal  research. 
However  its  use  in  animals  is  also  being  discouraged.  FCA’s  mineral  oil 
components  serve  as  an  antigen  depot  and  its  mycobacterial  cell  wall 
component  activates the  immune  system  in  a  non  antigen-specific manner 
(Billiau et al., 2001).
In the search for new adjuvants, microbial products and modifications of such 
products  have  been  studied.  A  big  proportion  of  these  have  been  TLR
59ligands,  for  instance  LPS,  a  TLR4  ligand  and  poly(l:C)  a  synthetic  double 
stranded RNA ligand for TLR3 (Lien et al., 2003).
Type  1   interferons  (IFNs) are  induced  by a  number of stimuli  such  as viral 
and  bacterial  infection.  Enhanced  antibody  responses  to  poorly
immunogenic proteins as well as immunological memory suggest type 1   IFNs 
to possess strong adjuvant properties (Le Bon et al.,  2001).  Dendritic cells 
have also been proposed as adjuvants due to their ability to capture antigens 
and  to  control  the  magnitude  of  the  immune  response  (Steinman  et  al.,
2002).
The  type  of  immune  response  can  be  determined  by  adjuvants.  A  Th2 
response  can  be  generated  by  alum  characterised  by  the  production  of 
cytokines such as IL-4 and IL-5, and lgG1  and IgE antibodies, but an absent 
CTL response. Adjuvants such as CpG  DNA are able to induce strong CTL 
responses and a more Th1  response characterised by the secretion of IFN-y, 
TNF-a and antibodies such as lgG2a (Weeratna et al., 2000).
A  large  number of infections occur at  mucosal  surfaces therefore  mucosal 
immunisation  has  been  suggested  as an  alternative  route of immunisation. 
However problems have arisen in being able to generate strong mucosal IgA 
immune  responses, which could  be important in  blocking the attachment of 
bacteria and viruses.  There are very few vaccines administered  mucosally, 
one being the oral polio vaccine.  Cholera toxin  (CT) and  E.  coll heat labile 
enterotoxin (LT) are widely used experimental mucosal adjuvants in animals. 
They have been shown to be powerful mucosal adjuvants, however they are
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using a combination of actions including enhancing antigen presentation by a 
variety of cell types and encouraging isotype switching in B cells.
As previously mentioned CpG DNA has been shown to be a strong adjuvant. 
Reports  have  been  made on the  use of CpG  DNA as a  mucosal  adjuvant. 
These  reports  have  indicated  CpG  DNA to  be  a  potent inducer of immune 
responses to Hepatitis B surface antigen (McCluskie et al.,  1998;  McCluskie 
et al.,  1999) and influenza virus (Moldoveanu et al.,  1998) when immunised 
i.n. in mice indicating CpG DNA as a promising new adjuvant,  its mechanism 
of  action  as  an  adjuvant  has  not  been  fully  resolved  but  it  has  been 
hypothesised  that  it  signals  through  TLR9  leading  to  cytokine  secretion 
(Freytag et al., 2005).
Another bacterially derived product which has been shown to induce mucosal 
and  systemic  antigen-specific  antibodies  following  i.n.  immunisation  is 
monophosphoryl lipid A (MPL) (Baldridge et al., 2000; Childers et al., 2000). 
MPL is isolated from the LPS of Salmonella Minnesota R595 and its activity 
is  associated  with  its  ability to  activate  APCs  and  signal  through  TLRs  to 
produce cytokines (Freytag et al., 2005).
The  use  of  meningococcal  OMVs  as  a  mucosal  adjuvant  has  not  been 
extensively studied,  van de Verg and colleagues (1996) demonstrated that 
OMPs  of serogroup  B  Nm  to  be  an  effective  mucosal  adjuvant for  LPS  of 
Brucella meliensis in mouse and guinea pig models, producing secretory IgA 
and IgG in the lungs and high levels of IgG in serum.
The  potential  of OMVs as a  mucosal adjuvant to inactivated  influenza virus 
was  first  shown  by  increases  in  systemic and  salivary antibody  responses
61(Haneberg  et  al.,  1998a).  It  was  then  established  that  whole  heat  and 
formalin-inactivated meningococci were also able to enhance serum IgG and 
serum and  salivary IgA responses to inactivated  influenza virus  (Berstad  et 
al.,  2000).  In  a  recent  study,  Bizanov  and  colleagues  (2005)  described 
protection  against  replication  virus  in  the  nasal  cavity  of  mice  after  i.n. 
immunisation with formalin-inactivated influenza whole virus with OMVs from 
serogroup  B  meningococci  indicating  the  effectiveness  of  bacteria-derived 
products as adjuvants.
1.8  Project Aims
NOMVs  are  known  to  induce  serum  bactericidal  antibodies  specific  for 
meningococcal  antigens  in  mice  and  humans  however the  adjuvanticity  of 
NOMVs  has  not  been  extensively  studied.  By  studying  the  adjuvant 
properties of NOMVs toward different antigens in vitro and in vivo we hope to 
establish  whether  NOMVs  are  a  safe  vaccine  with  inherent  mucosal 
adjuvanticity and to gain insights into the role of NOMVs in natural immunity 
or disease following meningococcal colonisation.
The main aims of this thesis are to investigate:
•  the adjuvanticity of NOMVs toward protein and carbohydrate antigens 
via different immunisation routes
•  the immunomodulatory properties of NOMVs
•  the  contribution  of  meningococcal  LPS  and  non-LPS  components 
towards the immunomodulatory properties of NOMVs
62•  the immunomodulatory effect of NOMVs in a mouse model of allergen 
and RSV induced airway eosinophilia
The  insights  provided  in  this  investigation  will  further  our  knowledge  of 
NOMV-induced  modulation  of  immune  responses  and  contribute  to  the 
development of new mucosal adjuvants.
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Materials and Methods
2.1  Materials
2.1.1 Antibodies
2.1.1a Antibodies used in ELISA assays
Product Conjugate Supplier Dilution Catalogue
number
Goat  anti­
mouse (y chain 
specific) IgG
Horseradish
peroxidase
Jackson
Immunoresearch
1/500 115-035-164
Goat  anti­
mouse  (p 
chain  specific) 
IgM
Horseradish
peroxidase
Jackson
Immunoresearch
1/500 115-035-020
Goat anti­
mouse IgA
Horseradish
peroxidase
SouthernBiotech 1/1000 1040-05
Goat anti­
mouse lgG1
Horseradish
peroxidase
SouthernBiotech 1/1000 1070-05
Goat anti­
mouse lgG1
Horseradish
peroxidase
SouthernBiotech 1/1000 1070-05
Goat anti­
mouse lgG2a
Horseradish
peroxidase
SouthernBiotech 1/1000 1080-05
Goat anti­
mouse lgG2b
Horseradish
peroxidase
SouthernBiotech 1/1000 1090-05
Goat anti­
mouse lgG3
Horseradish
peroxidase
SouthernBiotech 1/1000 1100-05
642.1.1b Antibodies used in flow cytometric analysis
Target molecule Isotype Conjugate Company Catalogue
number
Mouse CD11c Hamster
lgG1
PE BD Pharmingen 553802
Purified CD16/CD32 
(FcyIH/II receptor)
Rat
lgG2b
Purified BD Pharmingen 553142
Mouse CD45R/B220 Rat
lgG2a
APC BD Pharmingen 553092
Mouse CD3e Hamster
lgG1
PE BD Pharmingen 553063
Purified rat IgG!,  k 
isotype control
Rat lgG1,
K
Purified BD Pharmingen 554682
2.1.2 Immunological kits
Target Molecule Company Catalogue Number
Griess Reagent System Promega G2930
Mouse Inflammation 
Cytometric Bead Array
BD Pharmingen 552364
Mouse Th1/Th2 Cytokine 
Cytometric Bead Array
BD Pharmingen 551287
Mouse eotaxin/CCL11   ELISA 
Development kit
R&D Systems DY420
Mouse IgE ELISA set BD Pharmingen 555248
Mouse Interferon Alpha ELISA 
Kit
Biosource KMC4011
Mouse Interferon Beta ELISA 
Kit
Biosource KMC4041
Dynal Mouse B Cell Negative 
Isolation Kit
Dynal Biotech 114.21
652.1.3 Biochemical reagents
Reagent Company Catalogue number
ABTS (2,2 Azino-bis(3-
ethylbenthiazoline-6-sulfonic
acid)
Sigma A9941
Accustain Giemsa stain Sigma GS-500
Accustain Wright stain Sigma WS-16
Accutase PAA Laboratories L11-007
Acetic acid BDH 153103D
Acrylamide/bisacrylamide 30% 
(v/v) solution
Bio-rad 161-0156
Ammonium hydroxide Sigma A6899
Ammonium persulphate Bio-rad 161-0700
Betaplate scintillant Wallac SC/9200/21
Bio-safe Coomassie Stain Bio-Rad 161-0786
Bovine serum albumin Sigma A4503
Bromophenol blue Sigma B8026
Carboxyfluorescein diacetate 
succinimidyl ester (CFSE)
Molecular Probes V12883
Citric acid Sigma C0759
Dried skimmed milk Marvel Off shelf
Ethanol BDH 15338
Ethylenediaminetetraacetic 
acid (EDTA)
Sigma E5134
Formaldehyde (37% solution) Sigma F1635
Glycerol Sigma G6279
Hydrogen Peroxide Sigma H1009
lonomycin Sigma I0634
Ketamine Sigma K2753
Laemmli sample buffer Bio-Rad 161-0737
Lithium acetate dehydrate Sigma L4158
Methanol BDH 10158BG
2-Mercaptoethanol 50mM Gibco Invitrogen 31350-010
66N, N, N, N, -tetra-methyl- 
ethylenediamine (TEMED)
Bio-Rad 161-0800
Naphthylethylenediamine Sigma N9125
o-Phenylenediamine 
Dihydrochloride (OPD) tablet 
sets
Sigma P9187
Periodic acid Sigma P5463
Phenol Sigma P5566
Phorbol myristate acetate 
(PMA)
Sigma P8139
Phosphate buffered saline 
(PBS) 10x, without magnesium 
or calcium
Life Technologies 14200-067
Phosphoric acid Sigma P5811
p-Nitro-phenyl-phosphate
(pNpp)
Sigma N1891
Potassium hydroxide Sigma P5958
Sodium chloride Sigma S7653
Sodium hydroxide Sigma S8045
Sulphuric acid BDH 102761C
Tween 20 Sigma P7949
Vybrant CFDA SE Cell Tracer 
Kit
Molecular Probes V-12883
Xylazine Sigma X1251
672.1.4 Tissue culture reagents
Reagent Company Catalogue
number
Foetal bovine serum 
Lot 40G2027K
Gibco Invitrogen 10270-169
Gentamicin Life Technologies 15750-037
Penicillin/Streptomycin Gibco Invitrogen 15140-122
RBC lysing buffer Sigma R7757
RPMI 1640 (1 x) with 
Glutamax I, 25mM HEPES
Life Technologies 72400-054
Trypan blue Sigma T8154
Recombinant mouse GM- 
CSF
R&D Systems 415-ML
Recombinant murine M-CSF R&D Systems 416-ML-010
2.1.5 Plastics
Item Company Catalogue number
Beckman centrifuge bottle 
with cap (50ml)
Beckman 357001
Cell strainer 0.4uM Falcon 2340
Cell scrapers 25cm Fahrenheit 3086
24-well plates Falcon 3043
96-well immunoplates NUNC DIS-971-010P
96-well U bottomed plates Nunclon 163320
15ml round conical tubes Falcon 2096
50ml round conical tubes Falcon 2070
682.1.6 Miscellaneous
Reagent Company Catalogue Number
DNP-ficoll Biosearch
Technologies
F-1200-10
Pneumococcal cell wall 
polysaccharide
Statens Serum 
Institute
3459
Albumin from chicken egg 
white, grade VI
Sigma A2512
Type 3 purified 
pneumococcal 
polysaccharide
LGC 169-X
Type 4 purified 
pneumococcal 
polysaccharide
LGC 173-X
Type 14 purified
pneumococcal
polysaccharide
LGC 197-X
Type 19F purified
pneumococcal
polysaccharide
LGC 205-X
692.2  Methods
2.2.1  Preparation of NOMVs (supervised by Dr G Frith)
Mutant-4  N.  meningitidis  strain  44/76  was  plated  onto  BHI  agar  plates 
containing  1%  horse  serum  and  incubated  overnight at 37°C  in  a  5%  C02  
atmosphere.  Broth cultures were prepared  by scraping the bacteria off the 
plates  and  incubating  flasks  overnight  at  37°C  in  an  incubator  shaking  at 
120-140rpm. The bacteria was then harvested and centrifuged at 12,000 x g 
for 30 mins at 4°C using a Beckman centrifuge with a JA-10.500 rotor.  To kill 
any live bacteria in the supernatant, 1% phenol was added and incubated for 
1-2h.  An  aliquot  of supernatant was  plated  onto  BHI  agar  and  incubated 
overnight at 37°C,  5%  C02  to check for any remaining live bacteria.  Once 
established  there  was  no  live  bacteria,  the  culture  supernatants  were 
harvested and put through a continuous flow ultrafiltration system to prepare 
NOMVs.  Prior to use the filtration system was washed with 20% ethanol and 
water,  and  finally  autoclaved.  A  peristaltic  pump  was  used  to  feed  the 
supernatant  through  a  loop  of  plastic  tubing  which  is  connected  to  a  size 
exclusion  column  (molecular weight cut off of 500kDa),  until  approximately 
90%  of  the  media  was  removed  leaving  a  concentrated  suspension  of 
NOMVs.  The concentrated suspension was centrifuged at 12,000 x g for 20 
mins  at  4°C  (Beckman  rotor  JA-30.50)  to  remove  cell  debris.  The 
supernatant was collected and centrifuged again at 80,000 x g for 2h at 4°C 
to further concentrate the NOMVs.  The supernatant was then discarded and 
the  pellet was re-suspended  in sterile distilled water and  subjected to ultra­
centrifugation at 100,000 x g for 3h at 4°C.  The remaining pellet was then re­
suspended in Milli Q water and stored at 4°C.
702.2.2 BCA protein assay
The  protein  content  of  samples  was  measured  using  the  Micro  BCA™ 
Protein  Assay  Reagent  Kit  (Pierce  Chemical  Company).  The  assay  was 
carried out according to manufacturer’s instructions using the microwell plate 
protocol.  Briefly,  a  standard  curve  was  produced  using  bovine  serum 
albumin  (BSA)  diluted  in  running  buffer.  The  samples  were  diluted,  in 
duplicate at appropriate concentrations, to which working reagent was added 
to the samples and the standards.  The plate was then  incubated for 2h at 
37°C,  after which the optical density was read at 562nm on a  plate  reader 
[Spectra  MAX  340  (Molecular  Devices)].  Using  the  standard  curve,  the 
protein concentration of the samples was determined.
2.2.3 Characterisation of humoral responses 
2.2.3a Protocol for model antigen immunisations 
Mice
Female or male C57BI/6 and Balb/c mice were obtained from Charles River, 
UK  (Margate,  Kent,  UK)  or the  SPF  unit of the  Institute for Animal  Health, 
Compton.  The  animals were  kept  under specific pathogen  free  conditions 
and the mice were used between 6-10 weeks of age.
Intranasal protocol
Before  i.n.  immunisation,  mice  were  anaesthetised  by  administering  i.p. 
150pl of ketamine/xylazine mixture (90mg/ml ketamine and 20mg/ml xylazine 
in PBS, diluted  1   in  10 in PBS before use).  Once anaesthetised, mice were 
held  with  their  heads  tilted  back  and  50pl  of sample was  placed  onto  the
71entrance  of  the  nasal  passage  by  using  a  Gilson  P20  pipetter.  After 
immunisation  the  mice  were  placed  on  their  sides  in  their  cages  and  hot 
lamps were placed over them until they regained consciousness.
Immunisations
Groups  of  mice  were  immunised  either  by  the  intraperitoneal  (i.p.)  or  i.n. 
route with the model protein antigen Ovalbumin  (Ova) or the T-independent 
type II antigen DNP-ficoll, in the presence or absence of NOMVs.  Ova was 
used at a dose of 0.5mg and DNP-ficoll at 5pg in a 500pl or 50pl volume of 
sterile  PBS  when  immunised  i.p.  or  i.n.,  respectively.  Control  mice  were 
given  PBS  only.  The  schedule  for  immunisations  and  blood  sampling  is 
shown in figure 2.1.
2.2.3b Protocol for S. pneumoniae CPS immunisations 
Mice
Female or male C57BI/6 and Balb/c mice were obtained from either Charles 
River,  UK  (Margate,  Kent,  UK)  or the  SPF  unit  of the  Institute  for Animal 
Health,  Compton.  The  animals  were  kept  under  specific  pathogen  free 
conditions and the mice were used between 6-10 weeks of age.
Immunisations
Groups  of  mice  were  immunised  either  by  the  i.p.  or  i.n.  route  with 
pneumococcal CPSs (capsular serotypes 3, 4, 14 and 19F) obtained from the 
Statens Serum Institute, Copenhagen, Denmark in the presence or absence
72of NOMVs.  A range of doses of CPSs were used  (5-20|jg per mouse) in a 
500pl or 50pl volume of sterile PBS when immunised i.p. or i.n., respectively. 
Control  mice  were  given  PBS  only.  The  schedule  for  immunisations  and 
blood sampling is shown in figures 2.1  and 2.2.
2.2.3c Preparation of mouse serum
Mice were bled from either the tail vein or the chest cavity.  Blood was left for 
1h  at  room  temperature  and  left  overnight  at 4°C.  To  clarify  serum  from 
coagulated  blood,  samples were  centrifuged  at  14,000rpm for 20 mins in  a 
Beckman  microfuge.  Serum was then  removed and  placed  into new tubes 
and stored at -18°C until required.
2.2.4d Characterisation of serum antibody responses to NOMVs by 
ELISA
Immunoplates  were  coated  overnight  with  100pl/well  of 4pg/ml  NOMVs  in 
50mM  sodium  carbonate-bicarbonate  buffer,  pH  9.6  and  incubated  at 4°C. 
Plates were washed with PBS + 0.05% Tween 20 (PBS-T) and were blocked 
for 1h with  150pl of PBS + 0.5% BSA.  Plates were then washed again and 
sera were serially diluted starting at a 1   in 50 dilution, and 50pl was added to 
duplicate wells and incubated at room temperature for 2h in a moist box.  The 
plates  were  washed  again,  and  50pl/well  of  either  peroxidase-conjugated 
affinipure  goat  anti-mouse  IgM  or  peroxidase-conjugated  goat  anti-mouse 
IgG  (subclasses  1+2a+2b+3)  (Jackson  ImmunoResearch,  Inc.)  diluted  1   in 
500 in PBS-T were added to the plates and incubated for a further 2h at room
73Day 0
I.p. immunisation with 
antigen ± NOMV in 500ul 
PBS (control PBS only)
or
Day 0
I.n. immunisation with 
antigen ± NOMV in 50ul 
PBS (control PBS only)
Day 7
I.n. immunisation with 
antigen ± NOMV in 50ul 
PBS (control PBS only)
Day 14
I.n. immunisation with 
antigen ± NOMV in 50ul 
PBS (control PBS only)
Day 21
Terminal Bleed for 
both i.p. and i.n. 
immunisations
Figure  2.1  Schedule  for  i.p.  and  i.n.  immunisation  of  mice  with  model 
antigens  or  S.  pneumoniae  CPSs  with  or  without  NOMV  and  serum 
collectionDay 0
I.p. immunisation with 
CPS ± NOMV or NOMV 
in 500ul PBS (control 
PBS only)
Day 62
I.p. immunisation with CPS 
± NOMV or NOMV in 500ul 
PBS (control PBS only)
Day 21 Day 60 Day 67
Tail Bleed Tail Bleed Terminal Bleed
Figure 2.2 Schedule for immunisation  and serum  collection  of mice with 
S.  pneumoniae  CPSs  with  or  without  NOMV  for  memory  and  boosting 
effecttemperature.  The plates were washed again and 50pl/well of the substrate 
solution  o-phenylenediamine  dihydrochloride  [OPD  (a  horseradish 
peroxidase substrate, Sigma)] was added.  The reactions were stopped with 
15pl/well of 3M H2S04.  Optical densities were then read at 490nm on a plate 
reader.
2.2.3e  Characterisation  of  serum  antibody  responses  to  model 
antigens by ELISA.
Immunoplates were coated overnight with 50pl/well of 40pg/ml Ova in ELISA 
coating buffer pH 9.6 or 10pg/ml DNP-ficoll in 0.9% (w/v) NaCI and sealed in 
parafilm before incubation in a moist box at 37°C.  Plates were then washed 
three times with PBS-T,  and were blocked for 1h with  100pl of PBS-T + 4% 
dried skimmed milk.  Plates were then washed and sera were serially diluted 
starting  at  a  1   in  50  dilution,  and  50pl  was  added  to  duplicate  wells  and 
incubated  at  room  temperature  for  2h  in  a  moist  box.  The  plates  were 
washed again,  and 50pl/well of either peroxidase-conjugated affinipure goat 
anti-mouse  IgM  or peroxidase-conjugated goat anti-mouse  IgG  (subclasses 
1+2a+2b+3) (Jackson ImmunoResearch, Inc.) diluted 1   in 500 in PBS-T were 
added to the plates and incubated for a further 2h at room temperature.  The 
plates were washed  again  and 50pl/well of the substrate solution  OPD was 
added.  The  reactions  were  stopped  with  15pl/well  of 3M  H2S04.  Optical 
densities were then read at 490nm on a plate reader.
762.2.3f Characterisation of serum antibody responses to S. pneumoniae 
CPSs by ELISA.
Pneumococcal C polysaccharide or cell wall polysaccharide (CW-PS), which 
resides  in  the  pneumococcal  cell  wall  can  be  found  in  the  purified 
pneumococcal  CPSs.  Sera  were  preabsorbed  with  CW-PS  to  remove 
antibodies  to  the  cell  wall  polysaccharide  when  testing  for  antibodies  to 
pneumococcal  CPS  antigens  (Aaberge  et  al.,  1993).  Mouse  sera  were 
absorbed  with  100pg/ml  CW-PS  (Statens  Serum  Institute,  Copenhagen, 
Denmark) for 1h at room temperature, at a 1   in 100 serum dilution in PBS-T, 
prior to further dilution in buffer without CW-PS.
Immunoplates  were  coated  overnight with  50pl/well  of  CPS  at  10pg/ml  in 
0.9%  (w/v)  NaCI  and  sealed  in  parafilm  before  incubation  in  a  moist  box 
overnight at 37°C.  Plates were then washed three times, and in some cases 
plates  were  blocked  for  1h  with  100pl  of  PBS-T  +  4%  milk.  The  CW-PS 
absorbed sera were serially diluted starting at 1   in 50, and 50pl was added to 
duplicate wells and incubated at room temperature for 2h in a moist box.  The 
plates  were  washed  again,  and  50pl/well  of  either  peroxidase-conjugated 
affinipure  goat  anti-mouse  IgM  or  peroxidase-conjugated  goat  anti-mouse 
IgG  (subclasses  1+2a+2b+3)  (Jackson  ImmunoResearch,  Inc.)  diluted  1   in 
500 in PBS-T were added to the plates and incubated for a further 2h at room 
temperature.  The  plates  were  washed  again  and  50pl/well  of  substrate 
solution OPD was added.  The reactions were stopped with  15pl/well of 3M 
H2SO4.  Optical densities were then read at 490nm on a plate reader.
772.2.4  In vitro cell assays 
Mice
Female or male C3H/HeN (H-2k) and C3H/HeJ [LPS hyporesponsive (H-2k)] 
mice were obtained from  Harlan  UK Limited  (Blackthorn,  UK).  The animals 
were kept under specific pathogen free conditions and the mice were used 
between 6-12 weeks of age.
2.2.4a Cell proliferation assay using 3H-thymidine
Spleens from  naive  mice were  removed  aseptically and  placed  into  RPMI. 
Using the barrel of a 5ml syringe, a single cell suspension was produced by 
pushing the spleen through  a cell  strainer (40pm)  into a  50ml  Falcon tube. 
The cells were then centrifuged (Sorvall RT7 plus) for 5 mins at 1,000rpm at 
4°C.  After centrifugation, the supernatant was poured off and the red blood 
cells  were  lysed  with  red  blood  cell  lysis  buffer.  Approximately  40ml 
complete  RPMI  [c.  RPMI  (RPMI  1640  with  1%  penicillin/streptomycin  and 
10%  FCS)]  was  added  to  the  cells  and  the  cells  were  washed  by 
centrifugation as above.  The cells were then re-suspended  in  5ml c.RPMI, 
and a cell count was performed.  Cells were then re-suspended to a density 
of 2 x 106  cells/ml and  100pl of the cell suspension was added to wells of a 
sterile 96 U-bottomed well plate.  The cells were stimulated with 100pl of the 
test  samples  diluted  in  c.RPMI  and  added  in  triplicate.  Phorbol  myristate 
acetate (PMA) at 5pg/ml and ionomycin (200ng/ml) were used as a positive 
control,  whereas  medium  alone  was  used  as  a  negative  control  of  cell 
proliferation.  The  cells  were  then  incubated  at  37°C,  5%  CO2  for  48h. 
Tritiated  thymidine  (1pCi  in  20pl  c.RPMI)  (Amersham  Pharmacia  Biotech)
78was  then  added  to  each  well  and  incubated  overnight.  The  plates  were 
harvested  using  a  TOMTEC  96-well  harvester.  The filters were  dried  and 
sealed in a plastic bag with Betaplate scintillant.  Incorporated thymidine was 
measured using a MicroBeta TRILUX counter (Wallac, Turku, Finland).
2.2.4b CFSE labelling of mouse splenocytes
Spleens  were  aseptically  removed  from  mice  and  placed  in  PBS  as 
previously  described.  The  cells  were  prepared  as  described  in  the 
proliferation assay and re-suspended at 1x107  cells/ml in PBS + 0.01% BSA. 
A  5mM  stock  solution  of  carboxyfluorescein  diacetate  succinimidyl  ester 
(CFSE) in DMSO was added to the cells at a final concentration of 5pM and 
incubated at 37°C for 5 mins.  After incubation, the cells were washed three 
times with cold PBS + 5% FCS.  The cells were then re-suspended in c.RPMI 
and counted.
2.2.4c Negative isolation of mouse B cells
B  cell  proliferation was  measured  using  the  Dynal® Mouse  B  cell  Negative 
Isolation  Kit  (Dynal  Biotech)  and  CFSE  labelling  as  described  above.  The 
assay  was  carried  out  according  to  the  manufacturer’s  instructions  (Dynal 
Biotech).  Briefly,  spleens  from  naive  mice  were  aseptically  removed  and 
placed in c.RPMI.  Using the barrel of a 5ml syringe, a single cell suspension 
was  produced  by  pushing  the  spleen  through  a  cell  strainer (40pm)  into  a 
50ml  Falcon  tube.  The  cells  were  then  placed  in  cold  c.RPMI  and 
centrifuged  for  10  mins  at  1,000rpm  at  4°C.  After  centrifugation,  the
79supernatant was poured off and the red blood cells were lysed with red blood 
cell  lysis  buffer.  Approximately 40ml  RPMI  with  1%  penicillin/streptomycin 
and  1%  FCS  was  added  to  the  cells  and  the  cells  were  washed  by 
centrifugation as above.  The supernatant was again poured off and the cells 
were re-suspended to a density of 1   x 108  cells/ml in PBS/0.1% BSA.  To the 
desired number of cells (1  x 107  per 100pl), 20pl of heat inactivated FCS and 
20pl of antibody mix was added and incubated for 20 mins at 4°C.  The cells 
were then washed in PBS/0.1% BSA and centrifuged for 8 mins at 1,000rpm 
at 4°C.  After centrifugation the cells were  re-suspended  in  PBS/0.1%  BSA 
and pre-washed Mouse Depletion Dynabeads were added and incubated for 
15  mins  at  room  temperature  with  gentle  tilting  and  rotation.  The  bead- 
captured  cells  were  then  gently  re-suspended  by  pipetting  and  PBS/0.1 % 
BSA was added to the cells.  The tube was then  placed  in a  magnet for 2 
mins  and  the  supernatant  containing  the  negatively  isolated  B  cells  was 
transferred to a new tube.
2.2.4d Bone marrow derived macrophages
Mice  were  culled  by  increasing  concentrations  of carbon  dioxide  and  hind 
limbs were  removed  into sterile  PBS.  Excess fat and tissue were removed 
after which the ends of the bones were cut off.  Bone marrow was isolated by 
flushing the bone with c.RPMI using a 5ml syringe (Terumo) and 25G needle 
(Kendall).  The bone marrow was then transferred to a 50ml Falcon tube and 
a single cell suspension was made by pipetting.  The cell suspension was left 
to  stand  for  5  mins  to  allow  debris  to  settle  and  the  supernatant  was 
harvested  and centrifuged for 5 mins at  1,500rpm.  The pellet was then  re­
80suspended in 10ml c.RPMI with 10ng/ml rmM-CSF (R&D Systems) and a cell 
count performed.  Aliquots of 1-3 x  107  cells were placed  into 75cm3  tissue 
culture  flasks  and  incubated  at  37°C  and  5%  C02   for  16h.  Following 
incubation, the non-adherent cells were transferred into two 75cm3  flasks and 
15ml c.RPMI with  10ng/ml rmM-CSF added.  The flasks were incubated for 
two weeks,  with  a further  10ml  c.RPMI  with  10ng/ml  rM-CSF  added  every 
three days until the cells were harvested.
2.2.4e Bone marrow derived dendritic cells
Hind  limbs  were  prepared  as  mentioned  in  section  2.2.4c.  The  red  blood 
cells were then lysed with red blood cell lysis buffer for approximately 4 mins, 
after which 40ml c.RPMI was added.  The cells were again centrifuged, and 
the  pellet was  re-suspended  in  10ml  c.RPMI.  A cell  count was  performed 
and 2 x 106  cells/10ml were put into Petri dishes (non culture treated, Falcon) 
in  the  presence  of  20ng/ml  rmGM-CSF  (R&D  Systems)  and  incubated  at 
37°C,  5%  C02.  On day three,  10ml of 20ng/ml  rmGM-CSF  in  c.RPMI was 
added to each dish.  On day six,  10ml of medium was taken from each dish, 
spun  down  and  re-suspended  in  fresh  medium  containing  10ng/ml  rmGM- 
CSF.  The cells were then incubated for a further two days, and then the cells 
were  harvested.  The  non  adherent  cells  were  collected  by  pipetting  the 
medium from the plate, and the adherent cells were collected by adding 2ml 
Accutase per dish and  incubating for 15 mins at 37°C, then  being collected 
using a 1ml pipette.
812.2.4f Cytokine release assay
Mouse  splenocytes  were  prepared  and  stimulated  following  the  same 
protocol for thymidine proliferation assays.  Samples were tested in duplicate 
and supernatant was harvested after 18h, 24h and 48h.  Supernatants were 
stored at -18°C until used for cytokine analysis.
2.2.4g Griess Assay
Nitric  oxide  (NO)  production  was  measured  using  the  Griess  Reagent 
System (Promega), which measures nitrite, a breakdown product of NO.  The 
assay was carried out according to the manufacturer’s instructions.  Briefly, a 
nitrite  standard  reference  curve  was  produced  using  the  nitrite  solution 
provided.  The  samples  were  added  to  the  plate  in  duplicate,  and 
sulfanilamide solution was added to both the standards and the samples and 
incubated  in the dark,  at room temperature for 5 mins.  After this time N-1- 
napthylethylenediamine  dihydrochloride  (NED) was  added  to the  plate  and 
incubated for a further 5 mins.  The optical density was then measured within 
30 mins at 520nm on a plate reader.
2.2.4h Cytokine Cytometric Bead Array (CBA) assay
Cytokines  present in  the  supernatants from  stimulated  mouse  splenocytes, 
BMDCs,  and  lung  fragment  cultures  were  measured  using  the  mouse 
inflammation and Th1/Th2 cytokine bead array (CBA) kits (BD  Biosciences, 
Pharmingen).  The mouse inflammation CBA kit was used to detect IL-12p70, 
TNF-a, IFN-y, MCP-1, IL-10 and IL-6, and the mouse Th1/Th2 kit to measure
82IL-2,  IL-4,  IL-5,  IFN-y and TNF-a.  The assay was carried  out according to 
manufacturer’s  instructions.  Samples  were  examined  by  flow  cytometry 
using  a  FACScalibur  flow  cytometry.  Data  was  analysed  using  BD  CBA 
software (BD Biosciences, Pharmingen).
2.2.5  Allergen-induced eosinophilia model 
Ova mouse model
Female C57BI/6 mice aged 6-8 weeks were given two-weekly i.p.  injections 
of 0.1 mg Ova (Sigma) in 500pl PBS.  Seven days after the last i.p. injection, 
sensitised  mice  were  anaesthetised  by  administering  150pl  of 
xylazine/ketamine  mixture  i.p.  (90mg/ml  ketamine  and  20mg/ml  xylazine  in 
PBS, diluted  1:10 in PBS before use) and immunised i.n. with 50pl of either 
PBS, 0.1 mg OVA, 5pg NOMV or 0.1 mg OVA + 5pg NOMV.  After a further 7 
days,  mice  were  culled  by  administration  of  a  fatal  dose  of  avertin,  and 
bronchoalveolar lavage (BAL) fluid, lungs and sera were harvested.  A further 
i.n. challenge of 0.1 mg OVA was given to some mice 7 days after the last i.n. 
immunisation.  These  mice were then culled  7 days after the challenge,  as 
described  above.  The  BAL  was  collected  as  briefly described.  After the 
administration  of  avertin,  the  thoracic  cavity  was  opened  by  careful 
dissection.  The trachea was then exposed, and a small transverse incision 
was  made.  BAL  was  then  carried  out  using  three  doses  of 0.8ml  PBS  +
0.1%  BSA, and the samples were stored individually on ice until processing. 
The cells were then centrifuged at 1000rpm for 5 mins, and the supernatant 
was removed.  The cells were then counted and re-suspended to a density of 
1   x  106   cells/ml.  BAL  eosinophils  and  other  inflammatory  cells  were
83enumerated by differential counts following cytospin preparations and Wright- 
Geimsa  staining.  The  percentage  cell  type was  calculated  by determining 
the number of different cell types in fifteen high-powered fields and dividing 
this number by the total  number of cells.  To obtain the absolute number of 
each cell type in the BAL fluid, the percentages were multiplied  by the total 
number of cells recovered from the BAL fluid.  The lungs were stored in PBS 
and  frozen  immediately  on  dry  ice  until  needed  for  measurement  of 
cytokines.  Serum was prepared as previously described.  See figure 2.3 for 
immunisation schedule.
Respiratory syncytial virus mouse model
Female  C57BI/6  mice  aged  6-8  weeks were  given  an  intramuscular  (i.m.) 
injection of 50pl (3-propiolactone-inactivated RSV (iRSV).  Control mice were 
given  PBS  only.  Two weeks  later,  mice were  anaesthetised  as  described 
above and immunised i.n. with 50pl of iRSV with or without 5pg NOMVs once 
a week for either one or three weeks.  After a further 2 weeks,  mice were 
intranasally challenged with live RSV.  After a further 7 days, the mice were 
culled  and  samples  were  harvested  as  above.  See  figure  2.4  for 
immunisation schedule
2.2.6  Statistics
Data  were  analysed  using  software  packages  Microsoft  Excel  2002  and 
Minitab  13  for  windows.  Statistical  analysis  was  performed  according  to 
directions  given  by  the  University  of  Reading  Statistical  Services  Centre. 
Statistical  significance  between  two  independent  groups  was  performed
84using a 2-test t-test whereas multiple groups were analysed using a General 
Linear Model ANOVA.
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Figure 2.4 Schedule for immunisation of mice for iRSV-induced eosinophilia model 
and BAL fluid, lung and serum collection of miceCHAPTER 3
The adjuvant properties of natural outer membrane vesicles 
from N. meningitidis serogroup B
3.1  Introduction
There  is  considerable  interest  in  identifying  adjuvant  candidates  suitable  for 
human  vaccines  because  of  the  generally  poor  immunogenicity  of  purified 
subunit vaccines  and  of the  lack of adjuvants  approved  for human  use.  Alum 
has until recently been the only one adjuvant used with human vaccines due its 
safety  record  and  its  proven  ability  to  enhance  humoral  responses  to  protein 
antigens and glycoconjugates.  However there is a dire need for adjuvants that 
can enhance T cell responses and ones that can be applied via mucosal routes. 
We are interested  in the adjuvant properties of NOMVs not only because it is a 
potential  mucosal  adjuvant candidate for human vaccines  but also  because  its 
role  in the establishment of natural  immunity to  meningococcal  infection  is  not 
clear.
It has been established that NOMVs possess adjuvant properties, and  modified 
forms  of  NOMVs  have  been  applied  as  an  adjuvant  in  approved  and 
experimental  vaccines.  One  of the  first  clinical  uses  of  meningococcal  outer 
membrane components was  in  the vaccine for Haemophilus influenzae type  b 
(Hib).  The outer membrane  protein  complex  (OMPC) of Nm  serogroup  B wasused to enhance antibody responses to the  CPS,  polyribosylphosphate (PRP). 
OMPC  was  covalently  attached  to  PRP  providing  a  classical  protein  carrier 
effect  in  eliciting  T  cell  help  to  the  polysaccharide-specific  B  cell  response. 
Although the reason for the OMPC adjuvant effect was not investigated in detail, 
it was shown that OMPC has mitogenic activity (Donnelly et a/.,  1990; Liu et al., 
1992).  It was later demonstrated that OMPC enhanced IgG antibody production 
to PRP in Balb/c and  C3H/HeJ  mice as well as the expression of costimulatory 
molecules, CD86, CD80 and CD40 on purified human B cells.  The production of 
IFN-y and TNF-a by human  blood mononuclear cells after stimulation of OMPC 
was also established (Perez-Melgosa et al., 2001).  Therefore OMPC enhances 
anti-PRP antibody responses by stimulating innate cells as well as lymphocytes. 
It  has  recently  been  shown  that  Hib-OMPC  conjugate  vaccines  binds  human 
TLR2 expressed on  human  embryonic kidney (HEK cells) and  mouse TLR2 on 
BMDCs.  Binding was shown to be MyD88 dependent as the production of TNF- 
a was abolished in MyD88 knockout mice (Latz et al., 2004).
A more recent application of meningococcal components is the use of very small 
size proteoliposomes (VSSPs) to enhance immune responses toward tumours. 
VSSPs  are different from  NOMVs  in  the  preparation  method  that  includes the 
incorporation  of  gangliosides,  sialylated  glycosphingolipids,  from  the  plasma 
membrane of mammalian cells (Estevez et al.,  1999).  Despite the high content 
of LPS, the safety and  immunogenicity of VSSPs  have been shown  in  phase  I 
trials  in  melanoma  and  cancer patients  (Carr et al.,  2003).  VSSPs  have  been
89shown  to  induce  strong  antibody  responses  to  a  model  protein  antigen  (Ova), 
and  to  increase the  expression  of costimulatory  molecules  on  murine  BMDCs 
and human moDC grown in vitro.  Upregulation of maturation markers were also 
found  on  DCs  from  C3H/HeJ  mice  indicating  that VSSPs  are  composed  of a 
variety  of  PAMPs,  which  can  bind  TLR4  as  well  as  other  TLRs  or  non-TLR 
receptors.  Since  the  start  of this  thesis  investigation,  T  cells  have  also  been 
shown  to  proliferate  and  to  secrete  IFN-y  upon  stimulation  with  VSSPs  in  the 
presence  of  Ova  (Mesa  et  al.,  2004).  From  these  studies,  it  is  clear  that 
modified  NOMVs have strong  B and T cell stimulating activities.  However,  it is 
uncertain whether VSSPs and NOMVs have identical adjuvant properties.
Since NOMVs are a natural  product produced by shedding of membrane ‘blebs’ 
from meningococci during colonisation of the human nasopharynx, a few studies 
have  investigated  its  use  as  a  mucosal  adjuvant.  Meningococcal  OMPs  of 
serogroup  B  induced  strong  antibody  responses  toward  LPS  of  Brucella 
melitensis  in  a  mouse  and  guinea  pig  i.n.  immunisation  model.  OMPs  were 
effective  in  enhancing  secretory IgA and  IgG  responses  in the  lungs,  and  high 
serum  IgG  levels  of predominantly  lgG1  subclass  (Van  De Verg  et al.,  1996). 
More  recent  studies  investigated  the  use  of  meningococci  and  NOMVs  as  a 
mucosal  adjuvant to  boost  immune  responses  to the  influenza  virus.  Results 
showed that after four weekly i.n. doses of virus plus whole killed meningococci, 
serum  IgG  and  IgA  and  salivary  IgA  responses  to the  virus  were  significantly 
increased  in  comparison  to  immunisation  with  the  virus  alone  (Berstad  et  al.,
902000).  Furthermore, a recent study showed that replication of influenza virus in 
the  nasal  cavity could  be  prevented  by  i.n.  immunisation  of mice with  NOMVs 
and  inactivated  influenza  virus  (Bizanov  et  al.,  2005).  The  specificity  of the 
antibody  response  was  not  determined,  but  it  is  clear from  these  studies  that 
OMPs  or  NOMVs  have  effective  mucosal  adjuvants  for  bacterial  and  viral 
antigens.
With  respect  to  meningococcal  disease,  i.n.  administered  NOMVs  have  been 
shown  to  be  immunogenic  and  induce  strong  systemic  bactericidal  antibody 
responses that are  similar to those  after i.p.  immunisation  as  well  as  inducing 
IgA responses in the lung (Saunders et al.,  1999).  A further study by Dalseg et 
al.,  (1999)  also demonstrated  enhanced  serum  IgG  levels  and  NOMV-specific 
IgA  in  saliva  in  a  dose-dependent  manner after four weekly  immunisations  of 
NOMVs via the mucosal  route  in the absence of the mucosal  adjuvant cholera 
toxin.  More importantly, despite the presence of LPS, NOMVs appear to be safe 
and  immunogenic when  immunised  i.n.  in  humans (Drabick, 2000;  Katial  et al., 
2002).  These  studies  demonstrated  that after three  i.n.  doses  of NOMVs  low 
titres of long lasting bactericidal antibodies, cross-reactive against other group B 
strains  were  induced.  Recently  the  same  group  demonstrated  that  rabbits 
immunised  i.n.  with  NOMVs  developed  substantial  levels of serum  bactericidal 
antibodies to a wide range of antigens.  They also observed mucosal responses 
characterised  by  IgA  in  saliva,  nasal  washes  and  lung  lavages,  indicating  that
91the rabbit model could  be useful for testing  NOMV vaccines (Shoemaker et al., 
2005).
It  has  been  suggested  that  i.n.  immunisation  of  NOMVs  could  provide  an 
effective way of inducing  both  mucosal  and  systemic  immunity  and  studies  in 
mice and  humans  as described  above support this theory.  The  importance  of 
antibody responses to CPSs in protection against serious human infections with 
extracellular bacteria  prompted  us to  investigate the  effect of i.n.  administered 
NOMVs on  humoral  responses toward Tl  antigens.  CPSs from  Streptococcus 
pneumoniae  were  selected  for  our  studies  for  the  following  reasons:  (1)  S. 
pneumoniae is  responsible for the  morbidity and  mortality of millions of people 
each  year  as  it  is  a  major  cause  of  pneumonia,  meningitis  and  bacteremia, 
affecting  the  young,  the  elderly  and  immunocompromised  individuals;  (2)  like 
Nm  it  colonises  the  nasopharynx,  and  prevention  of  pneumococcal  disease 
requires systemic and  mucosal  immune responses; and (3) the major virulence 
factor is the CPS, and anti-CPS antibodies correlate with protection.
CPSs  from  S.  pneumoniae  have  been  characterised  extensively.  They  are 
made up of units of repeating oligosaccharides (AlonsoDeVelasco et al.,  1995). 
Differences in the polysaccharide structure of CPSs account for the 90 different 
pneumococcal serotypes,  however most invasive disease is associated with  11 
serotypes.  Pneumococcal CPSs are classified as Tl antigens due to their ability 
to elicit antibody responses in nude mice (Mosier et al.,  1982; van de Wijgert et 
al.,  1991).  They are further classified  as type 2 Tl  antigens  (TI-2) due to their
92inability to induce antibody responses in CBA/N  mice (Amsbaugh  et al.,  1972). 
TI-2  antigens  are  poorly  metabolised,  their responses  are age  dependent  and 
characterised by limited isotype switching, low affinity antibodies and the inability 
to  generate  memory  (Mosier  et  al.,  1982).  A  23-valent  pneumococcal  CPS 
vaccine is currently licensed.  It is effective in  most adults,  however it is  poorly 
immunogenic in children under 18 months of age and therefore does not provide 
protection  against  infection.  To combat the  problem,  TD  protein  carriers were 
conjugated  to  the  CPSs,  resulting  in  the  recently  licensed  heptavalent 
pneumococcal  conjugate  vaccine  (Butler  et  al.,  1995;  Rennels  et  al.,  1998). 
These  have  proved  successful  as  shown  by  a  decline  in  the  rate  of  invasive 
pneumococcal  disease  in  children  due  to  serotypes  included  in  the  conjugate 
vaccine.  There  are  nevertheless  concerns  that  other  serotypes  will  become 
more  prevalent and  of the difficulties of manufacturing  conjugate vaccines that 
provide  coverage  for  all  disease-causing  serotypes.  Conjugate  vaccines  are 
also  unaffordable  to  populations  in  the  developing  world  where  the  burden  is 
highest.  Adjuvants that are able to improve anti-CPS antibody responses would 
provide further options against S. pneumoniae and other encapsulated bacterial 
pathogens.
3.2  Objectives
The aim of the work described in this chapter was to investigate the adjuvanticity 
of  NOMVs  by  using  model  TD  and  Tl  antigens  including  four  variably
93immunogenic  CPSs  from  S.  pneumoniae,  which  are  clinically  relevant  TI-2 
antigens.
3.3  Results
3.3.1 The humoral response to NOMVs in mice immunised i.p. and i.n.
To  investigate whether NOMVs  could  act as  an  adjuvant to different antigens, 
initial  experiments  were  carried  out  to  assess  the  serum  IgM,  IgG  and  IgA 
antibody  response  to  NOMVs  in  C57BI/6  and  Balb/c  mice.  Previous  studies 
have shown that NOMVs  immunised  both  i.p.  and  i.n.  generate  NOMV-specific 
antibodies  but  it  is  not  known  whether or  not  NOMVs  act  as  an  adjuvant  for 
different types of antigens.  For all  experiments,  unless stated  otherwise,  mice 
were  immunised  with  5pg  NOMVs  regardless  of  immunisation  route.  Mice 
immunised  by the  i.p.  route were  bled  21  days  post  immunisation  and  serum 
was collected.  Mice immunised  by the i.n.  route were immunised once a week 
for three consecutive weeks and serum was collected seven days after the final 
immunisation.  The  antibody  response to  NOMVs was  assessed  by  ELISA  as 
described in section 2.2.4d.
3.3.1.1  Serum  antibody  responses  to  NOMVs  in  C57BI/6  and  Balb/c  mice 
after i.p. immunisation
Figure 3.1  shows the serum IgM, total IgG and IgG subclass response to NOMV 
antigens in C57BI/6 mice immunised i.p. with NOMVs or PBS.  IgM levels were
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Figure 3.1  A comparison  of serum  antibody responses to  NOMVs 
in C57BI/6 mice after i.p. immunisation.
Groups of four C57BI/6  mice were  immunised  i.p.  with  PBS  or 5pg  of 
NOMVs.  Mice were  bled  21  days after immunisation,  and  serum was 
analysed for (A)  IgM  and  (B) total  IgG  and  IgG  subclasses  by  ELISA. 
IgM  was  detected  in  serum  of  individual  mice  (1  in  400  dilution)  with 
goat anti-mouse  IgM  HRP conjugate and  IgG was detected  (1  in  1,600 
dilution) with goat anti-mouse  IgG,  lgG1,  lgG2a,  lgG2b and  lgG3  HRP 
conjugates.  OPD  was  used  as  a  substrate.  Individual  mice  are 
indicated  by  (•)  and  the  mean  as  (—).  These  data  are the  means  of 
duplicate  wells  from  one  representative  study  out  of two.  Significant 
differences are indicated as ** p < 0.015.significantly  higher in  serum from  NOMV  immunised  mice than  in  PBS  control 
mice.  This  was  also  true  for  the  total  IgG  response.  Mice  immunised  with 
NOMVs  predominantly  produced  the  IgG  subclass  lgG2b  and  lower  levels  of 
lgG2a.
Comparable experiments were  also carried  out  in  Balb/c  mice  (figure 3.2)  and 
results  were  similar  to  those  in  C57BI/6  mice.  However  lgG2b  levels  were 
approximately half the level of those in C57BI/6 mice, but still significantly higher 
than in PBS immunised mice.
3.3.1.2  Serum  antibody  responses  to  NOMVs  in  C57BI/6  and  Balb/c  mice 
after i.n. immunisation
The  NOMV-specific  antibody  responses  after  i.n  immunisation  were  then 
assessed.  Figure  3.3A  shows that  C57BI/6  mice  immunised  i.n.  with  NOMVs 
have significantly higher levels of IgM than those of mice  immunised with  PBS 
alone.  Similar results were also found  in Balb/c mice (figure 3.4A).  The levels 
of total  IgG  (figure 3.3B  and  3.4B) were consistently and  significantly higher in 
both C57BI/6 and  Balb/c mice that received  NOMVs compared to control  mice. 
As with the  mice immunised  i.p.,  lgG2b was the subclass  predominantly found 
after i.n. immunisation with NOMVs.  Absorbance levels for lgG2b were lower in 
Balb/c mice than C57BI/6, indicating lower amounts of NOMV-specific lgG2b.
As fairly high levels of NOMV-specific IgG were observed, serum IgA responses 
were  also  investigated.  Figure  3.3C  shows  that  sera  from  NOMV  immunised 
C57BI/6 mice exhibited fairly high levels of IgA and approximately two fold less
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Figure  3.2 A comparison  of serum  antibody responses to  NOMVs 
in Balb/c mice after i.p. immunisation.
Groups  of four  Balb/c  mice  were  immunised  i.p.  with  PBS  or  5pg  of 
NOMVs.  Mice were  bled  21  days after immunisation,  and  serum was 
analysed for (A)  IgM  and  (B) total  IgG  and  IgG  subclasses  by  ELISA. 
IgM  was  detected  in  serum  of  individual  mice  (1  in  400  dilution)  with 
goat anti-mouse  IgM  HRP conjugate and  IgG was detected  (1  in  1,600 
dilution) with goat anti-mouse  IgG,  lgG1,  lgG2a,  lgG2b and  lgG3  HRP 
conjugates.  OPD  was  used  as  a  substrate.  Individual  mice  are 
indicated  by  (•)  and  the  mean  as  (—).  These  data  are  the  means  of 
duplicate  wells  from  one  representative  study  out  of two.  Significant 
differences are indicated as ** p < 0.015.
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Figure  3.3  Serum  antibody  responses  to  NOMVs  in  C57BI/6  mice 
after i.n. immunisation
Groups of three C57BI/6 mice were immunised i.n. with 50pl of either PBS 
or 5pg NOMV once a week for three weeks.  Mice were bled 7 days after 
the last immunisation,  and serum was analysed for (A) IgM;  (B) total  IgG 
and  IgG  subclasses and  (C)  IgA by ELISA.  IgM  was detected  in  serum 
from  individual  mice  (1  in  400  dilution)  with  goat  anti-mouse  IgM  HRP 
conjugate.  IgG  was  detected  (1  in  3,200  dilution) with  goat  anti-mouse 
IgG, lgG1, lgG2a, lgG2b and lgG3 HRP conjugates and IgA was detected 
(1  in  100  dilution)  with  goat  anti-mouse  IgA  HRP  conjugate.  Individual 
mice  are  indicated  by  (•)  and  the  mean  as  (—).  These  data  are  the 
means  of  duplicate  wells  from  one  representative  study  out  of  two. 
Statistical differences are indicated  as ** p< 0.015.
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Figure 3.4 Serum antibody responses to NOMVs in  Balb/c mice after
i.n. immunisation
Groups of three Balb/c mice were immunised  i.n. with 50pl of either PBS 
or 5pg NOMV once a week for three weeks.  Mice were bled 7 days after 
the last immunisation, and serum was analysed for (A) IgM;  (B) total  IgG 
and  IgG  subclasses and  (C)  IgA by ELISA.  IgM  was detected  in  serum 
from  individual  mice  (1  in  400  dilution)  with  goat  anti-mouse  IgM  HRP 
conjugate.  IgG  was  detected  (1  in  3,200  dilution) with  goat  anti-mouse 
IgG, lgG1, lgG2a, lgG2b and lgG3 HRP conjugates and IgA was detected 
(1  in  100  dilution)  with  goat  anti-mouse  IgA  HRP  conjugate.  Individual 
mice  are  indicated  by  (•)  and  the  mean  as  (—).  These  data  are  the 
means  of  duplicate  wells  from  one  representative  study  out  of  two. 
Statistical differences are indicated  as ** p < 0.015.
99was found  in Balb/c mice (figure 3.4C), compared to control  mice,  in which  IgA 
responses were undetectable.
3.3.1.3  Comparison of serum antibody responses to NOMVs in different 
strains of mice
As shown in figures 3.1  and 3.2, after i.p. immunisation there was no difference 
in the antibody isotype  response to  NOMVs  in  C57BI/6  and  Balb/c  mice.  The 
only  difference  was  in  the  magnitude  of  the  IgG  and  specifically  the  lgG2b 
response, which was greater in C57BI/6 mice than Balb/c mice.  This was also 
true for the IgG response after i.n. immunisation.  IgA levels were also higher in 
C57BI/6  mice than  Balb/c mice,  however the responses  in  both  strains of mice 
were significantly increased compared to NOMV-specific IgA responses in  PBS 
control mice.
3.3.2  The  adjuvant  effect  of  NOMVs  on  the  humoral  response  to  a  TD 
antigen
To investigate the adjuvant effect of NOMVs,  antibody responses to the  model 
protein antigen Ova were examined after immunisation by the i.p. and i.n. route. 
For the following  experiments,  groups  of C57BI/6  mice were  either immunised 
with PBS as a control or 0.5mg Ova in the presence or absence of 5pg  NOMV. 
Mice immunised i.p. were bled 21  days post immunisation.  Mice immunised i.n. 
received one 50pl dose once a week for three weeks, and were bled seven days
100after the final  immunisation.  Antibody responses were  measured  by ELISA as 
described in section 2.2.3e.
Figure  3.5  shows  the  Ova-specific  IgM,  total  IgG  and  IgG  subclass  response 
after i.p. immunisation.  It was observed that there was no significant increase in 
the  IgM  response  (figure  3.5A)  in  the  sera  of  mice  that  received  Ova  plus 
NOMVs  than  those  immunised  with  Ova  alone.  In  comparison,  a  significant 
increase in Ova-specific IgG (figure 3.5B) was observed in mice immunised with 
Ova plus NOMVs compared to immunisation with the antigen alone.  The Ova- 
specific  IgG  subclasses  were  also  determined  and  lgG1  was  predominantly 
found  in  sera  from  mice  immunised  with  Ova  alone  and  Ova  plus  NOMVs, 
however levels were higher in the mice immunised with adjuvanted Ova.
As  shown  in figure  3.6,  IgM  levels were  not significantly different  in  sera from 
mice  immunised  i.n.  with  Ova  alone  or Ova  plus  NOMVs,  however  IgG  levels 
were  significantly  increased  in  mice  that  received  Ova  plus  NOMVs  in 
comparison  to  mice  immunised  with  Ova  alone.  Examination  of  Ova-specific 
IgG  subclasses  revealed  that  mice  immunised  with  Ova  alone  produced 
predominantly  low  levels  of  lgG1.  Whereas,  mice  that  received  Ova  plus 
NOMVs produced  a  much  higher level  of lgG1  as seen  after i.p.  immunisation. 
Serum  IgA antibodies to Ova were also investigated.  Low but significant levels 
of Ova-specific IgA antibodies, indicated  by low absorbance values, were found 
in  mice  immunised  with  Ova  plus  NOMVs  compared  to  mice  immunised  with 
Ova alone.
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Figure  3.5  Serum  antibody responses to  Ova  in  C57BI/6  mice after
i.p. immunisation
Groups of four C57BI/6 mice were immunised i.p. with 0.5mg of Ova with 
or without 5pg  NOMV.  Mice were bled 21  days post immunisation,  and 
serum was analysed for (A) IgM and (B) total IgG and IgG subclasses by 
ELISA.  IgM  was  detected  in  serum  from  individual  mice  (1  in  200 
dilution) with goat anti-mouse IgM  HRP conjugate and total  IgG and  IgG 
subclasses  (1  in  100  dilution)  with  goat  anti-mouse  IgG,  lgG1,  lgG2a, 
lgG2b  and  lgG3  HRP  conjugates.  Individual  mice  are  indicated  by  (•) 
and the mean as (—).  These data are the means of duplicate wells from 
one representative study out of two.  Significant differences are indicated 
as ** p< 0.005.
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Figure  3.6  Serum  antibody  responses  to  Ova  after  i.n. 
immunisation in C57BI/6 mice.
Groups  of four  C57BI/6  mice  were  immunised  i.n.  with  0.5mg  of Ova 
with or without 5pg  NOMVs once a week for three weeks.  Mice were 
bled 7 days after the last immunisation, and serum was analysed for (A) 
IgM; (B) total IgG and  IgG subclasses and (C) IgA by ELISA.  IgM was 
detected  in serum from individual mice (1  in 200 dilution) with goat anti­
mouse  IgM  HRP  conjugate,  IgG  (1  in  12,800  dilution)  with  goat  anti­
mouse  IgG,  lgG1,  lgG2a,  lgG2b and  lgG3 HRP conjugates and  IgA (1 
in  100  dilution)  with  goat  anti-mouse  IgA  HRP  conjugate.  Individual 
mice  are  indicated  by  (•)  and  the  mean  as  (—).  These  data  are  the 
means  of  duplicate  wells  from  one  representative  study  out  of  two. 
Significant differences are indicated as ** p< 0.015.
1033.3.3  The  adjuvant effect of NOMVs  on  the  humoral  response  to  a  model 
TI-2 antigen
As improved IgG responses to Ova were seen after immunisation with Ova plus 
NOMVs,  the  adjuvant  potential  of  NOMVs  to  a  model  TI-2  antigen,  DNP-ficoll 
were examined after immunisation by the i.p. and i.n. route.
3.3.3.1  The  adjuvant  effect  of  NOMVs  on  DNP-ficoll  after  i.p.  and  i.n. 
immunisation
Serum  DNP-ficoll-specific  IgM,  total  IgG  and  IgG  subclass  responses  in  mice 
immunised i.p. with DNP-ficoll in the presence or absence of NOMVs are shown 
in  figure  3.7A  and  3.7B,  respectively.  Mice  immunised  with  DNP-ficoll  plus 
NOMVs  did  not  show  a  significant  increase  in  absorbance  therefore  no 
significant increase  in  IgM  compared to  mice  immunised with  DNP-ficoll  alone. 
In  contrast  a  significant  increase  in  the  DNP-ficoll  specific  IgG  response  was 
seen  in  mice  immunised  with  DNP-ficoll  plus  NOMVs.  Analysis  of  IgG 
subclasses  specific  for  DNP-ficoll  after  immunisation  with  the  antigen  alone 
revealed the  production  of lgG2b and  lgG3.  A  marked  increase  in  both these 
subclasses  was  observed  when  mice  were  immunised  with  DNP-ficoll  plus 
NOMVs.
DNP-ficoll  specific  antibody  responses  were  also  determined  in  sera  from  i.n. 
immunised  mice.  Figure  3.8  shows  the  (A)  IgM;  (B)  total  IgG  and  IgG 
subclasses and (C) IgA responses to DNP-ficoll after immunisation with DNP-
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Figure 3.7 A comparison of serum antibody responses to DNP-ficoll 
after i.p. immunisation in C57BI/6 mice using NOMVs as adjuvant.
Groups of eight C57BI/6 mice were immunised i.p. with 5pg of DNP-ficoll 
with or without 5pg NOMVs.  Mice were bled 21  days post immunisation, 
and  serum  was  analysed  for  (A)  IgM  and  (B)  total  IgG  and  IgG 
subclasses by ELISA.  IgM was detected in serum of individual mice (1  in 
200  dilution)  with  goat  anti-mouse  IgM  HRP  conjugate  and  IgG  and 
subclasses  (1  in  100  dilution)  with  goat  anti-mouse  IgG,  lgG1,  lgG2a, 
lgG2b and  lgG3  HRP  conjugates.  Individual  mice  are  indicated  by  (•) 
and the mean as (—).  These data are the means of duplicate wells from 
one representative study out of two.  Significant differences are indicated 
as ** p < 0.05.
105E
c
o
0>
0 O
c
(0 .Q
o
(0 .Q
<
1.2  -|
1.0  .
0.8 
0.6 
0.4  - 
0.2  - 
0  -
0.6
0.5
0.4
0.3
0.2
0.1
0
PBS DNP-ficoll DNP-ficoll+NOMV
Total IgG
iSSS  lgG2a
EZ3  lgG2b
777*  lgG3
PBS DNP-ficoll DNP-ficoll+NOMV
:
PBS DNP-ficoll DNP-ficoll+NOMV
Figure  3.8  Serum  antibody  responses  to  DNP-ficoil  after  i.n. 
immunisation in C57BI/6 mice using NOMVs as adjuvant.
Groups of four C57BI/6  mice were immunised  i.n. with 5pg of DNP-ficoll 
with  or without  5pg  NOMVs  once  a  week for three weeks.  Mice were 
bled 7 days after the last immunisation, and serum was analysed for (A) 
IgM;  (B) total  IgG and  IgG  subclasses and  (C)  IgA by ELISA.  IgM was 
detected  in  individual  mice  (1  in  200  dilution) with  goat anti-mouse  IgM 
HRP conjugate,  IgG  (1  in  100 dilution) with  goat anti-mouse  IgG,  lgG1, 
lgG2a,  lgG2b and  lgG3  HRP conjugates and  IgA (1  in  100 dilution) with 
goat anti-mouse IgA HRP conjugate.  Individual mice are indicated by (•) 
and the mean as (—).  These data are the means of duplicate wells from 
one representative study out of two.  Significant differences are indicated 
by **p< 0.015
106ficoll  alone  and  DNP-ficoll  plus  NOMVs.  Mice  immunised  with  DNP-ficoll  plus 
NOMV  had  significantly elevated  IgM, total  IgG  and  IgA antibody responses  in 
comparison to mice immunised with DNP-ficoll alone.  Examination of individual 
IgG  subclasses  revealed  that sera from  mice  immunised  with  DNP-ficoll  alone 
had  primarily low levels of all  IgG  subclasses.  In  comparison,  sera from  mice 
immunised with DNP-ficoll  plus NOMVs produced in the main lgG2b, with lower 
levels of lgG1, lgG2a and lgG3.
3.3.4  The  adjuvant  effect  of  NOMVs  on  the  humoral  responses  toward 
clinically relevant Tl antigens
The  antibody  responses  toward  CPSs  from  S.  pneumoniae  were  investigated 
given  that  NOMVs  were  able  to  enhance  antibody  responses  to  DNP-ficoll,  a 
model  Tl  antigen,  after i.p.  and  i.n.  immunisation.  For all  experiments,  unless 
stated  otherwise,  C57BI/6  and  Balb/c mice were  immunised  with  either 5pg  of 
type 3, 4,  14 or 19F CPS in the presence or absence of 5pg NOMVs.  Previous 
work  done  in  the  laboratory  has  shown  that  5pg  of  CPS  to  be  adequate  in 
eliciting an antibody response therefore this dose was administered  (Hannah  E 
Jones,  PhD thesis).  Mice  immunised  by the i.p.  route were  bled  21  days  post 
immunisation  and  serum  was  collected.  Mice  immunised  by  the  i.n.  route 
received  three  50pl  doses  at weekly  intervals  and  were  bled  seven  days  after 
the final immunisation.  The CPS-specific antibody responses were assessed by 
ELISA as described in section 2.2.3f.
1073.3.4.1 The presence of natural IgM antibodies S. pneumoniae CPSs in 
serum of naive mice
Serum  from  naive  mice  has  been  shown  to  contain  natural  IgM  antibodies  to 
microbial  carbohydrates.  These  antibodies  are  an  important  part  of  innate 
immunity and  their  presence  may affect the  antibody  response towards  CPSs 
therefore it is important to determine the levels of natural IgM to the CPSs used 
in  this  study  (Goldblatt  et  a!.,  1992).  Analysis  of  sera  from  non-immunised 
C57BI/6  and  Balb/c  mice  showed  that  with  the  exception  to  type  4  CPS,  the 
levels  of  natural  IgM  tended  to  be  higher  in  Balb/c  mice  (figure  3.9).  It  is 
important to include data from PBS control mice due to the difference in levels of 
natural  IgM  specific  for  CPS  serotypes  in  different  strains  of  mice  when 
investigating antibody responses to CPSs.
3.3.4.2 The adjuvant effect of NOMVs on the humoral response to S. 
pneumoniae CPSs in mice after i.p. and i.n. immunisation
To examine the adjuvant activity of NOMVs to clinically relevant Tl antigens, the 
IgM and IgG antibody responses to S. pneumoniae CPSs type 3, 4,  14 and  19F 
were determined.
Figure 3.10 shows the CPS-specific IgM antibody response to type 3, 4,  14 and 
19F CPSs after i.p.  immunisation.  In  both C57BI/6 and Balb/c mice only type 4 
and type 19F CPSs elicited an IgM response.  At day 21, for all CPSs tested and 
in  both  strains  of  mice,  there  was  no  significant  increase  in  IgM  levels  after 
immunisation with the CPSs plus NOMVs compared to CPSs immunised alone.
108Figure 3.9 Serum IgM  levels to S. pneumoniae in  naYve C57BI/6 and 
Balb/c mice.
Sera from naive (A) Balb/c and  (B) C57BI/6 mice were analysed for IgM 
to four different CPSs  by ELISA at a  1   in 400 dilution  and  preabsorbed 
with  100pg/ml  of  CW-PS.  Goat  anti-mouse  IgM  HRP  conjugate  was 
used to detect IgM and OPD was used as a substrate.  Data represents 
the mean of eleven to fifteen mice ± s.e.m.
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Figure  3.10  A comparison  of serum  IgM  responses to  S.  pneumoniae 
CPSs after i.p. immunisation in C57BI/6 and Balb/c mice using NOMVs 
as an adjuvant.
Groups  of four  C57BI/6  (left  panels)  and  Balb/c  (right  panels)  mice  were 
immunised  i.p. with 5pg of CPS serotypes 3, 4,  14  19F with or without 5pg 
NOMVs  (C+N  or CPS  respectively) or with  PBS  only.  Mice were  bled  21 
days  post  immunisation  and  serum  was  analysed  for  IgM  to  the  CPS  by 
ELISA at a  1   in 400 dilution of serum.  Goat anti-mouse IgM HRP conjugate 
was used to detect IgM  and  OPD was used as a substrate.  Individual  mice 
are  indicated  by  (•)  and  the  mean  as  (— ).  These  data  are  the  means  of 
duplicate wells from one representative study out of two.It  is  evident from  the  data  in  this figure that  absorbance values  and  therefore 
antibody  responses  to  the  CPSs  are  variable.  CPS-specific  IgG  antibody 
responses were also  investigated.  Only  IgG  antibodies  specific to type  3  and 
type  14  CPS  were found  in  sera,  and  these  were  of isotypes  lgG3  and  lgG1 
(data not shown).
Mice  were  also  immunised  i.n.  with  CPSs  in  the  presence  or  absence  of 
NOMVs.  Figure  3.11  shows  the  IgM  response  to  CPSs  with  NOMVs  as 
adjuvant.  Seven  days  after  the  final  immunisation,  the  IgM  response  to  the 
CPSs tested showed there was no improvement in the antibody response when 
mice were immunised with the CPSs plus NOMVs in comparison to CPSs alone. 
Not all the CPSs immunised  i.n. elicited an  IgM response that was greater than 
the natural IgM response to the CPS.  In C57BI/6 mice, only type 4 CPS gave a 
CPS-specific  IgM  response.  In  Balb/c  mice,  none  of  the  CPSs  produced  a 
greater  antibody  response  compared  to  the  PBS  control  mice  after  i.n. 
immunisation.
3.3.4.3  Dose response to type 3 and type 4 CPSs immunised i.n.
Very  few  studies  have  investigated  the  humoral  response  to  S.  pneumoniae 
CPSs after i.n. immunisation in mice.  As the CPS-specific IgM response in mice 
after i.n. immunisation was low or undetectable, mice were immunised with type 
3  or  type  4  CPS  at  a  range  of  doses  (5  -  20pg).  As  with  the  previous 
experiments groups of C57BI/6 and Balb/c mice were immunised once a week
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Figure  3.11  A comparison  of serum  IgM  responses to  S.  pneumoniae 
CPSs after i.n. immunisation in C57BI/6 and Balb/c mice using NOMVs 
as an adjuvant.
Groups  of three  C57BI/6  (left  panels)  and  Balb/c  (right  panels)  mice  were 
immunised  i.n. with 50pl of 5pg type 3 (A); type 4 (B); type  14 (C) and type 
19F (D) CPS with or without 5pg  NOMVs or PBS alone, once a week for 3 
weeks.  Blood was taken 7 days after the last immunisation and serum  IgM 
to  the  serotypes was  analysed  by  ELISA.  IgM  was  detected  in  individual 
mice  at  a  1   in  400  dilution  of  serum  with  goat  anti-mouse  IgM  HRP 
conjugate.  OPD was used as a substrate.  Individual mice are indicated  by
(•) and the mean as (—). These data are the means of duplicate wells.
112for three weeks  and  blood  was taken  seven  days  after the  last  immunisation. 
Serum  was then  analysed  for  IgM  and  IgG  antibodies  by  ELISA.  Figure 3.12 
shows the dose response to type 3 CPS.  For each dose the absorbance was 
compared and any increase in absorbance reflected an increase in IgM levels in 
the serum.  In both strains of mice, there was no increase in absorbance with an 
increase in dose of the CPS.  This was also repeated for type 4 CPS (data not 
shown) and similar results were obtained.  The CPS-specific IgG response was 
also examined, and the results are shown in figure 3.13.  As shown in this figure, 
in  both  strains  of mice,  only  a  few  mice  in  some  of the  groups  produced  IgG 
antibodies specific to the immunised CPS.
3.3.4.4  The effect of a booster immunisation and memory response to S. 
pneumoniae CPSs
The  effect  of a  booster  immunisation  and  the  memory  response  to  the  CPSs 
was  also  investigated.  In  order  to  investigate  the  memory  response  to  the 
immunised  CPS,  groups  of  mice were  immunised  i.p.  as  previously described 
(see section  3.5) and then  again  at day 62  but with the CPS  alone.  The  mice 
were  then  bled  five  days  later  (see  immunisation  protocol  2.2).  Figure  3.14 
shows the serum  IgM  responses to the CPSs at day 21,  day 60  and five days 
after the second  immunisation.  Sixty days after the primary immunisation with 
either the  CPS  alone  or CPS  plus  NOMVs,  IgM  antibodies to  all  CPSs tested 
were at the same level,  as indicated  by similar absorbance levels as at day 21 
showing that the antibodies are relatively long lived.  After a second
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Figure 3.12 Comparison of serum IgM responses to S. pneumoniae 
type 3 CPS at different doses in C57BI/6 and Balb/c mice.
Groups  of four  (A)  C57BI/6  and  (B)  Balb/c  mice  were  immunised  i.n. 
with 50/vl of type 3 CPS at a range of doses (5 -  20/vg in sterile PBS) or 
PBS alone, once a week for 3 weeks.  Blood was taken 7 days after the 
last  immunisation  and  analysed  for type  3  specific  IgM  by  goat  anti­
mouse  IgM  HRP conjugate and  OPD  as a  substrate.  These data  are 
the means of duplicate wells.
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Figure  3.13  A  comparison  of  serum  IgG  responses  to  S. 
pneumoniae type  3  CPS  at  different  doses  in  C57BI/6  and  Balb/c 
mice after i.n. immunisation.
Groups  of four  (A)  C57BI/6  and  (B)  Balb/c  mice  were  immunised  i.n. 
with 50pl of type 3 CPS at a range of doses (5 - 20pg in sterile PBS) or 
PBS alone, once a week for three weeks.  Blood was taken seven days 
after the last immunisation and  serum  IgG to serotype 3 was analysed 
by ELISA.  IgG was detected using goat anti-mouse IgG HRP conjugate 
and  OPD  as  a  substrate.  Individual  mice  are  indicated  by  (•)  and  the 
mean as (—).  These data are the means of duplicate wells.
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Figure  3.14  Serum  IgM  responses  to  S.  pneumoniae  CPSs  in 
C57BI/6 using NOMVs as an adjuvant.
Groups of four C57BI/6 mice were immunised  i.p.  at day 0 with 5pg of 
CPS serotype 3, 4,  14 or 19F with or without 5pg NOMVs or with  PBS 
and at day 61  with CPS or PBS only.  Mice were bled at day 21  and 60 
after the first  immunisation  and  seven days  after the second  injection. 
Serum was analysed for IgM to the CPS by ELISA at a 1   in 200 dilution 
of serum.  Goat anti-mouse IgM HRP conjugate was used to detect IgM 
and OPD was used as a substrate.  Individual mice are indicated by (•) 
and the mean as (— ). These data are the means of duplicate wells from 
one study.
116immunisation with the CPS alone, there was little difference in the IgM response 
at day 60 or day 67 therefore there was no memory response.
To  examine  the  effect  of  a  booster  immunisation,  groups  of  mice  received  a 
second  immunisation  at  day  62  with  the  same  antigen  in  the  presence  or 
absence of NOMVs  as they  received  in  the  primary immunisation.  Mice were 
bled 21  days and 60 days after the primary immunisation, and five days after the 
booster  immunisation.  The  results  were  comparable  to  those  in  figure  3.12, 
indicating that a  booster immunisation with the CPS alone or CPS  plus  NOMV 
did  not  result  in  an  increase  in  antibody  response to the  CPS,  therefore there 
was no booster effect (data not shown).
3.3.5  Serum  antibody  responses  to  S.  pneumoniae  CPSs  in  mice 
immunised with NOMVs
Sera  from  mice  immunised  with  NOMVs  were  analysed  for  CPS-specific 
antibodies.  Groups  of C57BI/6  and  Balb/c  mice were  immunised  i.p.  with  5pg 
NOMVs  and  blood  was  collected  21  days  post  immunisation  and  analysed  for 
IgM  antibodies  to  type  3,  4  14  and  19F  CPSs.  Figure  3.15  shows  the  CPS- 
specific IgM responses in both PBS control and NOMV immunised mice.  In both 
strains  of  mice  there  was  no  significant  difference  in  absorbance  levels  and 
therefore no difference in IgM levels between naive and NOMV immunised mice 
to the CPSs.
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Figure  3.15  Serum  IgM  levels  in  NOMV  immunised  C57BI/6  and 
Balb/c  mice to S. pneumoniae CPSs.
Sera from (A) Balb/c and (B) C57BI/6 mice immunised with 5pg NOMVs 
were  analysed  for  IgM  to four different  CPSs  by  ELISA  at  a  1   in  400 
dilution  and  preabsorbed  with  100pg/ml  of CW-PS.  Goat  anti-mouse 
IgM  HRP conjugate was  used  to detect  IgM  and  OPD was  used  as  a 
substrate.  Data represents the mean of four to eleven mice ± s.e.m.
1183.3.5.1  Booster effect of NOMV immunisation
CPS-specific antibodies  in  the  sera  of NOMV  immunised  mice  after a  booster 
immunisation with NOMVs was also investigated.  Briefly, mice were immunised 
on day 0 and then at day 62 with either PBS or 5pg NOMV.  The mice were bled 
at day 21  and day 60, and five days after the booster immunisation.  Figure 3.16 
shows  the  CPS-specific  IgM  antibodies  in  sera from  C57BI/6  and  Balb/c  mice 
after 21  days and  after the  booster immunisation.  In  both strains of mice,  and 
for all CPS serotypes examined, an increase in IgM levels was observed after a 
booster immunisation with NOMVs.
3.4  Discussion
Previous  reports  have  demonstrated  that  NOMVs  from  serogroup  B 
meningococci  to  be  highly  immunogenic  and  display  adjuvant  properties, 
therefore  NOMVs  in  one  form  or  other  have  been  used  in  vaccines.  The 
immunogenicity of NOMVs has been attributed to components such as LPS and 
porins.  Neisserial porins can induce inflammation and activate B cells and DCs, 
which  has  been  shown  by  upregulation  of  the  costimulatory  molecule  B7-2 
(CD86),  increasing  the  involvement  of T  cells  via  CD28.  The  activation  of  B 
cells  and  DCs  was  shown  to  be  dependent  on  TLR2  and  MyD88  by  using 
knockout mice  (Mackinnon  et a/.,  1999;  Massari  et al.,  2002;  Massari  P,  2003; 
Singleton  et  al.,  2005).  LPS  has  been  shown  to  have  a  major  effect  on  the 
immune system via TLR4 and therefore possesses adjuvant properties
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Figure  3.16  Serum  IgM  levels  in  NOMV  immunised  C57BI/6  and 
Balb/c  mice  to  S.  pneumoniae  CPSs  before  and  after  booster 
immunisation.
Groups  of  three  or  four  (A)  Balb/c  and  (B)  C57BI/6  mice  were 
immunised with 5pg NOMV or PBS only.  A booster was given at day 61 
(same as the first immunisation).  Mice were bled at day 21  and day 67 
and serum was analysed by ELISA to four different CPSs at a  1   in 400 
dilution.  Goat anti-mouse  IgM  HRP conjugate was used to detect IgM 
and OPD was used as a substrate.  Data represents the mean of eight 
to twelve mice ± s.e.m.
120(Armerding et al., 1974; Skidmore et al.,  1975).  In this chapter, the adjuvanticity 
of NOMVs was further investigated using model and clinically relevant antigens.
Before  assessing  the  adjuvanticity of  NOMVs  with  model  TD  and  Tl  antigens 
and  CPSs,  the  primary  antibody  response  to  NOMVs  was  established  in 
C57BI/6 and Balb/c mice.  By both immunisation routes NOMV-specific IgM and 
IgG levels were significantly higher in sera from NOMV immunised  mice than in 
PBS  control  mice.  Sera from  NOMV-immunised  mice contained  high  levels of 
lgG2b  and  low  levels  of  lgG2a  (figures  3.1  -   3.4),  which  are  the  primary 
antibodies  associated  with  a  Th1  response  and  that  mediate  complement 
fixation  in  mice.  After i.n.  immunisation,  NOMVs also induced fairly high levels 
of serum  IgA.  These  results  are  consistent with  other studies  in  the  literature 
including  one from  this  laboratory  investigating  antibody  responses to  NOMVs 
after i.n. immunisation (Guthrie et al., 2004).
With the primary antibody response to NOMVs determined, the adjuvanticity of 
NOMVs  to  the  model  protein  antigen  Ova  was  established  in  C57BI/6  mice. 
Immunisation  of mice with  Ova  in the  presence  or absence  of  NOMVs  by  i.p. 
and  i.n.  routes  induced  similar  levels  of  Ova-specific  IgM,  however  levels  of 
Ova-specific  IgG  were  much  higher in  serum from  mice that received  both the 
antigen  and  adjuvant  (figures  3.5  and  3.6).  Mice  immunised  with  Ova  alone 
exhibited  low  levels  of  Ova-specific  lgG1,  the  isotype  primarily  induced  by 
protein  antigens  in  mice  and  humans,  and  lgG2b.  Mice  that  were  also
121immunised  with  NOMVs  displayed  enhanced  lgG1  responses.  Low  levels  of 
Ova-specific  IgA antibodies were  also found  in  the sera from  mice  immunised 
i.n. with Ova plus NOMVs.  These results confirm that NOMVs have the ability to 
enhance antibody responses to a model TD antigen such as Ova.
To further establish the ability of NOMVs as an  adjuvant, the effect of NOMVs 
on the antibody responses toward DNP-ficoll were investigated in C57BI/6 mice. 
After i.p.  immunisation,  DNP-ficoll  specific  IgM  responses were similar in  mice 
that  received  either  DNP-ficoll  alone  or with  NOMVs  and  the  responses  were 
greater than that in the sera of PBS control mice.  In contrast the IgM response 
to DNP-ficoll after i.n. immunisation was significantly higher when DNP-ficoll was 
immunised with  NOMVs than DNP-ficoll alone.  The IgG response to DNP-ficoll 
was  significantly  higher  in  mice that  received  DNP-ficoll  plus  NOMVs  by  both 
immunisation  routes, with  improved  lgG2b and  lgG3 responses.  Serum  IgA to 
DNP-ficoll  was  absent  in  mice  immunised  with  DNP-ficoll  alone,  however high 
levels were detected in sera from mice immunised with DNP-ficoll plus NOMVs. 
These data show that NOMVs can act as a  mucosal  adjuvant for DNP-ficoll,  a 
TI-2 antigen that is often used as a model for anti-CPS antibody responses.
Polysaccharide  vaccines  are  in  general  weakly  immunogenic  in  children  less 
than  two  years  old  and  in  the  elderly  due  to  their  Tl  nature.  The  immune 
response to CPSs  is also age dependent and  studies have shown that despite 
conversion to TD forms through conjugation to proteins, polysaccharide induced
122responses are still deficient in many aspects and therefore additional adjuvant is 
added to the CPS and carrier proteins.  Previous studies have shown that type 
14  and type  19F CPSs are only weakly immunogenic in  Balb/c mice when  not 
conjugated  to  a  carrier  protein  (Mawas  et al.,  2000)  as  is  type  3  CPS  which 
induces  weak  IgM  and  lgG3  responses  (Dullforce  et al.,  1998).  The  immune 
response to type 3 CPS has also been shown to be dependent on complement 
characterised  by  low  IgM  levels  and  a  lack  of  isotype  switching  in  C3-  and 
complement  receptor  2-deficient  mice  (Pozdnyakova  et  al.,  2003).  Antibody 
responses to type  19F and  6 B CPSs after conjugation to a non-toxic mutant of 
diphtheria  toxin  CRM197  were  enhanced,  characterised  by  increasing  titres  of 
serum  lgG2a and  lgG3,  by the addition of CpG  DNA which  has been shown to 
be  an  effective  adjuvant  (Chu  et  al.,  2000).  Moreno-Fierros  and  colleagues 
(2003)  described  the  antibody  response to  type  6 B  CPS  in  the  presence  and 
absence of recombinant CrylAc protoxin from Bacillus thuringiensis as a carrier 
protein  and  adjuvant  after  i.n.  immunisation.  Their  results  described  higher 
systemic  and  mucosal  responses  with  the  CPS  plus  CrylAc.  However there 
was an absence of CPS-specific IgG antibodies.
With  encouraging  results  with  NOMVs  as  an  adjuvant to  DNP-ficoll,  we  were 
interested in investigating whether NOMVs could act as an adjuvant to clinically 
relevant  polysaccharides.  The  polysaccharide  capsule  of  S.  pneumoniae 
protects the  bacteria from  innate  immune defences  and therefore the antibody 
response  to  the  capsule  is  crucial.  Before  investigating  the  differences  in
123antibody responses to type 3, 4,  14 and  19F CPSs with or without NOMVs, the 
levels of natural serum IgM antibodies to the CPSs were determined in C57BI/6 
and  Balb/c  mice.  Natural  antibodies  are generally of the  IgM  isotype  and  are 
produced by B-1a cells, which are mostly generated in the spleen.  Wardemann 
et al.,  (2002) have shown that in mice the spleen is essential for the generation 
and  survival  of B-1a  cells  and that mice lacking  B-1a cells  have a  low level of 
natural  IgM.  Natural  IgM  antibodies  were  found  to  all  serotypes  tested,  but 
levels  differed  not  only  between  serotypes  but  also  in  the  different  strains  of 
mice (figure 3.9).  The levels to type 4 CPS were very low in both C57BI/6 and 
Balb/c mice.  In comparison in Balb/c mice the level of natural IgM to type 3 CPS 
was fairly high.
After determining  the  levels  of natural  IgM,  the  primary antibody  responses to 
the  CPSs  tested  in  the  presence  or  absence  of  NOMV  were  determined  in 
C57BI/6 and Balb/c mice by i.p. and i.n. immunisation routes.  The CPSs used in 
the study were selected because they vary in immunogenicity as indicated  by a 
previous study done in the laboratory (Jones et al., submitted manuscript).  The 
IgM  response was  found  to vary depending  on  the  mouse  strain,  the  route  of 
immunisation and the response in individual mice.  Via the i.p. route, and in both 
strains of mice, type 4 and  19F CPS produced an IgM response to the CPS that 
was greater than the natural  IgM  response to the CPS.  However the response 
was  not  enhanced  by  immunisation  with  the  CPS  plus  NOMVs.  After  i.n. 
immunisation  apart  from  type  4  CPS  in  C57BI/6  mice,  none  of  the  CPSs
124immunised alone produced an IgM response greater than the natural levels, and 
again  this  response  was  not  improved  by  immunisation  with  the  CPS  plus 
NOMVs.  Mice also didn’t respond  in a dose-dependent manner to type 3 or 4 
CPS after i.n.  immunisation.  The spleen, and importantly marginal zone B cells 
have been shown to have a greater capacity to respond to TI-2 antigens, which 
could  explain  the  failure  to  see  enhanced  antibody  responses  after  i.n. 
immunisation.  However  antibody  responses  did  not  improve  after  i.p. 
immunisation with the CPSs plus NOMVs.  IgG responses were rarely observed, 
which  is  consistent  with  previous  results  on  a  large  panel  of  CPS  that  were 
carried  out  in  our  laboratory  (Jones  et  a/.,  submitted  manuscript).  However 
where  an  IgG  response  was  detected,  lgG3  and  lgG1  subclasses  dominated 
which  is  consistent with  previous  reports  (Mosier et al.,  1982;  Dullforce  et al., 
1998;  Mawas et al.,  2000).  This  is in contrast to immunisation with  DNP-ficoll, 
which always produced high IgG responses.
It  was  unexpected  that  immunisation  of  NOMVs  with  the  CPSs  would  fail  to 
enhance IgM and IgG responses due to enhanced antibody responses observed 
after  immunisation  with  DNP-ficoll  plus  NOMVs.  Although  DNP-ficoll  is 
considered  as a  model T-l  2  antigen,  DNP  is a  hapten  and ficoll  is a synthetic 
polysaccharide.  Epitope size and conformation of DNP-ficoll are different to that 
of  CPSs  and  its  interaction  with  the  innate  immune  system  could  also  be 
different from that of CPSs.  Antibody responses to  DNP-ficoll  have also  been 
shown to be influenced  by APCs and T cells (Boswell et a/.,  1980;  Mond et al.,
1251980).  Meltzer and  Goldblatt  (2006)  have  recently shown  that  pneumococcal 
CPSs  can  interact directly with  human  DCs  by  binding  receptors  such  as  the 
macrophage  mannose  receptor  described  by  Zamze  et  al.  (2002)  or  other 
receptors  such  as  DC-SIGN.  They  also  demonstrated  that  uptake  did  not 
induce DC maturation  unless  in the presence of a second signal  such as LPS. 
A  study  has  also determined  the  requirement of CD1  molecules,  found  on the 
surface of APCs and CD8+  T cells to provide help for antibody production to TI-2 
antigens (Kobrynski et a/., 2005).  Therefore antibody responses to Tl  antigens 
could be influenced by the nature of the antigen.  This has been demonstrated in 
a study using CpG  motifs as an adjuvant to TI-2 antigens.  Enhanced antibody 
responses to TNP-ficoll were seen when CpG was coadministered i.p., whereas 
CpG  failed  to  enhance  responses  to  18  CPSs  unless  the  pneumococcal 
serotypes were conjugated to tetanus toxoid.  They suggested that this might be 
due to the  degree  of involvement  of immune  cells  such  as APCs  and  T  cells 
after stimulation with the adjuvant (Kovarik et al., 2001).  This could be also true 
for NOMVs in the studies carried out.
As the CPSs immunised i.n. failed to produce an antibody response greater than 
the  natural  IgM  response,  the  dose  of  the  CPSs  was  increased.  It  was 
established that mice did  not respond in a dose dependent manner to type 3 or 
type  4  CPS  after  i.n.  immunisation  and  once  again  the  IgG  response  was 
variable in individual mice.  For some of the CPSs,  IgM responses were greater 
after i.p.  immunisation than i.n..  This is most likely due to the presence of B1-a
126cells  in  the  spleen  producing  natural  IgM  and  Igs  to  the  CPSs  after  i.p. 
immunisation and not after i.n. immunisation.  MZ B cells of the spleen have also 
been  implicated  in response to TI-2 antigens, and  it has been shown that mice 
possessing B1-a cells but not MZ B cells have impaired responses to TNP-ficoll 
after i.p.  immunisation  (Guinamard  et al., 2000).  This suggests that the spleen 
and  route of immunisation is also important in the production and enhancement 
of humoral responses to TI-2 antigens.
For all  CPSs tested the level of IgM to the CPSs was sustained for at least 60 
days  indicated  by  similar  absorbance  levels,  supporting  data  previously 
generated in our laboratory (Jones et al., submitted paper).  This is probably due 
to  the  fact  that  pneumococcal  CPSs  have  a  high  molecular  weight  with  a 
relatively long half-life therefore they degrade slowly in vivo sustaining antibody 
levels (Sela etal.,  1972).
A booster immunisation of CPS given 62 days after the initial immunisation with 
either the CPS alone or CPS plus NOMV had no effect on the antibody levels to 
the CPSs used.  This  is not unusual and  is consistent with other studies that a 
booster  effect  or  memory  response  was  not  observed  with  polysaccharide 
antigens (Baker et al.,  1971; Mond etal., 1995a; Mond etal., 1995b).
It  was  seen  that  serum  from  mice  immunised  i.p.  with  NOMVs  displayed  a 
similar level of CPS-specific IgM to that of naive mice.  A second  immunisation 
with NOMVs 62 days after the initial immunisation markedly increased the CPS- 
specific  IgM  response  to  all  four  CPSs  tested  that  included  cross-reactive
127antibodies.  This  indicates  that  immunisation  with  NOMVs  may  confer  cross­
protection  to the  CPSs  tested  in  this  study,  however this  needs  to  be  further 
investigated in more detail.  It is clear from the results with NOMV that anti-CPS 
antibody  responses  are  poorly  induced  and  are  difficult  to  enhance  via  the 
intranasal route.  This raises the question to the identity of the protective antigen 
induced  by  natural  colonisation  of  Nm,  even  though  CPS-protein  conjugate 
vaccines induce protective immunity in vaccinated individuals.
There were certain  limitations with the assays carried out in this chapter.  One 
limitation was that controls were not included when determining whether NOMVs 
could act as an adjuvant to different antigens.  Controls would have enabled us 
to  assess  whether  there  was  any  variability  during  immunisation  with  the 
different  antigens.  This  could  have  been  determined  when  measuring  the 
antibody responses  by  ELISA,  as any difference in the  response to the control 
could  indicate  variability  in  the  other samples.  In  order to  determine  whether 
NOMVs  could  act  as  an  adjuvant,  antibody  responses  were  assessed  by 
measuring  changes  in  the  OD  of  the  serum  samples  from  the  different 
immunised  mice.  Different  experiments  were  not  analysed  by  ELISA  in  the 
same  assay  therefore  it  was  not  possible  to  directly  compare  the  effect  of 
NOMVs on different antigens.  It could have been more accurate to use antibody 
standards  so  that  OD’s  could  have  been  converted  to  concentrations,  which 
would have taken into account the variability of measuring OD’s.
128In contrast to CPS antigens,  previous studies performed in this laboratory have 
shown  that  mice  immunised  i.n.  with  NOMVs  can  induce  anti-LPS  antibodies, 
which  are cross-reactive  between  LPS variants (Andersen  et al.,  2002).  Thus, 
poor anti-CPS antibody responses in the presence of NOMV are unlikely due to 
the  insufficient  stimulation  of  APCs,  but  may  result  in  the  lack  of  number  or 
activation of a different B cell subset.  B cell subsets for DNP and similarly small 
epitopes are potentially different from those present on CPS.  The mechanism of 
B cell activation by purified CPS requires further investigation.  Understanding of 
the  antibody  response  towards  carbohydrate  epitopes  is  of  interest  in  the 
development of vaccines against group B meningococcal disease because LPS 
is  one  of  the  subcapsular  antigens  being  assessed  as  a  potential  vaccine 
candidate (Plested,  2003;  Gidney et al., 2004).  Plested and colleagues (2003) 
have provided proof-of-principle of a strategy of using only inner core epitopes of 
LPS  conjugated  to  a  protein  carrier  to  induce  protective  antibodies  that  are 
cross-reactive to full-length LPS on live meningococci B strains, but the anti-LPS 
antibody generated were  not optimal  in  protection  studies.  We therefore  have 
tried to isolate high affinity antibodies against inner core LPS after immunisation 
with  NOMV  preparations  derived  from  Nm  strain  44/76  (Mu-4).  We  have 
analysed  several  high  affinity  anti-mut  4  LPS  antibodies  but  found  that  these 
antibodies were  non-cross  reactive with wild-type  meningococci  (MacKenzie et 
al.,  unpublished  data).  Although  our  results  indicate that  NOMVs  are  a  good 
adjuvant for inducing high affinity anti-LPS antibodies, the strategy of using inner 
core LPS epitopes in the context of NOMVs to generate a universal serogroup B
129vaccine  requires  optimisation  and  identification  of inner core  epitopes that are 
exposed on live Nm.
In  conclusion,  although  NOMVs  increase  primary antibody responses to model 
antigens  such  as  Ova,  DNP-ficoll  and  LPS  it  does  not  appear  to  act  as  an 
adjuvant towards CPSs from S. pneumoniae.  However as shown with Ova and 
DNP-ficoll,  NOMVs  could  prove to  be suitable as a mucosal  adjuvant boosting 
antibody  responses  for  TD  and  TI-1  antigens  via  the  i.n.  route.  Naturally 
occurring  microbial  products such as  NOMVs would  also provide an avenue to 
understand  mucosal  immune  responses  generated  i.n.  under  more 
physiologically relevant conditions.  Finally, natural immunity induced by NOMV- 
shedding  Nm  in  serogroup  B  or other groups  may not involve the  induction  of 
anti-CPS antibodies in the nasopharynx.
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The possible mechanisms of adjuvant action and 
immunomodulatory properties of NOMVs
4.1  Introduction
Adjuvants  can  be  described  as  any  component  or  product  that  when  co­
administered  with  a  vaccine  enhances  the  immunogenicity  of  the  vaccine 
antigen via humoral or cell-mediated immunity.  The mechanism of action of 
some adjuvants is  poorly defined  however the effect they can  have on the 
immune system is better documented.  Aluminium adjuvants (e.g. Alum) are 
an example of adjuvants that are approved for human use.  Their mechanism 
of  action  is  thought  to  be  through  a  depot  effect  where  the  antigen  and 
adjuvant stay around the injection site to produce a prolonged effect targeting 
APCs.  Alum  is  typically  effective  in  enhancing  antibody  responses  and 
producing a predominantly Th2 response to protein antigens.
Particulate adjuvants, such as immune stimulating complexes (ISCOMs) are 
used in veterinary vaccines and induce strong Th1  and Th2 responses.  They 
form  aggregates  by  binding  antigens,  which  are  then  engulfed  by  APCs. 
However  more  effective  targeting  of APCs  is  achieved  by  using  adjuvants 
whose ligands are recognised by receptors on APCs.
Microbial  products  have  also  been  shown  to  be  strong  adjuvants.  For 
example complete Freund’s adjuvant (CFA) is a potent adjuvant composed of 
paraffin oil and heat-killed mycobacteria.  It is frequently used in experimental 
animal models but is deemed too toxic for human use (Billiau et al., 2001).
131Immune responses to  pathogens can  be enhanced  by the activation of the 
immune system through TLRs.  Binding of PAMPs such as LPS, flagellin and 
bacterial CpG DNA to TLRs leads to the activation of signalling pathways and 
results  in  the  production  of  pro-inflammatory  cytokines  and  enhanced 
expression  of  costimulatory  molecules  on  immune  cells.  This  ultimately 
affects  both  the  innate  and  acquired  immune  systems.  Hence  TLRs  are 
potent mediators of adjuvant activities.  For example LPS,  one of the best- 
characterised PAMPs can influence and stimulate the production of IL-12 and 
NO  by  binding  and  signalling through TLR4.  Bacterial  CpG  DNA has also 
been shown to have adjuvant properties when administered with an antigen. 
Its  activity  comes  from  binding  to  TLR9  which  in  mice  results  in  a 
predominantly Th1  response  (Krieg,  2002).  It  has  also  been  shown  to  be 
effective  as  a  mucosal  adjuvant  promoting  mucosal  IgA  production 
(McCluskie et al., 2000).
Mucosal  immunisation  is  thought  to  have  advantages  over  traditional 
immunisation including the ability to induce local/mucosal as well as systemic 
immunity,  and  the  production  of  secretory  IgA  to  specific  pathogens  at 
mucosal surfaces to prevent the binding of pathogens and therefore prevent 
infection (Freytag et al., 2005).  The elimination of the need of using needles 
for vaccination  would  also  be  of a  practical  benefit.  The  most  investigated 
mucosal adjuvants are cholera toxin (CT) and E.  coli heat labile enterotoxin 
(LT).  They  are  strong  mucosal  adjuvants  although  they  are  too  toxic for 
human  use.  The  mechanism  of  action  has  been  attributed  to  enhanced 
presentation  to  a  variety  of  cell  types  especially  APCs,  the  induction  of
132isotype  switching  in  B  cells  to  increase  the  production  of  IgA,  influencing 
cytokine production and enhancing the uptake of the co-administered antigen 
(Holmgren et al., 2003).
As  mentioned  in  the  previous  chapter,  NOMVs  and  its  components  have 
been  shown  to  have  immunomodulatory  properties,  including  enhancing 
antibody  responses,  inducing  cytokine  production  and  upregulation  of 
costimulatory molecules on  immune cells (Saunders et al.,  1999;  Sprong  et 
al., 2001; Al-Bader et al., 2003; Massari P, 2003).  The mechanism by which 
NOMVs exert their action is not fully understood and we sought to determine 
further the immunomodulatory potential of NOMVs by investigating the role of 
LPS and non-LPS components.
4.2 Objectives
The  aim  of  the  work  in  this  chapter  was  to  investigate  the  possible 
mechanisms  of  adjuvant  action  and  the  immunomodulatory  properties  of 
NOMVs.
4.3 Results
4.3.1  Proliferation of splenocytes from C3H/HeN and C3H/HeJ mice in 
response to NOMVs.
Studies  were  carried  out  to  investigate  the  proliferation  of splenocytes  by 
NOMVs  using  splenocytes  from  C3H/HeN  and  C3H/HeJ  mice.  By  using 
C3H/HeJ  mice,  which  are  hyporesponsive to  LPS,  the effects  that are  not 
due to LPS were also examined.  Figure 4.1 A shows the proliferation of
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Figure 4.1  Proliferation  of splenocytes from  C3H/HeN  and  C3H/HeJ 
mice stimulated with NOMVs.
Spleens  were  taken  from  naive  C3H/HeN  and  C3H/HeJ  mice  and  cell 
suspensions  were  prepared.  Cells  (2  x  105  /well)  were  cultured  with 
medium alone or NOMVs (0.01-10/yg/ml).  Cells were pulsed with tritiated 
thymidine after 48h of culture and were frozen  18h  later.  Upon thawing 
proliferation  was  determined  using  a  scintillation  counter.  Panel  (A) 
compares splenocyte proliferation between C3H/HeN and C3H/HeJ mice, 
and  panel  (B)  proliferation  of  splenocytes  from  C3H/HeJ  mice.  Data 
represents the  mean  of three  experiments  ±  SEM.  For (A) C3H/HeN  ^  
C3H/HeJ and (B) media only  ^sample; * p<0.05, ** p<0.005.
134C3H/HeN  and  C3H/HeJ  splenocytes after stimulation for 48h  with  different 
concentrations of NOMVs.  Proliferation of splenocytes was measured by the 
incorporation of tritiated thymidine into DNA of dividing cells.  Both C3H/HeN 
and  C3H/HeJ  splenocytes  proliferated  in  a  dose  dependent  manner  to 
NOMVs and  proliferation  between  the two strains of mice was  significantly 
different (p < 0.05) when stimulated with different concentrations of NOMVs. 
Although  proliferation  in  C3H/HeJ  mice  (figure  4.1B)  was  also  dose 
dependent,  the  level  of  proliferation  was  approximately  six  fold  less, 
indicating that proliferation is not wholly dependent on LPS.
4.3.2  Proliferation of C3H/HeN and C3H/HeJ T and B cells in response to 
NOMVs.
It has been shown that splenocytes from C3H/HeN and C3H/HeJ are able to 
proliferate after culture with  NOMVs.  In order to determine which cell type 
was proliferating,  splenocytes were labelled with CFSE.  After labelling, the 
cells were cultured for 48h with NOMVs, and then labelled with anti-CD3 and 
anti-B220  antibodies,  markers  for  T  and  B  cells,  respectively.  As  cells 
proliferate,  the  intensity  of  CFSE  labelling  reduces,  which  is  shown  by 
individual  peaks.  PMA and  ionomycin  were  used  as  a  positive  control  to 
show  that  splenocytes  from  C3H/HeN  and  C3H/HeJ  mice  are  able  to 
proliferate.  PMA  and  ionomycin  are  commonly  used  to  induce  the 
proliferation  of T cells.  Figure 4.2 shows the lack of proliferation of T cells 
after  stimulation  with  NOMVs.  T  cells  from  both  C3H/HeN  and  C3H/HeJ 
mice did not show any proliferation in response to NOMVs, and their profiles 
are similar to those of splenocytes after stimulation with media only.
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Figure  4.2  CFSE  analysis  of  T  cell  proliferation  in  response  to 
NOMVs
Spleens  from  naive  C3H/HeN  and  C3H/HeJ  mice  were  taken  and  cell 
suspensions were  prepared.  Cells (1  x  107  cells/ml) were labelled with 
5/yM  CFSE  at  37°C  for  10mins.  Cells  were  then  cultured  with  either 
NOMVs,  PMA (5ng/ml)  +  ionomycin  (200ng/mi),  or media  alone.  After 
48hr,  cells were  labelled  with  anti-CD3  antibody and  examined  by flow 
cytometry.  The  CD3  positive  population  was  gated  on  to  determine 
proliferation.
136Figure 4.3 shows the proliferation of B cells in response to NOMVs.  B cells 
from  both  the  C3H/HeN  and  C3H/HeJ  splenocyte  populations  showed 
proliferation in response to NOMVs.  However proliferation was greater in B 
cells from the C3H/HeN  splenocyte population  indicating that although  LPS 
induced most of the proliferation, it was not totally dependent on LPS.
After determining that it was the  B cell  population  in  splenocytes that were 
proliferating, we wanted to ascertain whether the B cells were being directly 
stimulated to proliferate or that they were receiving help from other cells.  We 
therefore isolated B cells by negative selection and labelled them with CFSE, 
after which the cells were stimulated with NOMVs for 48h.  Figure 4.4 shows 
the proliferation of isolated B cells to NOMVs.  As shown isolated B cells from 
both  C3H/HeN  and  C3H/HeJ  mice  proliferated  in  response  to  NOMVs 
indicating that both  LPS  and  non-LPS components can  induce  proliferation 
and that there is direct stimulation of the cell population, indicating that other 
cell types are not necessary.
4.3.3  NOMVs stimulate the production of bactericidal NO by BMDMs.
Binding  of  bacterial  products  to  macrophages  stimulates  phagocytosis, 
producing toxic products such as NO, which are directly toxic to bacteria.  In 
order  to  investigate  whether  NOMVs  can  stimulate  the  production  of  NO, 
BMDMs  from  C3H/HeN  and  C3H/HeJ  mice  were  used.  BMDMs  were 
cultured  for  48h  with  different  concentrations  of  NOMVs  after  which  the 
supernatant was removed and NO production was measured using theC3H/HeN C3H/HeJ
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Figure  4.3  CFSE  analysis  of  B  cell  proliferation  in  response  to 
NOMVs
Spleens from  naive  C3H/HeN  and  C3H/HeJ  mice  were taken  and  cell 
suspensions were  prepared.  Cells  (1  x 107  cells/ml) were labelled with 
5ji/M  CFSE  at  37°C  for  10mins.  Cells  were  then  cultured  with  either 
NOMVs or media alone.  After 48hr,  cells were labelled with  anti-B220 
antibody and examined by flow cytometry.  The B220 positive population 
was gated on to determine proliferation.
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Figure  4.4  CFSE  analysis  of  isolated  B  cell  proliferation  in 
response to NOMVs
Spleens  from  naive  C3H/HeN  and  C3H/HeJ  mice  were  taken  and  B 
cells were  isolated  using  a  Dynal  B  cell  negative  isolation  kit.  The  B 
cells (1  x 107  cells/ml) were then  labelled with  5//M  CFSE at 37°C for 
10mins.  The  cells  were  then  cultured  with  either  5/yg/ml  NOMVs  or 
media  alone.  After 48hr,  cells  were  labelled  with  anti-B220  antibody 
and  examined  by flow  cytometry.  The  B220  positive  population  was 
gated on to determine proliferation.
139Griess assay, which measures nitrite, a breakdown product of NO.  As shown 
in figure 4.5A,  NO  is  produced  in  a  dose  dependent manner by  BMDM  in 
response  to  stimulation  with  NOMVs.  Production  of  NO  was  significantly 
greater  (p<0.05)  in  BMDMs  from  C3H/HeN  mice  stimulated  with 
concentrations  of  0.01-1pg/ml  NOMVs.  BMDMs  from  C3H/HeJ  mice 
produced  approximately two  fold  less  NO  (figure  4.5B)  than  BMDMs from 
C3H/HeN  mice  demonstrating  that  non-LPS  components  are  also  able  to 
produce toxic products.  The level of NO production was significantly higher 
(p<0.005)  in  BMDMs  from  C3H/HeJ  mice  when  stimulated  at  10pg/ml 
compared to the other concentrations.
4.3.4  Cytokine production from C3H/HeN and C3H/HeJ BMDCs after 
stimulation with NOMVs.
BMDCs from  C3H/HeN  and  C3H/HeJ  mice were cultured with  NOMVs and 
the  cytokine  profile was determined.  Supernatants were  removed  after 24 
and 48h and analysed using a cytokine Cytometric Bead Array (CBA) assay. 
Figure  4.6  shows  the  cytokine  release  from  BMDCs.  The  production  of 
IL12p70, IFN-y and IL-10 is shown in figure 4.6A.  Stimulation of BMDCs with 
NOMVs  for  24h  increases  the  production  of  IL12p70  and  IL-10  in  both 
C3H/HeN and C3H/HeJ mice.  After 48h the levels of both of these cytokines 
is  still  slightly  increased  in  NOMV  stimulated  cells  than  in  cells  stimulated 
with media alone.  Figure 4.6B shows the production of TNF-a,  MCP-1  and 
IL-6.  A  vast  increase  is  seen  in  the  production  of TNF-a  and  IL-6  after 
stimulation with NOMVs in both strains of mice.  There is considerable
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Figure  4.5  Nitrite  production  from  BMDMs  from  C3H/HeN  and 
C3H/HeJ mice stimulated with NOMVs.
BMDMs  from  C3H/HeN  and  C3H/HeJ  mice  were  stimulated  with 
medium  alone  and  NOMVs.  After 48hrs,  cell  culture supernatant was 
removed  and  the  Griess  assay  was  used  to  measure  nitrite  as  an 
indicator of NO production.  Panel (A) compares nitrite production from 
BMDMs of C3H/HeN and C3H/HeJ mice, and (B) nitrite production from 
C3H/HeJ mice.  Data represents the mean of three experiments ± SEM. 
For (A) C3H/HeN  ^C3H/HeJ and (B) media only  ^sample; * p<0.05, ** 
p<0.005.
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Figure 4.6 Cytokine release from C3H/HeN and C3H/HeJ mouse 
BMDCs after culture with NOMVs.
BMDCs from  naive C3H/HeN  and  C3H/HeJ  mice were prepared  and 
(2  x  106/tube)  cultured  with  5//g/ml  of  NOMVs.  Supernatant  was 
removed from each tube after 24 and 48h.  Cytokines IL12p70,  IFN-y, 
IL-10  (A)  TNF-a,  MCP-1  and  IL-6  (B)  were  analysed  by  a  cytokine 
Cytometric  Bead  Array  (CBA)  assay  (BD  Biosciences,  Pharmingen). 
Data represents the mean of five experiments ± s.e.m.
142production of IL-6 from BMDCs from both C3H/HeN and C3H/HeJ mice and 
these levels are consistent over the two periods of time measured.
4.3.5  Cytokine production from C3H/HeN and C3H/HeJ splenocytes after 
stimulation with NOMVs.
Splenocytes from  C3H/HeN  and  C3H/HeJ  mice were cultured with  NOMVs 
and the cytokine profile was determined.  Supernatants were removed after 
48h  and  analysed  using  a  CBA  assay.  Figure  4.7  shows  the  release  of 
cytokines  from  C3H/HeN  and  C3H/HeJ  splenocytes  when  stimulated  with 
5pg/ml  NOMVs.  Splenocytes from C3H/HeN and C3H/HeJ  mice stimulated 
with  media  alone  produced  very  little  cytokines,  whereas  stimulation  with 
NOMVs  produced  TNF-a,  IFN-y,  IL-10,  MCP-1  and  IL-6.  Notably 
splenocytes from C3H/HeJ produced less IL-10 but greater amounts of IFN-y 
than splenocytes from C3H/HeN mice.  However levels of TNF-a, MCP-1 and 
IL-6  were  similar  in  supernatants  from  both  sets  of  splenocytes.  The 
differences in cytokine production from C3H/HeN and C3H/HeJ splenocytes 
could  be  as  a  result  of  the  effect  of  LPS  as  C3H/HeJ  mice  are  hypo- 
responsive  to  LPS.  The  production  of  IL12p70  was  not  detectable  in 
splenocytes  from  either  strain  of  mice  after 48h,  therefore  IL12p70  levels 
were studied at various time points (18h and 24h), however production of the 
cytokine was not detected by the CBA assay.
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Figure 4.7 Cytokine release from C3H/HeN and C3H/HeJ mouse 
splenocytes after culture with NOMVs.
Spleens  from  naive  C3H/HeN  and  C3H/HeJ  mice  were  removed  and 
single  cell  suspensions  were  prepared.  Cells  (2  x  105 /well)  were 
cultured with  5//g/ml of NOMVs.  Supernatant was removed from each 
well after 48h.  Cytokines were analysed by a cytokine Cytometric Bead 
Array (CBA) assay (BD Biosciences,  Pharmingen).  Data represents the 
mean of three experiments ± s.e.m.
1444.3.6 Cytokine production from C3H/HeN and C3H/HeJ splenocytes after 
stimulation with NOMVs and anti IL-10 receptor antibody.
After  stimulation  with  NOMVs,  splenocytes  from  C3H/HeN  and  C3H/HeJ 
mice produced a fairly large amount of IL-10 but no IL12p70.  We therefore 
wanted  to  investigate  whether  the  production  of  IL-10  was  inhibiting  the 
production of IL12p70.  In order to do this the splenocytes were cultured for 
1h  with  10pg/ml  anti-mouse  IL-10  receptor  (IL-10R)  antibody  before 
stimulation  with  NOMVs.  The  supernatants  were  removed  after 48h  and 
analysed  using  a  CBA  assay.  As  previously  described,  stimulation  with 
media  alone  produced  very  little  cytokines.  Figure  4.8A  shows  that 
splenocytes from  both  strains of mice  cultured with  IL-10R antibody before 
stimulation  with  NOMVs  produced  more  TNF-a,  INF-y  and  IL-6.  The 
splenocytes from C3H/HeN mice cultured with the IL-10R antibody produced 
a three-fold increase of IL12p70, and the splenocytes from C3H/HeJ mice a 
two-fold  increase  (figure  4.8B).  Splenocytes  from  both  C3H/HeN  and 
C3H/HeJ  mice  produced  cytokines  in  a  dose  dependent  manner  when 
stimulated with  IL-10R at concentrations from 0.001  -  10pg/ml and  NOMVs 
(data not shown).
4.3.7 The production of type 1  interferons from splenocytes stimulated 
with NOMVs and anti IL-10R antibody.
The supernatant from splenocytes in the above study were also assayed for 
IFN-a and IFN-(3 using ELISA kits.  Figure 4.9 shows the production of IFN-p 
from splenocytes of C3H/HeN and C3H/HeJ mice.  After 24h stimulation with
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Figure 4.8 Cytokine release from C3H/HeN and C3H/HeJ mouse 
splenocytes after culture with NOMVs and anti IL-10R antibody
Spleens  from  naive  C3H/HeN  and  C3H/HeJ  mice  were  removed  and 
single  cell  suspensions  were  prepared.  Cells  (2  x  105/well)  were 
cultured with anti  IL-10R (10/yg/ml) for one hour before stimulation with 
5/yg/ml of NOMVs.  Supernatant was removed from each well after 48h 
and cytokines  IL12p70,  IFN-y,  MCP-1, TNF-a,  IL10 and  IL-6 (A), or IL- 
12p70  (B)  were  analysed  by  a  cytokine  CBA  assay  (BD  Biosciences, 
Pharmingen).  Data represents the mean of three experiments ± s.e.m.
146250
■  C3H/HeN 24h  ^C 3H /H eJ 24h 
EIin]C3H/HeN 48h  EM]C3H/HeJ 48h
O )
o.
200
150
100
50
0 - lfa k i£ iii-----
RPMI NOMV IL-10R + NOMV
Figure 4.9 IFN-/? release from C3H/HeN and C3H/HeJ splenocytes 
after culture with NOMVs and anti IL-10R antibody
Spleens  from  naive  C3H/HeN  and  C3H/HeJ  mice  were  removed  and 
single  cell  suspensions  were  prepared.  Cells  (2  x  105/well)  were 
cultured  with  10//g/ml  anti  IL-10R for one  hour before  stimulation  with 
5/yg/ml of NOMVs.  Supernatant was removed from each well after 24h 
and  48h.  IFN-£  was  analysed  by  a  mouse  interferon  beta  ELISA  kit 
(Biosource).  Data represents the mean of four experiments ± s.e.m.
147NOMVs, the splenocytes from  C3H/HeN  mice produced  IFN-(3,  with slightly 
decreased  levels  after  48h  stimulation.  After  24h  and  48h  stimulation  of 
splenocytes from C3H/HeJ mice, there was no detection of IFN-p.  A two-fold 
increase in  IFN-p  production from  splenocytes of C3H/HeN  mice was seen 
after 24h stimulation with IL-10R antibody and NOMVs than after stimulation 
with NOMVs alone.  There was no significant difference in IFN-p production 
when  splenocytes from  C3H/HeJ  mice were  cultured  with  IL-10R  antibody 
before  stimulation  with  NOMVs  than  after  stimulation  with  NOMVs  alone, 
indicating  that  LPS  influences  the  production  of  IFN-p.  Splenocytes 
stimulated with media alone produced very little IFN-p.
Supernatants from  the  same assays were also assayed for IFN-a.  In  both 
strains of mice, and after 24h and 48h stimulation with NOMVs no IFN-a was 
detected.
4.4  Discussion
Previous  results  in  this  thesis  have  indicated  that  NOMVs  are  able  to 
augment  antibody  responses  to  certain  antigens  therefore  possessing 
adjuvant and  immunomodulatory activity.  This chapter examined the effect 
of NOMVs on  different cell  populations from  C3H/HeN  and  C3H/HeJ  mice. 
NOMVs  induced  the  proliferation  of splenocytes from  both  strains  of mice, 
shown  by  thymidine  incorporation,  indicating  that  proliferation  was  not 
dependent  on  LPS.  Proliferation  was  approximately  five  times  higher  in 
splenocytes from C3H/HeN mice than C3H/HeJ mice and the response was 
shown  to  be  dose  dependent.  Further  experiments  were  carried  out  to 
determine  which  cell  population  was  proliferating.  By  CFSE-labelling  of
148splenocytes  it was shown  that  B  cells,  but  not T  cells were  proliferating  in 
response to NOMVs, in both strains of mice.  PMA and ionomycin was used 
as a control to measure T cell proliferation.  Ionomycin is a calcium ionophore 
that is used in conjunction with PMA.  PMA activates protein kinase C, which 
is important in cell division and can only induce proliferation in the presence 
of calcium ions.
Proliferation of B cells was shown to be by the direct action of NOMVs and 
that other cell types were  not involved,  by negatively isolating  B cells from 
splenocytes  of  both  strains  of  mice.  Greater  proliferation  was  most  likely 
seen in total splenocytes and B cells from C3H/HeN mice, as LPS is a known 
polyclonal activator of B cells.  However these studies have also shown that 
proliferation  can  also  occur  independently of LPS.  Previous  studies  have 
shown that meningococcal outer membrane preparations consisting of mainly 
porins  are  able to act as  B  cell  mitogens  (Melancon  et al.,  1983).  A later 
study  by Wetzler  and  colleagues  (1996)  confirmed  that  purified  neisserial 
porins  can  induce  B  cell  proliferation,  and  that  proliferation  was  not  as  a 
result  of  LPS  contamination  by  using  isolated  B  cell  populations  from 
C3H/HeJ  mice.  They  also  described  upregulation  of  the  costimulatory 
molecule, B7-2 on the surface of B cells suggesting a possible mechanism of 
adjuvant activity.  The ability of porins to stimulate B cells and to upregulate 
the expression of B7-2 was shown to be dependent on TLR2 and MyD88 by 
using TLR2- and MyD88-knockout mice (Massari et al., 2002).
The  work  in  this  chapter and  published  findings  by other groups  suggests 
that  NOMVs  are  able  to  activate  immune  cells  through  TLR2  and  TLR4.
149Work  carried  out  in  collaboration  with  Valerie  Quesniaux  and  colleagues 
further  established  that  NOMVs  could  signal  through  either  of  these 
receptors.  This was shown by the production of TNF-a and NO by BMDCs 
and  BMDMs from  TLR2*7 '  and  TLR4'7 '  knockout  mice  after stimulation  with 
NOMVs.  The response in double knockout mice was little to absent implying 
that signalling occurs mostly through TLR2 and TLR4.
The  ability  of  NOMVs  to  stimulate  the  production  of  NO  was  further 
established using BMDMs from C3H/HeN and C3H/HeJ mice.  Phagocytosis 
of  pathogens  by  macrophages  and  neutrophils  produces  a  variety of toxic 
products including NO and hydrogen peroxide to help kill the pathogen.  NO 
is produced  by inducible nitric oxide synthase,  iNOS2.  NO production was 
seen in the supernatant of BMDMs from both strains of mice and in a dose 
dependent  manner.  Levels  of NO  production  were  approximately two fold 
less  in  BMDMs from  C3H/HeJ  mice,  indicating  that  LPS  to  an  extent  can 
influence the production of NO.  Previous reports have shown NO production 
by  peritoneal  macrophages  stimulated  with  Nm.  This  response  was  also 
shown  to  be  mostly  dependent  on  LPS  by  using  C3H/HeJ  mice 
(Mukhopadhyay et al., 2004).  An earlier study indicated both protective and 
pathological  roles  of  NO.  This  study  showed  that  although  NO  could 
increase levels of TNF-a induced by meningococcal LPS, which is known to 
initiate endotoxic shock, NO may also have a beneficial role for macrophages 
anti-Nm bactericidal activity (Padron et al., 1999).  The production of NO has 
also been shown to be regulated by IFN-y, which can induce iNOS catalysing 
the oxidation of arginine to produce NO (Nathan, 1997).
150The effect of NOMVs on the release of cytokines from  BMDCs of C3H/HeN 
and C3H/HeJ mice were investigated after culture for 24 and 48h.  Moderate 
levels  of  IL-10,  low  levels  of  IL12p70  and  no  IFN-y  were  found  in  the 
supernatants  of  BMDCs  from  both  strains  of  mice  after  stimulation  with 
NOMVs for 24h in comparison to cells cultured with media alone.  After 48h 
levels of IL-10 decreased by approximately two fold.  At both time points very 
high levels of IL-6 were exhibited in both strains of mice.  TNF-a production 
was  also  fairly  high  after  24h  in  both  strains  of  mice,  with  slightly  lesser 
amounts produced after 48h.  These results show that the profile of cytokine 
production  by  BMDCs  is  not dependent on  LPS.  The activation  of human 
monocyte-derived  DCs  by  components  of  the  meningococcal  outer 
membrane  has  been  described  and  demonstrated  by  an  increase  in  the 
production of proinflammatory cytokines and the expression of costimulatory 
molecules such as CD80 and  CD86 (Dixon et al., 2001;  Kolb-Maurer et al., 
2001; Al-Bader et al., 2003).  A recent paper has also described the ability of 
PorB to induce the maturation of murine splenic DCs and BMDCs as shown 
by increased expression of CD86,  MHC  II  and  the production of IL-6.  The 
activation of DCs was found to be dependent on TLR2 and MyD88 (Singleton 
et  al.,  2005).  This  work  further  demonstrates  the  immunomodulatory 
properties of non-LPS components of meningococci.
Cytokine release from splenocytes of C3H/HeN and C3H/HeJ mice was also 
investigated  after  culture  with  NOMVs.  Splenocytes  from  C3H/HeN  mice 
produced high levels of TNF-a and  IL-10, and lower levels of IFN-y,  MCP-1
151and IL-6 in response to stimulation with NOMVs.  In comparison splenocytes 
from  C3H/HeJ  mice  produced  similar amounts of TNF-a,  MCP-1  and  IL-6, 
but higher levels of IFN-y and lower amounts of IL-10.  Culture of splenocytes 
from both strains of mice with media only induced very little amounts of any 
of  the  cytokines.  Our  findings  are  in  agreement  with  others,  which 
demonstrate that LPS  is  not the  only component of meningococci  that can 
induce cytokine production (Uronen et al., 2000; Sprong et al., 2001).
The production of IFN-y by cells stimulated with NOMVs could partly explain 
why there was  production  of  lgG3  and  lgG2a when  mice were  immunised 
with  NOMVs  in  the  previous  chapter,  as  IFN-y  is  known  to  induce  isotype 
switching to these subclasses.  IL-6 has also been reported to be involved in 
the differentiation of B cells to antibody producing  plasma cells, which also 
induces isotype switching (Hirano,  1998).  The production of IL-6 was seen 
from  BMDCs  and  splenocytes  from  C3H/HeN  and  C3H/HeJ  mice  after 
stimulation with  NOMVs.  IL-6  has  been  shown to  be  produced  by several 
cell types including APCs, T cells and B cells and can induce the proliferation 
of B cells, which could explain the splenocyte proliferation seen in this study. 
There  was  no  production  of  IL12p70  by  splenocytes  from  either  strain  of 
mice.  IL-12 is a heterodimeric cytokine composed of p40 and p35 subunits. 
The  p40  subunit is  produced  in  greater quantities than the  p35  unit,  which 
requires  coexpression  of  the  p40  subunit  for  secretion  of  the  biologically 
active cytokine.  Free  p40 can  be  present as monomers or homodimers in 
mice, and  both have been proposed as inhibitors of biologically active IL-12 
(Gillessen  et  al.,  1995).  In  our  investigation  we  only  measured  IL12p70, 
therefore large amounts of IL12p40 could have been produced inhibiting the
152production of IL-12.  IL-12 induces T cells and  NK cells to produce several 
cytokines  including  IFN-y.  Surprisingly,  even  though  there  was  no  IL-12 
production, there was still production of IFN-y.
IL-18 has been described as an IFN-y-inducing factor, that is similar to IL-12 
and that is required to produce IFN-y (Okamura et al.,  1995).  It is generally 
thought  that  IL-18  alone  is  unable  to  stimulate  IFN-y  production  and  the 
presence  of both  IL-12  and  IL-18  is  required for the efficient production  of 
IFN-y.  However reports have indicated IL-12-independent IFN-y production, 
which is dependent on IL-18  (Xing et al., 2000; Muller et al., 2001).  Another 
member of the IL-12 family,  IL-27, has also been discovered that synergises 
with  IL-12  to  produce  IFN-y  in  T  cells.  IL-27  is  a  heterodimeric  protein 
composed of Epstein-Barr virus (EBV)-induced gene 3 (EBI3), a p40-related 
protein and  p28 (Pflanz et al.,  2002).  Therefore in future studies it may be 
necessary to measure  IL-18 and  IL-27 in order to determine whether these 
cytokines are also influencing IFN-y production.
The  production  of  IL-12  is  regulated  by  several  mechanisms.  Negative 
regulation of IL-12 production can be due to the production of IL-10, which is 
a potent inhibitor of IL-12 (D'Andrea et al., 1993; Aste-Amezaga et al., 1998). 
As  seen  in  figure  4.6,  splenocytes from  both  strains  of mice  cultured  with 
NOMVs produced IL-10, although levels were greater in C3H/HeN mice than 
in C3H/HeJ mice.  In order to determine whether the production of IL-10 was 
having a negative effect on the production of IL-12, before stimulation of the 
splenocytes  with  NOMVs,  the  cells  were  cultured  with  IL-1 OR  antibody 
therefore  preventing  the  binding  of  IL-10  to  its  receptor  and  not  the 
production  of  IL-10.  The  cytokine  profile  from  the  splenocytes  from  both
153strains of mice indicated that pre-incubation with the IL-1 OR antibody before 
stimulation with NOMVs increased the production of IL12p70 in comparison 
to  cells  cultured  with  NOMVs  or  media  alone.  An  increase  in  IFN-y 
production was also observed  in the supernatants from splenocytes treated 
with IL-1 OR antibody and NOMVs.  The production of IL12p70 by splenocytes 
was shown to be dose dependent on the amount of IL-1 OR cultured with the 
cells  indicating  that  even  the  smallest  amount  of  IL-10  can  inhibit  the 
production of IL-12.  This dose dependency was also seen to a certain extent 
for  the  production  of  IFN-y,  indicating  that  IL-12  production  could  have  a 
positive influence on IFN-y production.
Type  1   interferons  (IFN-a/p)  are  most commonly  known to  be  produced  in 
response to viral infection however they can also be expressed as a result of 
bacterial  infection or by components of bacteria such as LPS and  bacterial 
DNA (Bogdan, 2000).  A recent study has shown that type I IFNs signal as a 
link between innate and adaptive immunity by demonstrating that not only are 
type I IFNs produced by DCs, but they can cause the maturation of DCs (Le 
Bon et al., 2002).  In humans the type  1   IFNs consist of 14 IFN-a subtypes 
and  IFN-p,  -5,  - t ,   -to ,  - k   and  limitin.  Our results showed  NOMVs induced 
the  production of IFN-p from  splenocytes of C3H/HeN  mice,  but not IFN-a. 
The production of IFN-p was shown to be dependent on LPS, as there was 
very little to none produced from splenocytes of C3H/HeJ mice.  It has been 
previously shown that LPS induces predominantly IFN-p (Toshchakov et al., 
2002) and that it can regulate the differentiation or activation of most effector 
cells  including  DCs  and  B  cells  (Bellardelli  et  al.,  1996).  Analysis  of
154supernatants  from  splenocytes  cultured  with  IL-1 OR  antibody  and  NOMVs 
showed an increase in IFN-p production implying that levels of IFN-p can be 
influenced  by the  production  of  IL-12,  whose  production  is  increased  after 
blocking the action  of IL-10.  A recent study has demonstrated  that type  1  
IFN is required for the production of IL-12 in an autocrine manner (Gautier et 
al.,  2005).  Further studies  in  our  laboratory  (Durand  et al.,  manuscript  in 
preparation)  demonstrated  that  i.m.  injection  of  NOMVs  in  C3H/HeN  mice 
produced  a  rapid  and  short-lasting  production  of  IFN-p  in  sera  2h  post 
immunisation, and this production was not seen in C3H/HeJ mice, supporting 
the work carried  out in  vitro.  Lower levels of  IFN-a were  demonstrated  in 
sera  from  both  C3H/HeN  and  C3H/HeJ  mice  however the  levels  declined 
rapidly after 2h.  NOMVs were also able to induce cross-priming against Ova 
indicated  by  a  significant  increase  in  CD8+  T cells after i.m.  immunisation. 
Cross-priming was found to be dependent on the IFN-a/p pathway indicated 
by a decrease in CD8+  T cells in IFN-a/pR-deficient mice.
Our results indicate that NOMVs have the potential to be an adjuvant as they 
are able to target cells of the immune system inducing mechanisms that link 
innate and adaptive responses.  NOMVs are able to stimulate the production 
of  cytokines  that  can  target  APCs.  For  example  TNF-a  can  induce  DC 
maturation, influencing the migration of DCs to T cell areas in tissues and to 
present antigen (McWilliam et al., 1996).  The production of cytokines by DCs 
and other cell types is important in T cell differentiation, for instance IL-12 is 
crucial  in  the  development of Th1  responses  (Trinchieri,  1993;  Celia  et al., 
1996).
155In conclusion, our results suggest that NOMVs have adjuvant properties that 
stimulated  APC  functions  and  proliferation,  and  enhanced  production  of 
cytokines that are  important for B  and  T cell  responses.  More  importantly 
NOMVs’  effects are  not wholly dependent on  LPS.  Having  shown this we 
wanted  to  investigate  the  effect  of  NOMVs  on  mucosal  immunity  that 
operates in mainly a Th2-biased microenvironment.
156CHAPTER 5
The effect of NOMVs on lung inflammation and immunity
5.1  Introduction
Asthma is a common chronic disease in children and a major risk factor for 
asthma is allergy.  Allergic asthma is a Th2-associated disease characterised 
by chronic airway inflammation, the secretion of IL-4,  IL-5 and  IL-13 by Th2 
lymphocytes,  the  infiltration  of  eosinophils  in  response  to  certain  antigens 
and  elevated  levels  of  serum  IgE  (Savelkoul  et al.,  2000;  Barends  et  al., 
2004).
Lung eosinophilia is a characteristic of allergic asthma and it is thought that 
the  infiltration  of  eosinophils  is  key  to  the  pathogenesis  of  the  disease. 
Eosinophilia is regulated in three ways: (1) adhesion receptors that allow firm 
adhesion  of  eosinophils  to  the  vascular  endothelium;  (2)  factors  such  as 
cytokines and  chemokines which  influence the recruitment and migration of 
eosinophils to the  inflammatory site;  and  (3)  leukocytes which  regulate the 
expression and  release of cytokines and chemokines.  Eosinophils are able 
to  cause  tissue  damage  by  releasing  inflammatory  mediators  such  as 
eosinophil peroxidase and eosinophil-derived neurotoxin, as well as being a 
source  of the  majority  of Th2  cytokines  (Boehme  et al.,  2004;  Zhu  et al.,
2004).
A  strong  correlation  has  been  shown  between  the  level  of  cytokines 
produced  by  activated  T  cells  and  the  degree  of  damage  in  the  lung  by
157eosinophils.  IL-4  is  a  principle  Th2  cytokine,  which  drives  Ig  isotype 
switching by B cells towards IgE synthesis and whose main role is during the 
initial  priming  of  Th2  effector  cells  (Herrick  et  al.,  2003).  IL-5,  primarily
produced  by activated  T  cells,  promotes the differentiation,  maturation  and 
recruitment  of  eosinophils  (Sanderson,  1992;  Delayre-Orthez  et  al.,  2004; 
Kay et al., 2004).
Chemokines  such  as  eotaxin  (CCL11),  RANTES  (CCL5)  and  monocyte 
chemoattractant protein (MCP-1/CCL2) have also been shown to be involved 
in  the  development  of asthma  (Wohlleben  et al.,  2003).  Eotaxin  was first 
identified  in  BAL  fluid  of  Ova-sensitised  guinea  pigs  (Jose  et  al.,  1994), 
however  human  eotaxin  (Ponath  et al.,  1996a;  Ponath  et al.,  1996b)  and 
murine eotaxin (Gonzalo et al., 1996) have also been described.  Eotaxin has 
been  shown  to  bind  CCR3,  which  is  highly  expressed  on  eosinophils and 
basophils,  but  is  also  present  on  T  cells  and  epithelial  cells.  It  is  able to 
induce  the  migration  of  eosinophils  as  well  as  attract  basophils  and  Th2 
lymphocytes (Daugherty etal., 1996; Teran, 2000; Lukacs, 2001).
The  incidence  of  asthma  is  steadily  increasing  and  the  reason  for  this  is 
unknown.  Changes  in  the  environment,  such  as  exposure  to  microbial 
compounds and  improved  health care and  hygiene practice have led to the 
hygiene  hypothesis.  This  hypothesis  states  that  decreased  exposure  to 
infections early on  in  life is increasing the prevalence of allergic disease as 
lack  of  exposure  to  infectious  diseases  hinders  the  establishment  of Th1 
biased immunity (Herz et al., 2000).  The prevalence of allergic disease tends 
to  be  higher  in  the  developed  world  rather  than  the  developing  world
158(Hawrylowicz et al., 2005).  Infection with heat-killed Listeria monocytogenes, 
a  Gram  positive  bacteria,  has  been  shown  to  provoke  a  Th1-dominated 
response  that  is  able  to  reduce  airway  inflammation  and  eosinophilia  in  a 
murine model of asthma (Yeung et al.,  1998; Hansen et al., 2000).  Similarly 
Erb  and  colleagues  (1998)  demonstrated  using  a  murine  model  of  Ova- 
induced  airway  eosinophilia  that  i.n.  infection  with  Mycobacterium  bovis- 
Bacillus  Calmette-Guerin  (BCG)  four  or  12  weeks  before  allergen  airway 
challenge resulted in a significant reduction in eosinophilia in the lungs.  They 
reported  that  Th2  responses  were  suppressed  by  IFN-y  produced  in 
response to BCG infection and they have demonstrated similar results using 
heat  killed  BCG  (Major  et al.,  2002).  More  recently  heat-killed  Bordetella 
pertussis  has  been  shown  to  inhibit  Ova-induced  allergic  responses  in  a 
murine model, again characterised by a decrease in eosinophil accumulation 
in  the airway and down-regulation  of Th2 cytokines.  This was found to be 
due  to  unmethylated  CpG  motifs  in  the  DNA of the  bacteria  activating  the 
TLR9  pathway  (Kim  et  al.,  2004).  Previous  to  these  studies  it  has  been 
shown  that  administration  of  unmethylated  CpG  oligodeoxynucleotides 
(ODNs)  before  allergen  challenge  could  decrease  allergen-induced 
eosinophilia and the number of allergen-specific IgE-producing cells, and that 
IFN-y has a crucial role in aiding these effects (Broide et al.,  1998;  Kline et 
al.,  1998; Sur et al., 1999).  The mechanism of how this is achieved has been 
partly described  in a recent study by Hessel et al.,  (2005).  They described 
two distinct pathways.  The first is by preventing the induction of cytokines by 
Th2 cells, which is achieved by APCs being unable to present antigen to Th2
159cells, but not Th1  cells.  The second pathway is by inhibiting cytokines such 
as IL-4 that influence the production of IgE.
Experiments carried out by Etchart and colleagues (2006) in mice sensitised 
with  iRSV  demonstrated  that  i.n.  immunisation  of  NOMVs  were  able  to 
prevent the accumulation of eosinophilia in the lungs of mice after live RSV 
challenge.  Viral  respiratory infection  by RSV in infants has been described 
as  a  risk factor  in  acquiring  allergic asthma,  as well  as frequently causing 
bronchiolitis and  pneumonia  in  infants and  young  children  (Connors  et al., 
1992;  Schwarze et al.,  1998).  It has been shown that mice immunised with 
iRSV  produce  a  predominantly Th2-like  response,  characterised  by a  high 
ratio of IL-4 to IFN-y mRNA in the lungs (Waris et al., 1996).  It has also been 
shown that IL-4 and  IL-5 both  have a major role in lung eosinophilia during 
RSV infection, as mice treated with anti-IL-5 prevented eosinophilia and IL-4 
deficient mice were devoid of eosinophils (Schwarze et al., 2000).
It  is  not just the effects of bacteria  or bacterial  products, which  have  been 
shown to prevent allergic inflammation.  IL-15 has been previously shown to 
accelerate  allergic  sensitisation  in  mice.  By  blocking  the  effects  of  IL-15 
using  a  soluble  IL-15  receptor antibody,  the  production  of allergen-specific 
IgE and eosinophil recruitment were reduced (Ruckert etal., 2005).
Recent  studies  have  also  indicated  that  Th2  allergic  responses  could  be 
regulated  by T regulatory (Tr) cells.  Naturally occurring Tr cells originate in 
the thymus and represent 5-10% of CD4+  T cells in humans and mice.  It has 
been  proposed that they do this by secreting large amounts of IL-10, which
160has been shown to protect mice from allergen-induced Th2 responses.  IL-10 
is able to suppress both total and allergen-specific IgE  but can also induce 
lgG4  production.  It can  also down-regulate eosinophil function and  activity 
as well as inhibiting the production of IL-5.  Several reports have described 
this possible association in humans and as Tr cells are major producers of IL- 
10 this  has  been  proposed  as  a  possible  mechanism,  however there have 
also been some contradictory results suggesting that IL-10 has no effect on 
Th2 responses (Erb et al.,  2002;  Robinson  et al., 2004;  Hawrylowicz et al.,
2005).
Taking into account previous reports and our preliminary data we wanted to 
determine whether i.n.  immunisation of NOMVs could  have the same effect 
as shown with CpG ODNs and BCG and be able to reduce lung inflammation 
pathology  for  example  by  inhibiting  the  characteristics  of  allergic  asthma, 
such  as  the  development  of eosinophilia  by  using  murine  models  of  Ova- 
induced and iRSV-induced eosinophilia.
5.2  Objective
The  aim  of  the  work  in  this  chapter  was  to  investigate  the  effect  of  i.n. 
immunisation  of  NOMVs  on  lung  inflammation  using  murine  models  of 
allergen-induced allergy.
1615.3 Results
5.3.1  The effect of NOMVs on the development of lung inflammation
To address whether i.n. immunisation with NOMVs would have an effect on 
the  development of lung  inflammation,  C57BI/6  mice were  immunised  in  a 
model of Ova-induced allergy (see figure 2.3 for immunisation schedule).  In 
order  to  determine  whether  NOMVs  have  an  effect  the  number  of 
eosinophils,  lymphocytes  and  macrophages  was  assessed.  Figure  5.1 
shows the morphology of the cell types, which were enumerated  after BAL 
and  Wright-Geimsa  staining.  The  percentage  cell  type  and  absolute  cell 
numbers  in  the  BAL  fluid  were  calculated  as  described  in  the  methods 
(section 2.2.5).
Figure  5.2A  shows  that  Ova-sensitised  C57BI/6  mice  immunised  i.n.  with 
NOMVs  either  in  the  presence  or  absence  of  Ova  showed  a  significant 
decrease  (p<0.017) in the percentage of eosinophils in comparison to mice 
immunised with Ova alone.  There was no statistically significant difference in 
the  percentage  of  macrophages  and  lymphocytes  among  the  different 
immunised  groups  of  mice  (figure  5.2B  and  5.2C  respectively)  and  the 
percentage  of  macrophages  dominated  over  the  number  of  lymphocytes 
found in the BAL fluid.
Figure 5.3 shows the total number of the different cell types in the BAL fluid. 
As shown  in figure 5.3A, a  significant decrease (p<0.005) in the  number of 
eosinophils  was  observed  after  i.n.  immunisation  with  NOMVs  in  the 
presence or absence of Ova.  The number of macrophages and lymphocytes 
were slightly increased after immunisation with Ova plus NOMV however this 
increase was not statistically significant.
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Figure  5.1  Morphology  of  cell  types  after  BAL  and  Wright-Giemsa 
staining
C57BI/6 mice were immunised i.p. with either PBS or Ova once a week for 
two weeks.  Two weeks later the mice were then split into five groups and 
immunised  i.n.  with  either  PBS,  Ova,  NOMVs  or  Ova+NOMVs.  After  a 
further seven  days the  mice  were  culled  and  BAL was  carried  out.  The 
number  of  eosinophils  (Eo),  macrophages  (M)  and  lymphocytes  (L)  was 
enumerated by Wright-Giemsa staining.
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Figure 5.2 The effect of NOMVs on the percentage of Ova-induced cell 
infiltrates in the lungs.
C57BI/6  mice were  immunised  i.p.  with  Ova  once a week for two weeks. 
Two weeks later the mice were then split into four groups and  immunised 
i.n. with  either PBS,  Ova,  NOMVs or Ova+NOMVs.  After a further seven 
days the  mice were culled  and  BAL was carried  out.  The  number of (A) 
eosinophils;  (B)  macrophages  and  (C)  lymphocytes were  enumerated  by 
counting  15  random  fields  after Wright-Giemsa  staining.  The  results  are 
expressed  as  the  mean  and  SEM  of four  mice  from  one  representative 
experiment out of three.  Asterisks  indicate  a  value  significantly  different 
from that observed after i.n. infection with Ova, * p < 0.017
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Figure  5.3 The  effect of NOMVs  on  the total  number of Ova-induced 
cell infiltrates in BAL fluid.
C57BI/6  mice were  immunised  i.p.  with  Ova  once a week for two weeks. 
Two weeks later the  mice were then  split into four groups and  immunised 
i.n. with either PBS,  Ova,  NOMVs or Ova+NOMVs.  After a further seven 
days the  mice were  culled  and  BAL was carried  out.  The  number of (A) 
eosinophils;  (B)  macrophages  and  (C)  lymphocytes  were  enumerated  by 
Wright-Giemsa staining.  Individual mice are indicated by (•) and the mean 
as  (—).  These  data  represent  one  experiment  out  of  three.  Asterisks 
indicate a value significantly different from that observed after i.n.  infection 
with Ova, * p < 0.005.
1655.3.2  The  effect  of  NOMVs  on  preventing  lung  inflammation  after Ova 
challenge
Preliminary experiments indicated a decrease in eosinophil numbers after i.n. 
immunisation  with  NOMVs  either  in  the  presence  or  absence  of  Ova, 
therefore  we  wanted  to  determine  whether  i.n.  immunisation  with  NOMVs 
before  Ova  airway challenge would  reduce  or prevent further eosinophilia. 
Figure  5.4  shows  the  percentage  of  eosinophils,  lymphocytes  and 
macrophages in BAL fluid.  An increase in the percentage of eosinophils was 
seen  in  mice  that  were  immunised  with  Ova  before  challenge  with  Ova, 
compared to control mice.  I.n. immunisation with NOMVs in the presence or 
absence of Ova before Ova challenge brought about a significant decrease in 
eosinophil  numbers  (p=0)  in  the  BAL  fluid  in  comparison  to  Ova-only 
immunised  mice.  As previously observed,  the  percentage of macrophages 
dominated  over the  numbers of eosinophils and  lymphocytes  (figure 5.4B). 
The percentage of macrophages stayed constant among the different groups 
of  immunised  mice,  and  although  the  percentage  of  lymphocytes  differed 
slightly among the groups the difference was not statistically significant.  The 
total number of cells in the BAL fluid was calculated as previously described. 
Again  a  significant  decrease  (p<0.002)  in  the  number  of  eosinophils  was 
seen  in  mice  immunised with  NOMVs or Ova  plus NOMVs  before  i.n.  Ova 
challenge.  As  shown  in  figure  5.5B  and  5.5C  there  was  no  significant 
difference  in  the  number  of  macrophages  and  lymphocytes  after  i.n. 
challenge  with  Ova,  however a  slightly greater number of these  cell  types 
was found after immunisation with NOMVs.O
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Figure  5.4  The  effect  of  NOMVs  on  the  percentage  cell  type  in  the 
lungs of mice after sensitisation and challenge with Ova.
C57BI/6 mice were immunised  i.p. with Ova or PBS (control) once a week 
for two weeks.  Two weeks later the mice were then  split into five groups 
and immunised i.n. with either PBS, Ova, NOMVs or Ova+NOMVs.  After a 
further two  weeks  the  mice  were  all  immunised  i.n.  with  Ova  and  seven 
days later the mice were culled  and  BAL was carried out.  The number of 
(A) eosinophils;  (B)  macrophages  and  (C)  lymphocytes were  enumerated 
by counting the cell types in 15 random fields after Wright-Giemsa staining. 
The results are expressed  as the mean and  SEM from four mice and  are 
representative of one  experiment out of three.  Asterisks  indicate  a  value 
significantly different from that observed after i.n.  infection with Ova,  *  p =
0.
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Figure  5.5 The  effect of NOMVs  on  the total  cell  number in  the  BAL 
fluid of mice sensitised and challenged with Ova.
C57BI/6 mice were immunised  i.p. with Ova or PBS (control) once a week 
for two weeks.  Two weeks later the mice were then  split into five groups 
and immunised i.n. with either PBS, Ova, NOMVs or Ova+NOMVs.  After a 
further two weeks the  mice were  all  immunised  i.n.  with  Ova  and  seven 
days later the mice were culled  and  BAL was carried out.  The number of 
(A) eosinophils;  (B)  macrophages  and  (C)  lymphocytes were  enumerated 
by Wright-Giemsa  staining.  Individual  mice  are  indicated  by  (•)  and  the 
mean as (—).  These data represent one experiment out of three.  Asterisks 
indicate a value significantly different from that observed after i.n.  infection 
with Ova, * p < 0.002.
1685.3.3  The  effect  of  NOMVs  on  the  production  of  eotaxin  and  IgE 
antibodies.
The results in the above section suggest that immunisation with NOMVs can 
suppress  the  development  of  eosinophilia.  We  were  then  interested  to 
examine the  levels of eotaxin  in the supernatant of lung  homogenates and 
the levels of total  IgE  in the sera of infected  mice, which is shown  in figure 
5.6.  As demonstrated in figure 5.6A the amount of eotaxin found in each of 
the groups of mice was fairly constant,  indicating that NOMVs did  not have 
an effect on eotaxin levels.  The average amount of total serum IgE was also 
found  to  be  consistent  and  fairly  low  in  all  groups  of  mice  (figure  5.6B), 
however there was a considerable degree of variation in the amount of IgE 
produced ranging from 0 to 22ng/ml between individual mice of the different 
groups.
5.3.4 The effect of NOMVs on  lung  inflammation  using a RSV infection 
model.
As  a  decrease  in  lung  eosinophilia  was  observed  after  immunisation  of 
NOMVs in a murine model of Ova-induced lung eosinophilia, we then wanted 
to  determine  the  effect  of  NOMVs  after  i.n.  immunisation  with  RSV which 
induces a strongly Th2-biased environment (see figure 2.4 for immunisation 
schedule).
Figure  5.7  shows  the  percentage  of  eosinophils,  macrophages  and 
lymphocytes in BAL fluid of iRSV-sensitised mice, after i.n. immunisation with 
NOMVs in the presence or absence of iRSV prior to challenge with live RSV. 
A significant decrease (p<0.04) in the percentage of eosinophils was
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Figure 5.6  The effect of NOMVs on the production of eotaxin and 
IgE antibodies after sensitisation and challenge with Ova.
C57BI/6  mice were  immunised  i.p.  with  Ova  or PBS  (control) once  a 
week  for two  weeks.  Two  weeks  later the  mice  were  split  into  five 
groups  and  immunised  i.n.  with  either  PBS,  Ova,  NOMVs  or 
Ova+NOMVs.  After a further seven days the mice were all immunised 
i.n. with  Ova  and  seven days  later the  mice were terminally bled  and 
the lungs were  removed.  Supernatants from lung  homogenates were 
assayed for (A) eotaxin (1  in  10 dilution) and sera was assayed for (B) 
total  IgE (1  in 50 dilution).  Individual mice are indicated  by (•) and the 
mean  as  (—).  These data are the means of duplicate wells from  one 
representative study out of two.
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Figure  5.7  The  effect  of  NOMVs  on  the  percentage  of  iRSV-induced 
cell infiltrates after iRSV sensitisation and challenge with live RSV.
C57BI/6 mice were immunised i.m. with iRSV or PBS (control) once a week 
for two weeks.  Two weeks  later the mice were then  split into five groups 
and immunised i.n. with either PBS, iRSV, NOMVs or iRSV+NOMVs.  After 
a  further two  weeks  the  mice  were  all  immunised  i.n.  with  live  RSV  and 
seven  days  later  the  mice  were  culled  and  BAL  was  carried  out.  The 
number  of  (A)  eosinophils;  (B)  macrophages  and  (C)  lymphocytes  were 
enumerated  by  counting  15  random  fields  after Wright-Giemsa  staining. 
The results are expressed as the mean and SEM from four mice.  Asterisks 
indicate a value significantly different from that observed after i.n.  infection 
with iRSV before live RSV challenge, *p < 0.04.
171observed in mice that received  NOMVs alone or with iRSV before live RSV 
challenge  compared  to  mice  i.n.  immunised  with  iRSV  alone.  The 
percentage  of  macrophages  was  almost twice the  amount  in  control  mice 
than  in  mice  that were  sensitised  i.m.  with  iRSV.  However there  was  no 
statistically significant difference between the percentage of macrophages or 
lymphocytes among the different immunised groups of mice.
The absolute number of each cell type in the BAL fluid was calculated and as 
figure 5.8 shows, when  cell  numbers were calculated via this method there 
was  no  statistically significant decrease  in  the  number of eosinophils  after 
immunisation with  NOMVs either in the presence or absence of iRSV.  The 
average  number  of  macrophages  and  lymphocytes  (figure  5.8B  and  5.8C) 
was  again  constant  among  the  different  infected  groups of  mice,  however 
there was significant mouse-to-mouse variation in some of the groups.
In  order to  determine  further whether  NOMVs  could  significantly  decrease 
lung  inflammation  using this  model,  the  mice were immunised  i.n.  for three 
consecutive  weeks  instead  of one week with  PBS,  iRSV,  NOMVs or iRSV 
plus NOMVs before live RSV challenge.  Once again a significant decrease 
(p<0.025) in the percentage of eosinophils was observed after immunisation 
with  NOMVs  alone  or  NOMVs  plus  iRSV  compared  to  immunisation  with 
iRSV alone (figure 5.9A).  The percentage of macrophages and lymphocytes 
observed  after  three  i.n.  immunisations  were  similar  to  that  after  one 
immunisation (figure 5.9B and 5.9C).  The total number of cells per ml of BAL 
fluid  also  indicated  a  significant  decrease  (p<0.04)  in  the  number  of 
eosinophils  after  immunisation  with  NOMVs  with  or  without  iRSV  (figure 
5.10A).  The average number of macrophages was consistent among the
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Figure 5.8 The effect of NOMVs on the total cell numbers in  BAL fluid 
of mice sensitised and challenged with RSV.
C57BI/6 mice were immunised i.m. with iRSV or PBS (control) once a week 
for two weeks.  Two weeks  later the mice were then  split into five groups 
and immunised i.n. with either PBS, iRSV, NOMVs or iRSV+NOMVs.  After 
a  further two  weeks  the  mice were  all  immunised  i.n.  with  live  RSV  and 
seven  days  later  the  mice  were  culled  and  BAL  was  carried  out.  The 
number  of  (A)  eosinophils;  (B)  macrophages  and  (C)  lymphocytes  were 
enumerated  by Wright-Giemsa  staining.  Individual  mice  are  indicated  by 
(•) and the mean as (—).
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Figure  5.9  The  effect  of  repeated  exposure  of  NOMVs  on  the 
percentage  of  iRSV-induced  cell  infiltrates  after  sensitisation  and 
challenge with RSV.
C57BI/6 mice were immunised i.m. with iRSV or PBS (control) once a week 
for two weeks.  Two weeks later the mice were then split into five groups 
and  immunised  i.n.  once  a  week for three weeks  with  either  PBS,  iRSV, 
NOMVs  or  iRSV+NOMVs.  After  a  further  two  weeks  the  mice  were 
immunised  i.n.  with  live  RSV  and  seven  days  later the  mice were  culled 
and BAL was carried out.  The number of (A) eosinophils; (B) macrophages 
and  (C) lymphocytes were enumerated  by counting  15 random fields after 
Wright-Giemsa staining.  The results are expressed as the mean and SEM 
from four mice.  Asterisks  indicate a value significantly different from that 
observed  after  i.n.  infection  with  iRSV  before  challenge  with  live  RSV 
immunisation, * p < 0.025 and ** p? = 0.007.250
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Figure  5.10  The  effect  of  repeated  exposure  of  NOMVs  on  the  total 
cell  numbers  in  BAL  fluid  of  mice  sensitised  and  challenged  with 
RSV.
C57BI/6 mice were immunised  i.m. with either iRSV or PBS (control) once 
a week for two weeks.  Two weeks later the mice were then split into five 
groups and  immunised  i.n.  once a week for three weeks with  either PBS, 
iRSV,  NOMVs or iRSV+NOMVs.  After a further two weeks the mice were 
challenged  i.n.  with  live  RSV  and  seven  days  later the  mice were  culled 
and BAL was carried out.  The number of (A) eosinophils; (B) macrophages 
and  (C)  lymphocytes  were  enumerated  by  Wright-Giemsa  staining. 
Individual  mice  are  indicated  as  (•)  and  the  mean  as  (—).  Asterisks 
indicate a value significantly different from that observed after infection with 
iRSV before challenge with live RSV, * p < 0.04.
175different  immunised  groups  of  mice  (figure  5.1 OB),  however  the  average 
number of lymphocytes in the groups immunised with  PBS or NOMVs plus 
iRSV before live  RSV challenge were slightly higher than the other groups, 
but  this  difference  was  not  statistically  significant.  There  was  again 
significant mouse-to-mouse variation in the groups as observed previously.
5.3.5 The effect of NOMVs on the production of eotaxin.
The level of eotaxin in the supernatant of lung homogenates was determined 
after  one  and  three  i.n.  immunisations  with  NOMVs  in  the  presence  or 
absence  of  iRSV  before  i.n.  challenge  with  live  RSV.  After  one  i.n. 
immunisation  (figure  5.11 A)  there  was  slightly  less  eotaxin  found  in  the 
supernatant  of  mice  that  received  NOMVs  alone  or  NOMVs  plus  iRSV 
compared  to  mice  receiving  PBS  or iRSV,  however this decrease was  not 
statistically significant.  The level of eotaxin after three i.n. immunisations was 
fairly consistent among the different immunised groups, with levels between 
40 -  60pg/ml as shown in figure 5.11B.
5.3.6 The effect of NOMVs on anti-NOMV antibody responses.
The  amount of total  IgE  in  serum was determined  in  individual  mice of the 
different  groups  after  one  or  three  i.n.  immunisations  before  challenge. 
Figure  5.12  shows  that  similar amounts  of total  IgE were found  in  sera of 
mice  that  received  either one  or three  i.n.  immunisations  before  challenge 
with  live  RSV.  IgE  antibodies  were  barely  detected  in  mice  that  were 
immunised i.n. with PBS before live RSV challenge.  The levels of IgE varied
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Figure  5.11  The  effect  of  NOMVs  on  the  production  of eotaxin 
after sensitisation and challenge with RSV.
C57BI/6 mice were immunised  i.m. with  iRSV or PBS (control) once a 
week  for two  weeks.  Two  weeks  later the  mice  were  split  into  five 
groups and  immunised  i.n. with  PBS,  iRSV,  NOMVs or iRSV+NOMVs 
(A) once a week, or (B) once a week for three weeks.  After a further 
two weeks the  mice were all  immunised  i.n. with  live  RSV and  seven 
days  later  the  mice  were  culled  and  the  lungs  were  removed. 
Supernatants from  lung  homogenates were assayed  for eotaxin  (1  in 
10  dilution)  using  a  mouse  Eotaxin  ELISA  kit  (R&D  systems).  Error 
bars represent the S.E.M.
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Figure 5.12  The effect of NOMVs  on the  levels  of IgE  antibodies 
in the serum of mice sensitised and challenged with RSV.
C57BI/6  mice were  immunised  i.m.  with  either iRSV or  PBS  (control) 
once a week for two weeks.  Two weeks later the mice were split into 
five  groups  and  immunised  i.n.  with  either  PBS,  iRSV,  NOMVs  or 
iRSV+NOMVs for (A)  one week or (B) once a week for three weeks. 
After  a  further two  weeks  the  mice  were  all  immunised  i.n.  with  live 
RSV and seven days later the mice were terminally bled.  Serum from 
individual  mice  were  assayed  for total  IgE  (1  in  50  dilution)  using  a 
mouse  IgE  ELISA set (BD  Pharmingen).  Individual  mice are  indicated 
by (•) and the mean as (—).
178quite  considerably  in  individual  mice  of  groups  that  were  immunised  with 
NOMVs in the presence or absence of iRSV.
The  amount  of  NOMV-specific  total  IgG  and  IgG  subclasses  was  also 
examined.  Figure 5.13A shows a three-fold  increase in the amount of total 
IgG in mice that were immunised with NOMVs in the presence or absence of 
iRSV.  After a  single  i.n.  immunisation,  the  lgG2b  subclass  predominated. 
Similar results were  observed  after three  i.n.  immunisations  (figure  5.13B), 
however  the  levels  of  total  IgG  were  slightly  increased  and  the  levels  of 
lgG2b increased by approximately three-fold.  The levels of lgG1, lgG2a and 
lgG3  were  also  slightly  increased  in  mice  that  received  NOMVs  with  or 
without iRSV after three i.n. immunisations.
5.3.7  The  effect of  NOMVs  on  the  cytokines  produced  in  response to 
lung inflammation.
We  then  determined  whether  NOMVs  influenced  the  cytokine  profile  by 
measuring cytokine production in the supernatant of lung homogenates after 
one or three i.n. immunisations using a Th1/Th2 CBA assay.  An increase in 
TNF-a  production  was  seen  after an  increase  of i.n.  immunisations  (figure 
5.14B)  however  the  pattern  of  cytokine  release  in  the  groups  was  not 
consistent  between  the  two  experiments.  The  level  of  IFN-y  also  varied 
among the different immunised  groups,  however the levels were consistent 
after either one or three immunisations.
Figure 5.15 shows the amount of IL-2, IL-4 and IL-5 in the supernatant of the 
lung homogenates of individual mice.  The level of IL-2 was low in all groups 
after one immunisation and did not increase after three immunisations.  This
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Figure 5.13  The effect of NOMVs on the production of NOMV-specific 
total  IgG  and  IgG  subclasses  after sensitisation  and  challenge  with 
RSV.
C57BI/6 mice were immunised i.m. with iRSV or PBS (control) once a week 
for two weeks.  Two weeks  later the  mice were split into five groups and 
immunised i.n. with PBS, iRSV, NOMVs or iRSV+NOMVs for either (A) one 
week,  or (B) once a week for three weeks.  After a further two weeks the 
mice were all  immunised  i.n. with  live  RSV and seven days later the mice 
were  terminally  bled.  Serum from  individual  mice were  assayed  for total 
IgG and IgG subclasses (1  in 400 dilution).
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Figure  5.14  The  effect  of  NOMVs  on  the  production  of  Th1 
cytokines during sensitisation and challenge with RSV.
C57BI/6  mice were immunised  i.m. with iRSV or PBS (control) once a 
week  for two  weeks.  Two  weeks  later the  mice  were  split  into  five 
groups and  immunised  i.n. with  PBS,  iRSV,  NOMVs or iRSV+NOMVs 
for either (A) one week, or (B) once a week for three weeks.  After a 
further two weeks the mice were all  immunised  i.n. with  live  RSV and 
seven  days  later  the  lungs  were  removed.  The  lungs  were 
homogenised  and  the  supernatant  was  used  to  measure  cytokines 
using  an  inflammation  cytokine  bead  array  (CBA)  kit.  Error  bars 
represent the S.E.M.
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Figure  5.15  The  effect  of  NOMVs  on  the  production  of  Th2 
cytokines during sensitisation and challenge with RSV.
C57BI/6 mice were  immunised  i.m. with  iRSV or PBS (control) once a 
week  for two  weeks.  Two  weeks  later the  mice  were  split  into  five 
groups and  immunised  i.n. with  PBS,  iRSV,  NOMVs or iRSV+NOMVs 
for either (A) one week,  or (B) once a week for three weeks.  After a 
further two weeks the  mice were all  immunised  i.n. with  live RSV and 
seven  days  later  the  lungs  were  removed.  The  lungs  were 
homogenated  and  the  supernatant  was  used  to  measure  cytokines 
using an Th1/Th2 cytokine bead array (CBA) kit.  Error bars represent 
the S.E.M.
182was also true for IL-4.  The levels of IL-5 were higher in groups that received 
one  i.n.  immunisation  with  either  PBS  or  iRSV  before  live  RSV  challenge. 
However  these  levels  were  not  significantly  decreased  after  immunisation 
with NOMVs in the presence or absence of iRSV.  The amount of IL-5 was 
found  to  be  approximately two fold  less  after three  i.n.  immunisations  and 
responses tended  to  be  higher  in  the groups that did  not  receive  NOMVs, 
however again this difference was not statistically significant.
5.4  Discussion
It has  been  previously shown in animal models of allergen-induced asthma 
that  exposure  of the  lung  to  bacteria  or  bacterial  products  can  inhibit  the 
development of lung inflammation and increase Th1  immune responses.  We 
have previously shown and it has been reported in the literature that NOMVs 
are  able  to  produce  a  Th1 -biased  immune  response  characterised  by  the 
production  of  IL-12  and  IFN-y.  Experiments  carried  out  by  Etchart  and 
colleagues  (2006)  demonstrated  that  i.n.  immunisation  of NOMVs  reduced 
and/or  prevented  lung  pathology  caused  by  immunisation  with  RSV. 
Therefore experiments were carried out using two murine models of allergen- 
induced  eosinophilia  to  further  examine  the  effect  of  i.n.  immunisation  of 
NOMVs on lung inflammation and pathology.
Initial  experiments  were  carried  out  using  a  model  of  Ova-induced 
eosinophilia.  Mice i.n. immunised with NOMVs in the presence or absence of 
Ova  showed  a  significant  decrease  in  the  percentage  (p  <  0.017) and  the 
total number of eosinophils (p < 0.005) present in the BAL fluid compared to
183mice  immunised with  Ova alone.  This supports previous observations that 
bacteria  and  bacterial  products  are  able  to  inhibit  the  accumulation  of 
eosinophils in the lungs of mice infected with allergens (Erb et al.,  1998; Sur 
et al.,  1999).  The percentage of each cell type in fifteen high-powered fields 
and  the  absolute  number  of  each  cell  type  in  the  BAL  fluid  were  both 
calculated  to  take  into  account  the  variation  in  the  total  number  of  cells 
recovered from the mice during BAL.
The total number of macrophages and lymphocytes were slightly increased in 
the  BAL fluid from  mice immunised  i.n. with  Ova plus NOMVs compared to 
the other groups (figure 5.3B and 5.3C).  It has been previously shown that 
macrophages infiltrate the lung during the sensitisation phase and after Ova 
challenge (Drazen et al.,  1996; Gonzalo et al.,  1996) and that the number of 
macrophages  can  increase  after  non-specific  stimulation  (Fokkens,  1999) 
therefore accounting for why we observed an increase of this cell type.
I.n.  immunisation  of  NOMVs  before  allergen  challenge  prevented  a  further 
increase of eosinophilia in the lungs.  This was demonstrated by a significant 
decrease in the percentage (p = 0) and the absolute number (p < 0.002) of 
eosinophils in the  BAL fluid from mice that were immunised with  NOMVs in 
the  presence  or  absence  of  Ova  compared  to  mice  immunised  with  Ova 
alone.  As  expected  the  group  of mice  that were  i.n.  immunised  with  Ova 
before challenge with the allergen had the highest percentage and number of 
eosinophils (figure 5.4A and 5.5A) in the BAL fluid.  As observed previously, 
higher  numbers  of  macrophages  and  lymphocytes  were  observed  in  mice 
immunised  with  NOMVs,  either  in  the  presence  or absence  of Ova  beforechallenge  with  Ova,  however this  increase  was  not  statistically  significant. 
The total  number of the different cell types varied among mice in the same 
immunised group, which could be due to factors beyond our control such as 
variation in the amount of sample reaching the lungs of mice due to sneezing 
or swallowing of the sample after i.n. administration.
An internal control group of mice were also included in these experiments to 
determine whether a single i.n. immunisation with Ova following sensitisation 
with  PBS would encourage lung inflammation and therefore eosinophilia.  A 
small  percentage  and  therefore small  number of eosinophils were found  in 
the BAL fluid of these mice, indicating that sensitisation with Ova was needed 
to develop eosinophilia.  These mice exhibited similar levels of macrophages 
and lymphocytes as the group of mice that were sensitised with Ova.
The  results  of  these  experiments  demonstrated  that  i.n.  immunisation  of 
NOMVs are able to influence lung inflammation in mice characterised by the 
suppression of eosinophilia, which  has not been previously demonstrated in 
literature and supports previous findings with other bacterial products.
Eotaxin  has  been  reported  to  have  a  key  role  in  allergic  inflammation  in 
particular its effect on eosinophils.  Gonzalo and colleagues (1996) showed 
that  neutralisation  of  eotaxin  results  in  a  decrease  in  the  recruitment  of 
eosinophils and therefore lung inflammation.  As shown in figure 5.6, eotaxin 
levels were similar among all groups of mice, indicating that i.n. immunisation 
of NOMVs in the presence or absence of Ova did not have an effect in this 
model.  Previous reports have determined the amount of eotaxin or the effect 
of eotaxin  in  several  different ways.  For example,  some groups measuredthe  expression  of eotaxin  in  the  lung  by  Northern  blot analysis  using  total 
RNA extracted from  the  lung  (Gonzalo  et al.,  1996),  whereas  others  have 
used an anti-eotaxin antibody or eotaxin-knockout mice to assess the effects 
of  eotaxin  on  the  recruitment  of  eosinophils  under  different  conditions 
(Boehme et al.,  2004).  Therefore it may be better in future experiments to 
examine  the  effect  of  NOMVs  on  eotaxin  levels  by  using  one  of  these 
approaches as it could prove to be more sensitive.
As  well  as  eosinophilia  and  eotaxin  production  being  characteristic  of 
allergen-induced asthma, another characteristic of a Th2-biased response is 
high levels of IgE.  IgE plays an important role in allergic disease as antigen- 
crosslinking  IgE, which is bound by high affinity receptors on mast cells and 
basophils causes the release of inflammatory mediators.  The production of 
IgE  is  up-regulated  by  IL-4  and  IL-13,  which  enhance the  proliferation  and 
class switching of B cells  (Sutton et al., 1993; Gould et al., 2003).  The levels 
of total IgE were found to be similar in all groups of mice, however there was 
considerable  variation  in  IgE  levels  among  mice  within  each  group  (figure 
5.6B).  The  difference  in  levels of total  IgE were  not statistically significant 
between  mice that were or were  not immunised  with  NOMVs,  although we 
did  not  investigate  the  possibility  that  IgG  antibodies  which  are  found  in 
higher concentrations could be competing for binding with IgE antibodies as 
suggested  by  Lewkowich  et  al.  (2004a;  2004b).  The  same  group  also 
describe how other researchers have developed ELISA systems that require 
extensive optimisation for each antigen examined which should be noted if in 
future  studies  the  amount  of Ova-specific and  NOMV-specific  IgE  is to  be 
measured.
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lung  inflammation  and  pathology demonstrated  by a significant decrease in 
lung eosinophilia.  We then examined whether NOMVs were able to produce 
a  similar response  in  a  murine  model  using  iRSV.  The  immune  response 
induced  by viruses is usually characterised  by the secretion of IFN-y by NK 
cells and  T cells which  has the potential to  inhibit Th2 responses,  however 
infection  with  RSV  has  been  found  to  increase  allergen-induced  airway 
eosinophilia  identifying  a  possible  link  between  RSV  infection  and  allergic 
asthma (Schwarze etal., 1997; Schwarze etai, 1999).
I.n.  immunisation of mice with NOMVs following sensitisation with iRSV and 
prior  to  challenge  with  live  RSV  significantly  reduced  the  percentage  of 
eosinophils in BAL fluid than in mice immunised with iRSV alone (figure 5.7). 
However a statistically significant decrease however was not observed when 
the  percentage  of  eosinophils  was  calculated  as  the  absolute  number  of 
eosinophils in the  BAL fluid.  From figure 5.8A it is apparent that there was 
mouse-to-mouse  variation  among  the  group that were  i.n.  immunised  with 
iRSV before challenge with live RSV, and this variation could have occurred 
due  to  reasons  previously  described  in  this  chapter.  The  total  number of 
macrophages  and  lymphocytes  among  the  groups  stayed  fairly  constant, 
however  mouse-to-mouse  variation  was  again  apparent  in  some  groups. 
Unlike in the Ova-model, NOMVs did not bring about a statistically significant 
decrease in the total number of eosinophils.  We have shown in Chapter one 
and previous studies have indicated that immune responses to NOMVs after
i.n.  immunisation can  benefit from  repeated exposure.  Experiments carried 
out by Etchart and colleagues (2006) indicated that mice received three i.n.
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challenge  with  live  RSV,  therefore  we  carried  out  further  experiments  to 
determine  whether  repeated  immunisation  of  NOMVs  would  decrease 
eosinophilia.  Using  this  method  a  significant  decrease  in  both  the 
percentage of eosinophils and the absolute number of eosinophils was seen 
in  mice that received  NOMVs i.n.  before live RSV challenge,  indicating that 
repeated  immunisation  with  NOMVs  can  significantly  decrease  lung 
pathology,  in  particular  the  accumulation  of  eosinophils.  As  previously 
observed  the  total  number  of  macrophages  stayed  constant  among  the 
different immunised groups, and although the numbers of lymphocytes varied 
this was not statistically significant.
The level of eotaxin in the supernatant of homogenised lungs from individual 
mice  among  the  different  immunised  groups  after  one  or  three  i.n. 
immunisations  was  not  significantly  different  however  levels  were  slightly 
lower  in  mice  that were  immunised  with  NOMVs.  It  has  been  shown  that 
eotaxin levels are upregulated after i.n. immunisation with  RSV (Haeberle et 
al.,  2001) and  a  recent study by Matthews et al.,  (2005)  demonstrated that 
neutralisation of eotaxin reduced the accumulation of eosinophils in the lung 
as well as decreasing the production of IL-5.  Therefore as well as measuring 
the  levels  of  eotaxin,  it  could  be  advantageous  in  future  experiments  to 
determine the effect of NOMVs on eotaxin levels by neutralising eotaxin and 
then measuring the level of eosinophilia.
188Unlike  the  Ova  model  where  we  did  not  observe  a  difference  in  total  IgE 
serum  responses  among  the  different groups  of mice,  the  levels  in  serum 
from  mice  in the  RSV  model varied among the groups.  Very little  IgE was 
detected  in the sera  of mice from  the control group or the group that were 
sensitised  with  iRSV  and  then  i.n.  immunised  with  PBS  before  being 
challenged with live RSV.  In the other groups, the amount of IgE varied from 
mouse-to-mouse  (0  -   100ng/ml)  therefore  there  was  no  statistically 
significant  difference  among  the  groups.  It  has  been  proposed  that virus 
specific T cells producing  IL-4 and  IL-5 may induce the production of virus- 
specific IgE, therefore this could explain why we have detected slightly more 
IgE production in the mice immunised with iRSV.  However it has also been 
reported that infection with RSV does not affect titres of total IgE in the serum 
of mice  (Barends  et al.,  2002;  Barends  et al.,  2004).  In  order to examine 
further  the  effect  of  NOMVs  on  the  production  of  IgE  it  would  also  be 
beneficial to measure RSV-specific IgE responses.
The  levels  of  NOMV-specific  total  IgG  and  IgG  subclasses  were  also 
determined.  Mice that received NOMVs either in the presence or absence of 
iRSV,  demonstrated  a  significant increase in total  IgG  levels.  These levels 
were  slightly  increased  in  mice  that  received  three  i.n.  immunisations 
compared to one immunisation before challenge with live RSV.  The subclass 
that  dominated  after  immunisation  with  NOMVs  was  lgG2b,  which  was 
previously  observed  and  shown  in  Chapter  three,  and  is  the  subclass 
predominantly associated  with  a  Th1  response.  The  levels of lgG2b were 
much higher after three immunisations and  increased levels of lgG1,  lgG2a
189and lgG3 were also seen.  Increased levels of lgG2a and lgG3 could be due 
to isotype switching  induced  by IFN-y released  by Th1  cells in response to 
stimulation  with  NOMVs,  whereas  an  increase  in  lgG1  could  have  been 
induced  by the  production  of IL-4  by Th2 cells, as a  result of immunisation 
with RSV.  In future experiments it would be advantageous to measure RSV- 
specific antibody production, allowing us to determine if NOMVs are able to 
influence the IgG subclasses produced after RSV immunisation and whether 
NOMVs can  reduce the level of Th2 cytokines or increase the level  of Th1 
cytokines inhibiting the production of lgG1 and IgE antibodies.
In  order  to  fully  understand  the  antibody  responses,  the  production  of 
cytokines  must  be  examined  in  order  to  determine  their  influence  on  the 
subclasses  produced.  Levels of Th1  and Th2 cytokines were  measured  in 
the  supernatant  of  lung  homogenates  to  determine  whether  immunisation 
with NOMVs had shifted a predominantly Th2 response associated with iRSV 
immunisation to a more Th1  response.  There was no trend in the production 
of TNF-a  or  IFN-y  among  the  groups  of mice  after either one or three  i.n. 
immunisations before challenge with live RSV.  However there was a slight 
increase in TNF-a production in mice that received three immunisations with 
NOMVs  either  in  the  presence  or  absence  of  iRSV.  After  one  i.n. 
immunisation, mice in all of the groups displayed similar amounts of IL-2 and 
IL-4, however increased levels of IL-5 were seen in mice that were sensitised 
and  immunised  with  PBS or iRSV,  but that did  not receive  NOMVs before 
challenge  with  live  RSV.  This  trend  was  also  observed  after  three  i.n. 
immunisations however the levels were decreased by approximately two-fold. 
This indicates that immunisation of mice with NOMVs either in the presence
190or absence  of iRSV  can  slightly  inhibit the  production  of  IL-5,  which  could 
explain why there was a decrease in the accumulation of eosinophils in the 
lungs, as IL-5 mediates the recruitment and activation of eosinophils.  It has 
also  been  shown  in  animal  models  that  inhibiting  IL-5  using  neutralising 
antibodies prevents the terminal differentiation of eosinophils (Coffman et al., 
1989;  Mauser  et al.,  1995),  over expression  of  IL-5  promotes  long  lasting 
eosinophilia  and  IL-5-deficient  mice  are  unable  to  increase  the  number of 
eosinophils  in  response to antigens  (Sanderson,  1992;  Foster et al.,  1996; 
Kopf et al., 1996).
Previous reports have determined cytokine levels in  BAL fluid  (Matthews et 
al.,  2005)  or by measuring  mRNA expression  of different cytokines  in  BAL 
fluid (Waris et al.,  1996; Barends et al., 2004), which could prove to be more 
sensitive and therefore more accurate.  It has also been described in a recent 
report  that  treatment  of  mice  with  an  anti-eotaxin  antibody  affected  IL-5 
levels,  but not levels of IFN-y (Matthews et al., 2005).  Therefore this could 
imply that although a change in Th1  cytokines may not be observed in mice 
immunised with NOMVs a change in Th2 cytokines would.
As previously mentioned  IL-10 has been shown to have an important role in 
allergic  responses  possibly through  inducing  IL-10-secretory Tr cells.  The 
results  in  Chapter  Four  indicate  that  NOMVs  are  able  to  stimulate  IL-10 
production in vitro and in vivo after i.m. injection, therefore this could indicate 
another possible  mechanism  in  the  suppression  of allergic Th2  responses. 
The  production  of  IL-10  in  mice  after  i.n.  immunisation  with  NOMVs  could 
also be investigated by measuring the levels in sera after each immunisation
191to determine when maximal production occurs, and see if that correlates with 
a decrease in allergic Th2 responses.
As demonstrated in this Chapter, NOMVs have been shown to have an effect 
on  lung  inflammation  after i.n.  immunisation  in the presence or absence of 
allergens.  In general,  the most obvious effect was the influence of NOMVs 
on the level  of eosinophilia  in the  lungs of mice.  Cytokine,  chemokine and 
antibody  responses  were  also  determined,  however  the  results  were  not 
conclusive  and  further  investigation  is  needed.  There  are  many  novel 
therapeutic  agents  and  adjuvants  being  described  as  being  able  to  inhibit 
airway inflammation and although the mechanism of how this is achieved is 
not  fully  understood,  a  couple  of  recent  studies  have  indicated  possible 
mechanisms.  For example  a  recent study by Patel  and  colleagues  (2005) 
described  how  the  synthetic  bacterial  lipopeptide  Pam3CSK4,  a  TLR2 
agonist, could  reduce eosinophilia and Th2 cytokine production  by an  IL-12 
dependent  mechanism.  This  has  been  followed  by  another  recent  study 
describing  how  lipoprotein  I  of  Pseudomonas  aeruginosa  could  decrease 
eosinophilia and  modulate Th2 effector cells by stimulating TLR2 and TLR4 
signalling  pathways  (Revets  et al.,  2005).  Delayre-Orthez and  colleagues 
(2004) examined the effect of LPS on allergen sensitisation and challenge in 
a murine model.  They found that LPS administered during the sensitisation 
phase prevented airway eosinophilia as seen in previous studies (Gerhold et 
al.,  2002a;  Gerhold  et  al.,  2002b),  whereas  LPS  given  during  challenge 
increased  airway eosinophilia  (Tulic  et al.,  2000).  This  suggests that  LPS 
may be an  important factor in the  severity of the disease, which  should  be
192taken into consideration when assessing whether NOMVs could be used as a 
vaccine or adjuvant.
Many groups have examined the expression of TLRs on epithelial cells of the 
airway and it has been shown that epithelial cells express mRNA for TLRs 1  
-1 0   (Becker et al.,  2000;  Muir et al.,  2004;  Greene et al.,  2005).  TLR2 is 
expressed  predominantly  on  the  cell  surface  along  with  TLR1  and  TLR9 
whereas  TLR3,  4  and  5  reside  intracellularly  or  at  low-level  surface 
expression.  Both TLR4 and TLR5 have been shown to be able to move to 
the membrane following stimulation (Monick etal., 2003; Adamo et al., 2004). 
Airway inflammation  is usually associated with bacterial or viral agents, and 
therefore  it  is  very  possible  that TLRs  are  activated  in  order to  produce  a 
rapid and effective innate response and that changes in TLR function could 
influence inflammatory lung diseases.
It  is  plausible  that  NOMVs  are  also  acting  through  TLR2  and/or  TLR4 
pathways  in  order  to  exert  its  effects.  We  have  shown  in  the  previous 
chapter that LPS and non-LPS components of NOMVs are able to cause cell 
proliferation and release cytokines therefore this is something that should be 
further studied  and  by  using  TLR  knockout  mice we could  ascertain which 
component/s contribute to the findings in this chapter.
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Final Discussion
6.1  The immunomodulatory properties and possible mechanisms of action 
of NOMVs
In  this  thesis  investigation  the  immunomodulatory  properties  of  NOMVs  from 
serogroup B meningococci were determined in order to assess the potential use 
of NOMVs and their components as a mucosal adjuvant, their ability to  modify 
immune  responses  and  to  gain  further  insights  into  their  role  in  establishing 
immunity against Nm.
Alum, the only adjuvant approved for human vaccines for many years, has been 
shown  to  enhance  mainly  humoral  responses  to  protein  antigens  and 
glycoconjugates.  However for a  number of viruses and tumours,  cell-mediated 
immunity correlates with protection.  Thus there is an urgent need of identifying 
adjuvants that can enhance T cell  responses for subunit vaccine candidates for 
viral  infections  and  cancer.  It  is  also  a  key  aim  in  vaccine  development that 
adjuvants and antigens can be administered mucosally because there are many 
infections occurring at mucosal surfaces where immune protection mechanisms 
need  to  be  activated.  It  is  important that  new  adjuvants  must  meet  rigorous 
safety requirements including having low toxicity, being stable and well defined. 
Most importantly adjuvants need to be able to stimulate strong and appropriate
194immune  responses.  It  has  been  established  that  initiation  of  an  immune 
response requires the activation of APCs by danger signals derived from foreign 
or  host  cells.  Not  surprisingly  microbial  products,  mainly  TLR  ligands,  have 
been extensively investigated  as adjuvant candidates.  For example, CpG DNA 
on binding TLR9 enhances immune responses resulting in a predominantly Th1 
response  and  LPS  has  been  shown  to  be  highly  immunogenic  and  display 
adjuvant properties on binding TLR4.
NOMVs from serogroup  B  meningococci are an  interesting adjuvant candidate. 
They  are  produced  naturally  by  Nm  and  are  exposed  to  mucosa  and  nasal 
associated  lymphoid  tissues  (NALT)  during  Nm  colonisation.  They  contain  a 
high  proportion  of  LPS  and  OMPs,  both  TLR  agonists,  and  therefore  they 
display adjuvant properties (Wetzler et al., 1996; Quakyi et al., 1997; Al-Bader et 
al.,  2003;  Al-Bader  et al.,  2004).  In  the  absence  of added  adjuvant,  NOMVs 
have  been  shown  to  be  effective  in  inducing  bactericidal  antibodies  when 
administered i.n. (Drabick, 2000; Guthrie et al., 2004).  The mechanism of action 
of NOMVs has not been defined clearly, but the engagement of LPS and porins 
with TLRs are thought to contribute significantly to their effects.  LPS is generally 
considered  to  be  toxic  due  to  the  lipid  A  moiety,  however the  removal  of this 
portion  brings about a decrease  in  immunogenicity including anti-LPS antibody 
responses.  Modified  forms  of  NOMVs  such  as  DOMVs  and  VSSPs  with 
reduced  LPS  content  and  its  associated  toxicity  have  been  used  in  vaccines 
against serogroup B  Nm  in favour of NOMVs (Bjune et al.,  1991;  Fredriksen et
195al.,  1991; Sierra et al.,  1991; Boslego et al.,  1995).  However studies in humans 
and  animals  using  NOMVs  i.n.  have  shown  them to  be well  tolerated  with  no 
harmful side-effects (Drabick, 2000).
The use of NOMVs as a mucosal adjuvant has not been extensively studied, but 
it has  been  demonstrated that i.n.  immunisation can  induce  both  systemic and 
mucosal  immunity  (Dalseg  et  al.,  1999;  Saunders  et al.,  1999;  Guthrie  et al., 
2004).  In  this  thesis  investigation,  it  was  shown  that  NOMVs  were  able  to 
enhance  serum  antibody  responses  to  model  TD  and  Tl  antigens.  I.n. 
immunisation  of  C57BI/6  mice  with  Ova  plus  NOMVs  significantly  increased 
Ova-specific  IgG  and  IgA  levels  compared  to  immunisation  with  the  antigen 
alone.  NOMVs were also able to significantly enhance  IgG and  IgA responses 
to  DNP-ficoll,  a  model  TI-2  type  antigen  after  i.n.  immunisation.  In  a  parallel 
study  in  the  Carbohydrate  Immunology  group,  it  was  demonstrated  that  the 
requirement for complement in IgM antibody responses to 11  of 12 CPSs tested 
was  not  identical  to  DNP-ficoll  (Jones  et al.,  submitted  manuscript).  We thus 
wished to determine whether or not NOMVs could enhance antibody responses 
toward  clinically relevant CPS antigens as they did to  DNP-ficoll,  a prototypical 
Tl-2 antigen.
We  focused  our  studies  on  antibody  responses  to  CPSs  because  they  have 
been  shown  to  be  important  in  protection  against  infection  with  extracellular 
bacteria. We chose to study CPSs from S. pneumoniae because this organism
196is important to world  health and  new pneumococcal vaccines and  improvement 
to existing vaccines are needed.  Developing vaccines against S. pneumoniae is 
problematic  due  to  the  presence  of  many  serotypes  that  cause  disease,  and 
antibody  responses  are  variable  with  their  responses  being  serotype  and  age 
dependent.  However,  antibody  responses  to  pneumococcal  CPSs  are 
characteristic of TI-2 antigens.  Anti-CPS antibodies are generally of low affinity 
with  limited  isotype  switching,  and  CPS  immunisation  does  not  generate 
memory (Mosier et a!.,  1982).  Although conjugate pneumococcal vaccines have 
proved  successful,  even  in  children,  to  the  serotypes  included  in  the  vaccine, 
there are nevertheless concerns that other serotypes not covered by the current 
conjugate  vaccines  will  become  prevalent.  Conjugate  vaccines  are  also 
unaffordable to  populations where the  burden  is  highest.  Adjuvants  are  being 
investigated  to  improve  anti-CPS  responses  in  young  children  that will  provide 
alternative means of protecting against S. pneumoniae and other encapsulated 
bacterial  pathogens.  NOMVs  having  demonstrated  adjuvant effects on  protein 
and  LPS  antigens  from  NOMVs  as  well  as  model  TD  and  Tl  antigens  were 
expected to have similar effects on anti-CPS antibody responses.
Serum  antibodies to the  CPSs were  mostly of the  IgM  subclass  after both  i.p. 
and  i.n.  immunisation  and  the  response  varied  due  to  the  difference  in 
immunogenicity of the CPSs.  Natural  IgM antibodies to the CPSs were seen in 
naive  mice  and  the  levels  varied  depending  on  the  strain  of mice.  B-1a  cells 
from the spleen have been shown to be a source of natural IgM and to respond
197rapidly  to  Tl  antigens  such  as  CPSs  (Hayakawa  et  al.,  2000),  which  could 
account  for  why  responses  to  some  CPSs  were  higher  after  i.p.  than  i.n. 
immunisation.  Immunisation  of the  CPSs  in  the  presence of NOMVs  by  both 
immunisation routes did not enhance the IgM response to the individual CPSs.
However  it  was  found  that  immunisation  with  the  CPSs  in  the  presence  or 
absence of NOMVs induced relatively long-lived antibody responses, which was 
demonstrated  by the presence of IgM antibodies specific to the CPSs in serum 
two months post immunisation.  Pneumococcal CPSs have a relatively long half- 
life,  therefore  they  degrade  slowly  which  would  account  for  the  sustained 
antibody levels seen (Sela et al., 1972).
Antibody responses to type 3 and type 4 CPSs after i.n. immunisation were not 
dependent on dose and  IgG  production was rare and varied  between individual 
mice.  Where  CPS-specific  IgG  antibodies  were  detected  after  i.p.  or  i.n. 
immunisation,  the  lgG3  subclass  predominated, which  is the subclass that has 
been shown to be protective against pneumococcal infection in mice (Perlmutter 
et al.,  1978;  Peeters  et al.,  1991).  A  booster  immunisation  with  CPS  did  not 
have any effect on the antibody response to the CPSs, which  is consistent with 
literature  that  Tl  antigens  are  unable  to  induce  memory  responses.  Mice 
immunised  i.n.  with  NOMVs  alone  displayed  levels  of  CPS-specific  IgM  that 
were  similar to  that  of  naive  mice  however further  immunisation  with  NOMVs 
produced  a  marked  increase  in  CPS-specific  IgM  indicating  an  antigen- 
independent mechanism  of activation  of CPS-specific B  cells  and/or of B  cells
198with  cross-specificity  for  CPS  structures.  Cross-reactivity  is  often  observed 
among polysaccharide antigens containing similar oligosaccharide residues, and 
the  ability to  produce a  broad  rather than  CPS  serotype-specific  IgM  response 
for  anti-bacterial  defences  is  beneficial.  It  is  possible  that  immunisation  with 
NOMVs  stimulates  a  B  cell  population  that has  already  been  pre-selected  or - 
activated by CPSs or cross-reacting antigens.
Evidence  suggests  that  natural  immunity  to  meningococcal  disease  may  also 
occur  due  to  colonisation  with  the  non-pathogenic  Neisseria  lactamica,  which 
shares  cross-reactive  antigens with  Nm.  It is worth  noting that OMVs from  N. 
lactamica only differ to meningococcal  NOMVs in that they do not contain  PorA 
(Sanchez et al.,  2001;  Oliver et al.,  2002;  Braun  et al.,  2004).  A recent study 
has shown that i.n. immunisation of mice with OMVs from N. lactamica to induce 
cross-reactive  protective  antibodies to  Nm and to enhance antibody responses 
to the model antigen HBsAg (Sardinas et al., 2006).  Data on natural immunity to 
Nm  by OMPs is limited, and  it is not clear whether antibody responses need to 
be  directed  toward  one  particular  antigen  or  several  antigens.  Antibody 
responses to serogroup B  CPSs  may not be important in  immunity against Nm 
in  our  studies  as  we  have  shown  that  NOMVs  are  able  to  stimulate  antibody 
responses  to  protein  and  LPS  as  well  as  model  TD  and  Tl  antigens,  but  not 
pneumococcal  CPS  antigens.  This  indicates  the  importance  of  non-capsular 
antigens  and  responses  to  multiple  antigens  would  be  beneficial  against  an 
organism such as Nm that demonstrates antigenic variation.  Natural immunity is
199thought to occur at mucosal surfaces and therefore both mucosal and systemic 
immune  responses  are  thought  to  be  involved.  Davenport  and  colleagues 
(2003)  demonstrated  mucosal  T  cell  responses  to  meningococci  following  in 
vitro  studies  with  cells  from  palatine  tonsils.  In  addition  i.n.  immunisation  of 
NOMVs  has  been  shown to  induce  mucosal  immunity in the  NALT with the  D- 
NALT being  a  major site for anti-meningococcal antibody forming cells,  as well 
as other mucosal surfaces (Guthrie et a/., 2004; Sardinas et al., 2006).  It would 
therefore  be  appropriate  to  investigate  further  mucosal  immune  responses  in 
future studies to complement findings described in this thesis.
Our  results  indicate  that  enhancement  of  antibody  responses  by  NOMVs  is 
dependent on the  nature of the Tl-antigen,  as humoral  responses to  DNP-ficoll 
were  enhanced  by  NOMVs  whereas  responses  to  pneumococcal  CPSs  were 
not.  Our results  support earlier findings by Kovarik et al.,  (2001) who  reported 
similar  results  but  using  CpG-ODN,  TNP-ficoll  and  CPSs  following  s.c. 
immunisation.  The group only observed enhancement of antibody responses to 
CPSs after conjugation of the CpG motifs to the CPSs, which was in agreement 
with  a  study  where  enhanced  antibody  responses  were  only  seen  after  CpG- 
ODN  was  conjugated  to  Hib  polysaccharide  (von  Hunolstein  et  a!.,  2000). 
Polysaccharide-protein  conjugates  are  generally  more  immunogenic  than 
polysaccharides on their own as they can recruit T cell help.  This enables class 
switching  of  antibodies  from  IgM  to  IgG  and  the  induction  of  a  stronger  and 
broader  antibody  response.  In  future  studies  it  would  therefore  be  worth
200investigating  whether  conjugation  of  NOMVs  or  addition  of  meningococcal 
OMPC  to  pneumococcal  CPSs  would  help  to  enhance  antibody  responses. 
Unmodified  OMPC  was  an  effective  adjuvant  and  protein  carrier  for  the 
polysaccharide, PRP, in the Hib vaccine (Heath, 1998).
The  possible  mechanisms  of  how  NOMVs  are  acting  as  an  adjuvant  were 
explored.  NOMVs  had  pleiotropic  effects  on  several  immune  cell  types  as 
suggested  by the production of key cytokines and factors involved in innate and 
adaptive  immunity.  These  include  NO,  interferons,  TNF-a,  IL-10  and  IL-12. 
NOMVs were  shown  to  cause the  release of NO,  a  versatile  molecule  in  host 
defence, from  C3H/HeN  and  C3H/HeJ  BMDMs.  The activation  of human  DCs 
with meningococci has been well documented as shown by upregulation of TNF- 
a,  IL-6  and  IL-8  and  costimulatory  molecules  such  as  CD86  and  MHC  II 
molecules (Dixon et al., 2001; Kolb-Maurer et al., 2001; Unkmeir et al., 2002; Al- 
Bader et al.,  2003).  In this study we showed the production of IL12p70,  IL-10, 
TNF-a,  MCP-1  and  IL-6  in  the  supernatant  of  BMDCs  from  C3H/HeN  and 
C3H/HeJ  mice  stimulated with  NOMVs.  In  contrast,  stimulation  of splenocytes 
induced IFN-y as well as the other cytokines mentioned, but not IL12p70.  IFN-y 
is  produced  by a  variety of cells  including  NK cells  and  Th1  cells.  It plays  an 
important  role  in  both  innate  and  adaptive  immunity  as  IFN-y  can  modulate 
cellular immunity mediated  by Th1  cells and  humoral  immunity by inducing the 
production of lgG2a and  lgG3, which  is characteristic of a Th1  response.  This 
makes  IFN-y  produced  after  stimulation  with  NOMVs  an  important  factor  in
201NOMVs being used as an adjuvant due to the effects it can have on the immune 
system.  Immunisation of mice with CPSs plus NOMVs led to the production of 
lgG3, which could have been as a result of the induction of IFN-y.  Splenocytes 
cultured with  IL-10R prior to stimulation with NOMVs,  induced the production of 
IL12p70  in  both  C3H/HeN  and  C3H/HeJ  mice  indicating  that  IL-10  was 
negatively  regulating  the  production  of  IL12p70.  Thus  identification  of  the 
source  of  IL-10  and  the  mechanism  of  its  induction  by  NOMVs  would  be 
important for the  application  of  NOMV  or  its  components  as  adjuvant for cell- 
mediated Th-1  responses.
In  addition  to  IFN-y,  NOMVs  also  stimulated  the  production  of  IFN-p  but 
predominantly from splenocytes of C3H/HeN  mice,  indicating that production  is 
dependent on LPS.  Further work carried out in the group showed the production 
of  IFN-p  as  well  as  IFN-a  in  sera  from  C3H/HeN  mice  after i.m.  immunisation 
with  NOMVs  (Durand  et al.,  manuscript in  preparation).  Type  I  interferons  are 
not only  important  in  innate  immunity  but  have  also  been  found  to  enhance T 
and  B  cell  responses  (Le  Bon  et al.,  2002).  In  this  thesis,  it was  shown  that 
NOMVs  were  able  to  stimulate  proliferation  of B  cells,  but  not T  cells,  in  both 
wild-type  and  LPS-hyporesponsive  mice,  indicating  that  LPS  and  non-LPS 
components are capable of inducing  B  cell  proliferation.  The  induction of IL-6, 
IL-10 and type  I  interferons  by NOMVs  is likely to contribute significantly to the 
quality and  magnitude of the antibody response,  although we have also shown 
that NOMVs are able to induce B cell proliferation directly.
202Our studies confirm and build on those already published that LPS and non-LPS 
components  of  NOMVs  contribute  to  its  immunomodulatory  and  adjuvant 
properties.  Preliminary investigations  into which components were  responsible 
for these  properties were carried  out.  Preparative SDS-PAGE  (Bio-Rad  Model 
491  Prep  Cell) was  used  to  separate the components of NOMVs.  Analysis of 
the  gels  by silver staining  revealed  that many of the fractions  showed  multiple 
bands  indicating that some of the  components were  not separated  sufficiently. 
Therefore  we  were  unable  to  determine  which  individual  components  had 
immunomodulatory  properties  because  several  attempts  of  purifying  individual 
components  by  preparative  SDS-PAGE  were  unsuccessful.  To truly  establish 
separation of individual components, optimisation of this method or the use of an 
alternative approach such as HPLC would be required.
Having  demonstrated  that  NOMVs  have  the  ability  to  activate  APC,  induce 
characteristics  of Th1  immune  responses  and  stimulate  B  cell  responses,  we 
went on to investigate its effect on Th2 immune bias responses.  Since allergen- 
induced  airway  inflammation  is  associated  with  Th2  cells  that  promote  airway 
eosinophilia, we studied the effects of NOMVs using murine models of allergen- 
induced eosinophilia.
2036.2  The effect of NOMVs on lung inflammation and immunity
Allergy  is  a  main  risk  factor  for  asthma  and  is  a  chronic  disease  in  children. 
Allergic  asthma  is  a  Th2-associated  disease  characterised  by  airway 
inflammation, the infiltration of eosinophils, elevated levels of serum IgE and the 
production of IL-4 and  IL-5.  The incidence of asthma is steadily increasing and 
it  has  been  hypothesised  that this  is  partially  due  to  a  decrease  in  exposure, 
early on in life, to infections that generally elicit Th1-biased immunity.  There has 
been  a  lot  of attention  on  novel  treatments  for  decreasing  allergic  responses 
using  bacteria  and  bacterial  products  that  induce  Th-1  responses.  We  have 
previously  shown  that  NOMVs  are  able  to  produce  a  characteristic  Th1 
response  as  indicated  by  the  production  of  IL-12p70  from  BMDCs  and 
splenocytes and  IFN-y from splenocytes.  Therefore the main aim of this part of 
the thesis was to determine whether i.n. immunisation of NOMVs can affect lung 
inflammation  in  murine  models  of  allergen-induced  asthma  by  biasing  the 
immune response.
Our  studies  demonstrated  that  NOMVs  were  able  to  significantly  decrease 
eosinophilia in the lungs of mice from both infection models, and challenge with 
the allergens did  not result in an  increase in eosinophilia.  The levels of eotaxin 
and total  IgE were found to be similar among all the groups of mice in the Ova- 
induced allergy model.  In contrast in the RSV model, the levels of eotaxin were 
slightly reduced in mice that received NOMVs and serum IgE levels were higher 
in  mice that received  iRSV  in the  presence or absence of NOMV compared  to
204control  mice,  although  the  responses  differed  among  mice  of  the  same 
immunisation  group.  High  levels  of NOMV-specific  lgG2b were  seen  after i.n. 
immunisation with  NOMVs or iRSV plus NOMVs, which supports the findings in 
chapter three.  In  future  experiments  it  would  be  important  to  examine  RSV- 
specific antibody responses to determine whether NOMVs are able to influence 
the subclass of antibody produced by iRSV therefore influencing either a Th1  or 
a  Th2  response.  The  cytokines  produced  in  response  to  immunisation  with 
NOMVs and the allergens can also influence the subclass of antibody produced. 
The  production  of  IL-4  would  drive  isotype  switching  of  B  cells  toward  the 
production of IgE, whereas IFN-y would encourage the production of lgG2a and 
lgG3,  which  are  characteristic  of  a  Th1  response.  However,  serum  levels  of 
IFN-y were found to be similar among  all the groups of mice,  as were levels of 
IL-4  in the  supernatant of lung  homogenates,  indicating that immunisation with 
NOMVs  either  in  the  presence  or absence  of iRSV  did  not  influence  cytokine 
production.  It  may  have  been  better to  measure cytokine  responses  in  BAL 
fluid  as other groups  have demonstrated this  method to be more sensitive and 
reliable and therefore this approach should be used in future investigations.
We have previously shown that components of NOMVs are able to produce Th1 
associated  cytokines  and  that  they  are  able  to  activate  immune  cells  through 
TLR2  and  TLR4.  TLR2  is  expressed  on  the  surface  of epithelial  cells  of the 
airway  and  TLR4  is  expressed  intracellularly  although  it  has  been  shown  to 
move  to  the  membrane  following  stimulation,  therefore  indicating  that  the
205interaction of NOMVs with TLR2 and TLR4 could favour the generation of a Th1 
rather than  a  Th2  immune  response.  In  order to  examine  this  further and  to 
dissect the  mechanism  of action  of  NOMVs  in  preventing  lung  inflammation  it 
would be interesting to carry out similar experiments as described in chapter five 
but in TLR2- and TLR4-deficient mice that were not available during the course 
of this thesis investigation.
As well as generating adaptive immune responses to pathogens,  recognition of 
PAMPs by TLRs can initiate the production of T regulatory (Tr) cells, which have 
been shown to suppress airway inflammatory responses.  This was shown  in a 
study  where  mice  pre-treated  with  killed  mycobacteria  resulted  in  the 
development  of a  CD4+  Tr  population  (Zuany-Amorim  et al.,  2002).  A further 
study  also  showed  this  response  following  infection  with  Bordetella  pertussis 
and  that  filamentous  haemagglutinin  induced  the  production  of  IL-10  by  DCs, 
which can induce the development of Tr cells from naive T cells (McGuirk et al., 
2002).  Studies in this thesis indicated the production of IL-10 in vitro by BMDCs 
and  splenocytes  and  in  vivo  after  injection  with  NOMVs.  This  could  provide 
another  mechanism  of how  responses  to  NOMVs  are  suppressing  the  effects 
seen  in  the  allergy-induced  models.  Therefore  it would  be  valuable  in  future 
studies to determine whether Tr cell populations are being induced.
The production of IL-10 has been reported as a consequence to stimulation with 
LPS  (Tulic  et al.,  2000)  and  as  previously described  in  Chapter five,  LPS  has
206been reported to have differing effects on allergic responses, which needs to be 
taken  into  account  if  NOMVs  are  going  to  be  used  as  an  adjuvant  or  novel 
therapy.  It  is  a  possibility  that  immunisation  with  NOMVs  could  also  cause 
inflammatory  responses  and  tissue  destruction  but this  does  not  appear to  be 
the  case  via  i.n.  immunisation  in  humans.  IL-10  and  TGF-b  contribute  to  the 
anti-inflammatory,  immunosuppressive  environment  of  the  upper  and  lower 
respiratory  tract,  and  there  was  no  indication  that  NOMV  applied  i.n.  can 
overcome a Th-2  bias.  It is  also  not certain what would  happen  after a  longer 
time  interval  before  rechallenge  with  the  allergen.  These  are  aspects  that 
should be examined in future experiments involving NOMVs and compared with 
other approaches in the literature such as CpG ODNs or BCG.
6.3  Final Summary
The  studies  in  this  thesis  have  built  on  the  previous  literature  describing 
immunomodulatory  properties  of  NOMVs.  We  have  shown  that  NOMVs  are 
immunogenic  when  administered  by  the  i.n.  route  and  display  adjuvant 
properties by increasing antibody responses against a model TD and a model Tl 
antigen.  In  contrast,  an  adjuvant response  by NOMVs was  not observed  after 
immunisation with  CPSs from  S.  pneumoniae, which are clinically relevant TI-2 
antigens.
Both  LPS  and  non-LPS  components  appear to  be  responsible for the adjuvant 
and immunomodulatory properties of NOMVs by their ability to stimulate BMDCs
207and splenocytes through TLR2 and TLR4 pathways.  The immune response was 
seen to be Th1  biased, in agreement with previous literature.
Pathogens  and  microbial  components  associated  with  producing  a  Th1 -biased 
immune  response  have  been  used  to  study  lung  inflammation,  allergic 
responses  and  their effect on  Th2  associated  responses.  The work  shown  in 
this  thesis  indicates  the  potential  of  NOMVs  as  an  adjuvant  to  prevent 
eosinophilia  in  murine  allergy-induced  models.  The  mechanism  of how this  is 
achieved needs further investigation but one possibility is that immunisation with 
NOMVs  enhances  the  maturation  of  APCs  via  TLR2  and  TLR4  pathways  to 
prime and differentiate some naive T cells to T regulatory cells.  Further studies 
need  to  be  carried  out to  determine the full  effect of NOMVs  in  these  models 
with  respect to  mucosal  antibody  and  cytokine  responses,  the  components  of 
NOMVs that are responsible for the effects and the potential dangers of inducing 
Th1  responses via the  i.n.  route  in  order to enhance cell-mediated  immunity or 
to attenuate lung inflammation.
Together  these  results  indicate  that  NOMVs  are  able  to  produce  immunity 
against meningococcal disease, and their immunomodulatory properties can  be 
utilised in future adjuvant development and immunotherapy.
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